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Cardiovascular# disease# remains# one# of# the# leading# causes# of# mortality# globally.#
Innovative# techniques# are# required# to# tackle# its# anticipated# rise# due# to# rising#
obesity,# diabetes# and# an# ageing# population.# Personalised# electronic# coaching# (eb
coaching)#using#the#Internet#and#emails#may#help#motivate#healthier#living#and#be#




effective# than# SOC# alone,# in# reducing# cardiovascular# risk# in# asymptomatic#
individuals#with# high# cardiovascular# risk.# I# lead# a# randomised# controlled# trial# of#
402#participants#using#robust#surrogate#markers#to#identify#change#over#6#months.#
I# assessed# the# feasibility# of# using# cardiovascular# magnetic# resonance# surrogate#
markers#to#guide#their#use#in#future#studies#of#lifestyle#interventions.#
#
I#performed#systematic# reviews# to# identify#1)# similarities# and#differences#among#
leading#primary#prevention#guidelines# that#address#cardiovascular#screening#and#
risk# assessment# and# 2)# guideline# recommendations# on# lifestyle# advice# and#
interventions# to# identify# how# ebcoaching# could# be# used# and# what# advice# to#
incorporate#in#ebcoaching#platforms.#
#
I# found#modest#but# statistically# significant# improvements# in#both#ebcoaching#and#
SOC# groups# to# a# similar# level.# Personalised# ebcoaching# did# not# show# additional#
benefit#in#a#highbrisk#primary#prevention#cohort.#It#is#feasible#to#use#cardiovascular#
surrogate# markers# derived# from# cardiovascular# magnetic# resonance# in# lifestyle#
interventions# studies.# However,# further# studies# correlating# change# in# these#
markers#with#longbterm#outcomes#are#required.#
#
Considerable# discrepancies# exist# in# the# guidelines# on# risk# on# cardiovascular#
screening# and# risk# assessment,# with# no# consensus# on# optimum# screening#
strategies# or# classification# of# high# risk# thus# affecting# treatment# threshold.#
Guidelines# did# highlight# the# importance# of# lifestyle# interventions# in# primary#
prevention#and#generally#provided#similar#advice.#
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that#are# implicated# in# its#development.# I#discuss# the#common# factors# that# can#be#
positively# modified# in# order# to# reduce# future# risk# and# discuss# the# role# that#
electronic#coaching#could#play#in#this#area.##The#influence#of#behavioural#coaching#










to# improve# cardiovascular# health.# Changes# in# the#body# leading# to# cardiovascular#
complications# usually# develop# over# decades# as# a# result# of# lifestyle,# concomitant#




and#thus#the#morbidity#associated#with#this#has# increased# in# the#UK# in#both#men#
(7.1%#to#9.1%)#and#women#(5.2%#to#6.3%)#between#1994#and#2003.#This#increase#
may# relate,# in# part,# to# the# epidemic# of# obesity# and# diabetes2,3.# The# long# latency#
period#in#the#development#of#CVD#provides#an#opportunity#for#early#preventative#




not# reduce# mortality# or# clinical# events# in# the# general# population# but# may# be#
effective# in# reducing# mortality# in# high# risk# populations# 5.# There# is# growing#
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evidence# that# behaviour# change# using# computer# tailoring# can# be# effective# in#
changing#lifestyle#and#risk#factors#6,7.#Electronic#media#and#particularly#the#use#of#










CVD# is# an# umbrella# term# for# diseases# that# affect# the# heart# and# the# circulatory#
system.# Conditions# that# account# for# the#majority# of# CVD# include# coronary# heart#
disease# (CHD),# stroke,#heart# failure,#atrial# fibrillation#and#cardiomyopathies.#CVD#
causes#over#161,000#deaths#in#the#UK#annually#accounting#for#over#a#quarter#of#all#
death.#This#has#a#direct#impact#not#just#on#the#patient,#with#alteration#in#the#quality#
and# length# of# life,# but# also# a# significant# societal# impact# due# to# the# costs# of#








to# an# atherosclerotic# plaque# rupture,# ulceration,# fissuring,# erosion# or# dissection#
that# results# in# intraluminal# thrombus# in# the# coronary# arteries# 9.# This# leads# to#
reduced# myocardial# blood# flow# or# distal# platelet# emboli# resulting# in# myocyte#





Individuals# that# survive# their# myocardial# infarction# may# be# left# with# chronic#
debilitation# due# to# heart# failure,# arrhythmias# or# angina.# The# British# Heart#
Foundation# has# published# statistics# on# the# occurrence# and# impact# of#myocardial#
infarction#and#other#related#cardiovascular#conditions# in#the#UK.#One#in#3#people#
who# have# a# heart# attack# will# die# before# they# even# reach# the# hospital# and# it# is#
estimated# that# every# 7# minutes# someone# in# the# UK# dies# of# a# heart# attack# 8.#











profound# debilitations# and# loss# of# independence.# This# has# an# adverse# impact# on#
quality# of# life# and# leads# to# further# complications# due# to# immobility,# need# for#
increased#care#and#has#financial#implications#on#the#individual#and#the#health#care#
system.#The# risk# factors# for#CHD#and# thrombotic# stroke#are#very# similar#and# the#






different# environmental# and# genetic# factors# have# been# identified# as# being#
important#in#the#development#of#atherosclerosis11.#Atherosclerosis#is#a#progressive#
condition# characterised# by# the# accumulation# of# lipid# and# fibrous# constituents# in#
the#large#arteries.#In#the#early#lesion#there#is#sub#endothelial#accumulation#of#‘foam#
cells’# which# are# macrophages# engorged# with# cholesterol.# Evidence# of# early#
atherosclerosis# can#be# seen#during# the# first# decade# in# humans.# These# early# fatty#
steaks# can# then# progress# to# more# complex# and# obstructive# lesions# and# may# be#
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large#enough#to#block#the#flow#causing#haemodynamic#consequences#to#blood#flow#
and# thus# symptoms# of# ischaemia.# An# acute# occlusion,# usually# due# to# rupture# or#




environment.# The# factors# that# have# been# associated#with# atherosclerosis# can# be#




blood#pressure# (BP)#and#diabetes#mellitus.#Factors# that#are#mainly# influenced#by#
the# environment# include# smoking,# poor# physical# activity,# high# fat# diet# and#
infectious#agents#11.#The#factors#mentioned#above#are#all#potentially#modifiable#but#
there#are#also#some#factors#such#that#are#not#amenable#to#modification#such#as#age,#





A# number# of# risk# factors# for# CVD# have# been# identified.# A# small# number# of#
commonly#occurring# factors#have# thus#been# incorporated# into#mathematical# risk#
calculators# around# the# world# in# order# to# estimate# an# individual’s# future# risk# of#
developing#CVD#and#with#the#aim#of#guiding#individualised#treatment,#which#may#
include# lifestyle# advice# and# pharmacotherapy.# These# factors# were# most# widely#
described# following# the# results# from# The# Framingham# Heart# Study# initially# and#
popularised#by#other#international#studies#including#the#INTERHEART#study#4,13.#
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The#Framingham#Heart# Study# recruited# its# first# volunteer# in#1948# and#has# since#
grown#into#a#large#epidemiological#study#which#now#also#includes#the#offspring#of#
the# original# participants.# This# was# a# large# landmark# effort# of# its# time# and# the#
origins#were#closely# linked#to#the#premature#death#of#the#president#of#the#United#
States# of# America# (USA),# Franklin# D# Roosevelt.# He# died# in# 1945# from# a# stroke#
secondary# to# hypertensive# heart# disease.#However,# his# treatment#was# extremely#
poor#by#current#standards#largely#due#to#the#very#limited#understanding#of#CVD,#its#




that# were# identified# to# be# linked# to# CVD# helped# physicians,# other# health# care#
professionals#and#researchers#to#better#understand#CVD#and#further#stimulated#the#
interest# in# preventative# cardiology# 15.# The# modifiable# risk# factors# that# were#
identified#gave#the#opportunity#to#find#candidates#who#may#be#asymptomatic#but#
could# be# susceptible# to# future# events.# With# the# ability# to# predict# and# treat# in#
advance#there#was#a#paradigm#shift#with#the#opinion#that#a#coronary#event#should#











The# INTERHEART# study# was# a# large# standardised# case# control# study# of# acute#
myocardial# infarction#(AMI)# involving#52#countries#around#the#world.# It# included#
15,152#cases#and#14,820#controls#in#the#study#and#represented#all#of#the#inhabited#








the# PAR# of# AMI# in# men# and# 94%# in# women4.# PAR# refers# to# the# proportion# (or#
number)# of# cases# that# would# not# occur# in# a# population# if# the# factors# were#





(odds# ratio# 2·67,# PAR# 32·5%),# diabetes# (odds# ratio# 2·37,# PAR# 9·9%),# history# of#
hypertension#(odds#ratio#1·91,#PAR#17·9%),#abdominal#obesity#(odds#ratio#1·12#for#
top#vs.#lowest#tertile#and#1·62#for#middle#vs.#lowest#tertile,#PAR#20·1%#for#top#two#
tertiles# vs.# lowest# tertile),# regular# alcohol# consumption# (odds# ratio# 0·91,# PAR#
6·7%),#daily#consumption#of#fruits#and#vegetables#(odds#ratio#0·70,#PAR#13·7%#for#




The# understanding# that# abnormal# lipids,# smoking,# hypertension,# diabetes,#
abdominal#obesity,#psychosocial#factors,#regular#consumption#of#fruits,#vegetables,#
and#alcohol,#and#regular#physical#activity#account#for#most#of#the#risk#of#myocardial#
infarction# worldwide# have# been# key# in# public# health# efforts# globally# and# in#
developing# guidelines# with# the# aim# of# reducing# the# burden# of# CVD# including#
preventing#a#large#proportion#of#premature#AMI#17b21.#It#is#also#evident#that#most#if#









The# prevalence# of# smoking# is# between# 20b25%# in# the# different# parts# of# the# UK.#
England# has# the# lowest# average# of# 20%#whereas# in# Scotland# this# is# about# 25%.#











It# can# also# lead# to# reduced# exercise# tolerance# especially# in# those#with# CHD# 24b26.#

















cholesterol# levels,# coinciding# with# a# number# of# evidence# based# pharmacological#
# 22#
therapies,# namely# statins,# becoming# cheaper# due# to# patent# expiry# 29.# Guidelines#
from# the# USA# now# advocate# using# statin# therapy# for# individuals# who# have# an#
estimated#10byear# risk#of#CVD#of#7.5%#or# above30.# In# the#UK# this#was# at# a#much#
higher# level#of#20%#annual#risk#at#which#point# treatment#was#deemed#to#be#cost#








important# step# in# reducing# the# occurrence# and# the# impact# of# CVD# and# is# now#
widely#recommended#in#guidelines.#The#treating#the#cholesterol# is#usually#guided#





Obesity# is# most# commonly# classified# according# to# the# body# mass# index# (BMI)#
calculation.# This# is# calculated# using# the# height# (in# meters)# and# weight# (in#
kilograms).# The# formula# used# is# weight/height2.# A# BMI# of# 25b30# kg/m2# is#
considered# as# overweight# and# between# 30b35# kg/m2# as# obese.# The# number# of#
people# categorised# as# obese# has# increased# greatly# on# a# global# scale# with# an#
estimated#2.1#billion#people#now#classified#as#overweight35.#Nearly#a#quarter#of#the#





A# subbstudy# of# the# INTERHEART# study# specifically# looked# at# dietary# patterns#
around# the#world# and# its# association#with#AMI.#They# identified#3#major# types#of#
diets.#They#classified#these#as#oriental,#western#and#prudent.#The#oriental#dietary#





first#quartile# adjusted#odds# ratio# for#2nd#quartile#was#0.87#but#of# the#3rd#quartile#
this#was#odds#ratio#1.12#and#for#the#4th#quartile#it#was#1.35#(95%#CI#1.21#to#1.42)#36.#
The# authors# estimated# that# the# adjusted# AMI# PAR# of# the# dietary# risk# score#was#
30%#when# comparing# the# top# 3# quartiles# with# the# bottom# quartile.# The# higher#
quartiles# were# representative# of# poorer# dietary# habits.# The# dietary# factors#





Primary# prevention# trials# in# the# high# risk# adult# population# and# secondary#
prevention#trials#in#cardiovascular#patients#have#shown#that#significant#reductions#
in# CVD# risk# can# be# obtained# through# lifestyle# interventions# 37,38.# Lifestyle#
intervention# may# be# useful# in# general# and# when# combined# with# additional#
motivational#tools#such#as#ebcoaching,#may#work#more#effectively#or#maintain#the#
enthusiasm.#The# INTERHEART# study#by#Yusuf# and# colleagues# suggested# that# the#





population# averages# and# it# is# very# difficult# to# make# exact# predictions# for# the#
individual#in#question#that#you#are#managing.#We#now#have#a#better#understanding#
of#the#factors#that#can#increase#the#chances#of#developing#heart#disease#and#have#
an# armamentarium# of# tools# that# we# can# utilise# to# control# these.# Advances# in#
pharmacology#for#hypertension,#elevated#cholesterol,#the#realisation#of#the#harmful#
effects# of# smoking# and# the# impact# of# lifestyle# factors# have# been# instrumental# in#
helping#to#control#common#risk#factors.#
#




do# some# form# of# physical# activity# despite# physical# limitations# and# if# done# in# a#
sensible# manner# then# few# adverse# side# effects# or# complications# can# occur.#
Countries# like# the# Netherlands# have# been# proactive# in# allowing# an# environment#
that#promotes#a#healthy#behaviour#including#placing#a#large#emphasis#on#physical#
activity# in#daily# life.#The#provision#of#safe#and#abundant#cycle# lanes,# for#example,#
has#allowed#both#adults#and#children#to#incorporate#this#form#of#physical#activity#
in#daily#life#41.#Countries#such#as#Australia#have#been#proactive#in#the#public#health#
arena# for# smoking# cessation.# with# smoking# cessation# programmes,# a# national#









to# try#and# identify#asymptomatic#patients# that#may#be#at#high# risk#of#developing#
their# first# CVD# event# in# order# that# they# may# get# timely# advice# on# lifestyle#
optimisation# and# pharmacological# therapy# if# required.# The# common# modifiable#
lifestyle# factors# that# have# been# targeted,# as# for# example# in# the# National# Health#
Service# (NHS)# Health# Check# in# the# UK,# include# smoking# cessation,# increased#
physical# activity# and# healthy# diet.# The# main# pharmacological# aims# have# been#
towards# lowering# cholesterol# and#BP#with# the# combined#aim#of# trying# to# reduce#




in# management.# This# includes# the# Pooled# Cohort# Equation# and# the# QRISK#














2007# and# in# patients#who#were# free# of# established# CVD# or# diabetes.# The# QRISK#







are# individualised# for# smoking# status,# systolic# BP,# diabetes# mellitus,# total#
cholesterol# to#HDL# ratio,#BMI# and#a# family#history#of#premature# coronary# artery#
disease.#Additional#factors#that#are#now#considered#in#the#newer#QRISK#calculators#
(i.e.# QRISK2# and# QRISKblifetime),# but# were# not# included# in# the# original#
Framingham#scoring# system#or# the#original#QRISK#calculator#are#ethnicity,# social#
deprivation# (Townsend# score,# based# on# postal# code),# a# diagnosis# of# atrial#






lower# thresholds# for# initiating# lipid#modifying# treatments#advocated#by# the#most#
recent#UK#and#American#guidelines#have#been#the#attention#of#much#discussion#34.#
Some#of# the# reasons#given# for# the# change#are# that# growing#evidence# regards# the#







There# has# been# a# recent# recognition# in# the# area# of# risk# estimation# about# the#
importance#of#relative#or#lifetime#risk#34.#This#is#based#on#the#observation#that#we#
may# be# underestimating# risk# in# younger# adults# who# would# be# categorised# as#
having#a#low#10byear#CVD#risk#but#who#are#likely#to#accumulate#this#risk#in#the#long#
run# due# to# high# levels# of# individual# risk# markers.# New# concepts# to# try# and#
communicate# this# risk# include# ‘heart# age’# in# the# JBS3# calculator,# ‘relative#
cardiovascular# risk’# in# the# European# Society# of# Cardiology# (ESC)# Systematic#
Coronary#Risk#Evaluation#(SCORE)#system#and# lifetime#risk#as#used# in# the#QRISK#







Exercise,# weight# loss# and# dietary# approaches# form# part# of# the# lifestyle#






loss#of# about#8#kg#was# shown# to# reduce#BP#by# about#8.5#mmHg# systolic# and#6.5#





feeding# trials,# in# order# to# gain# the# maximum# benefit,# the# individual# need# to#
# 27#
maintain# good# compliance# in# the# longer# term.#A# systematic# review#assessing# the#
compliance#to#the#diet#based#on#9#educational#intervention#studies#that#ran#for#at#
least# 12#months# showed# that# compliance# rates#were# lower# than# reported# in# the#









both#primary# and# secondary#prevention.#Other# cholesterol# lowering#medications#
do#not#have#as#robust#an#evidence#base#so#far#for#event#rate#reduction#and#thus#are#
predominantly# used# as# second# line# therapy# for# individuals# who# do# not# tolerate#
statins#17.#
#
Lifestyle#modification# can# help# to# achieve# target# cholesterol# levels# as# set# out# in#
various#guidelines.#The#changes#include#dietary#modification,#weight#reduction#and#
increased#physical#activity#with#the#aim#of#reducing#cholesterol# levels# to#below#5#
mmol/L# for# total# and# less# than#3#mmol/L# for# the# LDL# cholesterol# 47.# In# a# recent#
review,# dietary# constituents# such# as# green# tea,# soya# protein,# plant# stenols# and#
almonds# have# shown# potential# benefit# in# helping# to# reduce# total# and# LDL#
cholesterol#47.#Due#to#the#potential#disutility#of#medication,#people#may#prefer#nonb
pharmacological# means# for# reducing# cholesterol48.# However,# compliance# with#
lifestyle#modification#would#need#to#be#sustained#in#the#long#term#to#maintain#its#















to#0.93)# 50.# It#was#also#associated#with# significant# reductions# in# cancer# incidence#
and#mortality#and#neurodegenerative#disease.#This#has#also#been#demonstrated#in#
a# secondary# prevention# CVD# trial# in# 423# patients# enrolled# after# their# first#
myocardial#infarction#51.#A#significant#difference#was#seen#in#3#different#composite#
end#points#with#the#main#one#being#that#of#cardiac#death#and#nonbfatal#myocardial#
infarction# (14# events# in# Mediterranean# type# diet# group# vs.# 44# in# the# prudent#
western# type#diet# p=0.0001).#A# significant#difference#was# also# seen# in# the#broad#
composite# end#points,#which# included# the# occurrence# of# unstable# angina,# stroke,#








mixed# nuts# in# the# other.# The# 3rd#group#were# advised# to# take# a# low# fat# diet.# The#
study#was#conducted#over#6#years#between#2003#and#2009#with#a#median#follow#
up# period# of# 4.8# years.# The# study#was# stopped# early# following# the# results# of# an#
interim#analysis#52.#A#total#of#7447#participants#considered#to#be#high#risk#for#CVD#
were# enrolled# and# randomised# into# one# of# the# 3# arms.# All# participants# were#
considered#high# risk# based# on# a# history# of# diabetes# or# having# at# least# three# risk#
factors,#which#included#smoking,#hypertension,#elevated#LDL#cholesterol,#low#HDL,#













provided# free# of# charge.# Cost# implications# in# real# life# settings# may# limit# the#
adherence#to#this#type#of#diet#in#the#general#population.#Another#limitation#of#the#
study# was# that# for# the# first# 3# years# the# control# arm# received# less# educational#






and# encouraging# behaviour# that# is# seen# to# be# optimal# or# desirable.# The# most#
widely#known#concept# is# in# the# field#of# sports#but# this# can#equally#be#utilised# in#
several# other# contexts.# Coaching# is# now#widely# used# to# try# and# improve# healthy#
lifestyle# behaviours.# Weight# loss,# smoking# cessation# and# physical# activity#
programmes# are# a# few# examples# of# this# 53.# In# order# for# an# individual# to# be# able#
make#a#choice#to#lead#a#healthier#lifestyle#a#few#key#elements#are#required.#These#






physical# activity# and# smoking# cessation# 19.# The# progress# that# has# been#made# in#
treating# diseases# such# as# myocardial# infarction# has# greatly# improved# outcomes.#
This#has#been#the#result#of#improving#emergency#care#such#as#thrombolysis#in#the#
past# and# percutaneous# coronary# intervention# now.# The# contributions# of#
pharmacological#therapy#and#rehabilitation#in#the#post#infarction#phase#have#also#
# 30#










Vale# et# al# carried# out# a# study# on#Coaching# patients#On#Achieving# Cardiovascular#
Health# (COACH)# in# a#multicentre#RCT# in# patients#who# already# had# CHD.# From#6#
university# teaching# hospitals# they# randomised# 792# participants# to# either# usual#
care# or# usual# care# plus# the# COACH#programme#whereby# additional# personalised#
coaching#was#via#telephone#or#mail#to#assess#the#primary#end#point#of#cholesterol#
change.# The#mean# cholesterol# reduction# was# significantly# greater# in# the# COACH#






CVD#events#have#an# impact#on#morbidity#and#mortality.#Many# face#adverse# longb
term# consequences# on# quality# of# life# and# physical# independence.# The# American#
Heart#Association#(AHA)#and#other#bodies#predict#that#the#prevalence#of#CVD#and#
the# costs# associated# with# it# will# increase# substantially# in# the# future.# In# the# 2#
decades#from#2010#the#real#total#direct#medical#costs#of#CVD#are#projected#to#triple#
to# $818# billion# from# $272# billion.# Indirect# costs,# due# to# loss# of# productivity,# are#
estimated#to#increase#by#61%#by#2030#to#$276#billion#from#$172#billion#in#2010#59.#
#
Novel# techniques# in# the# primary# prevention# of# CVD# are# required# that# are# both#
clinically#and#costbeffective#in#the#current#climate#of#economic#austerity.#Use#of#the#




obesity# and# diabetes,# is# expected# to# have# a# heavy# toll# on# health# services.#
Responding#through#public#health#strategies#and#actively#reducing#risk#factors#has#
become# widely# accepted.# This# is# evident# from# published# medical# guidelines# for#









Cochrane# reviews#on#multiple# risk# factor#modification# for#primary#prevention#of#
CHD# from# 2006# and# 2011# noted# that# interventions# that# use# counselling# and#
education#aiming#at#behaviour#change#have#not#shown#a#reduction#in#total#or#CHD#
mortality#or#other#clinical#events#in#the#general#population#but#may#be#effective#in#
reducing#mortality# in# high# risk# patients#with# diabetes# and# hypertension.# On# the#







Ebcoaching# is# where# coaching# is# delivered# through# the# use# of# an# electronic#
medium.#The#aims#and#goals#are#the#same#as#regular#coaching.#Ebcoaching#can#be#










information,# there# has# also# been# a# rise# in# obesity# and# diabetes.# Although#
technology#may#be#partly#accountable#for#this,#through#more#sedentary#lifestyles,#it#





Computer# tailoring# assesses# the# individual# and# selecting# appropriate#
communication# content# using# databdriven# decision# rules# that# rely# on# data# input#
about# that# individual# 6.# Computer# tailoring# involves# “any# combination# of#
information#or#change#strategies# intended#to#reach#one#specific#person,#based#on#
characteristics# that# are#unique# to# that#person,# related# to# the#outcome#of# interest#
and#derived#from#an#individual#assessment”#64.#
A#metabanalysis#looked#at#the#effects#of#computer#tailored#interventions#aiming#to#
change# health# behaviours# compared# to# nonbtailored# comparison# groups.# The#
computer# tailoring# included# in# this# paper# had# to# be# primarily# provided# through#
electronic# communication# media# and# not# live# councillors.# The# control# groups#







effect# sizes#decreased#at# further# followbup#after# the# intervention#was# completed.#
Dynamic# interventions# had# increased# efficacy# over# those# that# were# one# off#
assessment.# Study# effects# were# similar# between# the# different# communication#







the# lack# of# validity# assessment# and# the# reliability# of# the# conclusions,# due# the#
heterogeneity# between# the# 88# controlled# studies# reviewed.# Also,# the#
generalisability# from# this# paper# is# limited# due# to# the# fact# that# 70%# of# the# study#
participants#were#females#and#most#of# the#studies#were#performed#in#the#USA#or#
Europe.#The#effect#size#was#calculated#using#Hedges#g#method#following#extraction#
of# outcome# data.# Overall# a# significantly# greater# effect# was# seen# for# tailored#
interventions#compared# to# the#control#group#with#a# small# to#medium#effect# seen#
with# the# interventions# (g=0.17)# but# with# evidence# of# statistically# significant#
heterogeneity#in#the#studies.#All#health#behaviours#were#reported#to#have#greater#
effects# for#the#tailored# interventions#compared#to#the#control#groups.#The# largest#
effect#was#documented#for#dietary#fat#reduction#(g=0.22,#95%#CI#0.18#to#0.26#from#
26# interventions)# and# also# for# other# health# behaviours# including# smoking#






The# earliest# computer# tailored# interventions# used# print# material# for#
communication.#Recent#advances#in#technology#have#resulted#in#the#availability#of#
this#communication#through#computers,#the#Internet,#mobile#phone#text#messages#
and#mobile# phone# applications.#With# the# advent# of#wearable# health# gadgets# this#
industry# has# seen# a# sharp# increase# in# investment# and# potential# capabilities65.#
Individuals# can# easily# track# their# activity# levels,# estimated# calorie# consumption,#
sleep# patterns# and# sedentary# time.# The# ability# to# track# serial# changes# and#make#
this# available# to# others# has# encouraged#many# to#maintain# healthier# lifestyle# and#
compete#with#others#sharing#the#same#platform#as#a#means#of#further#motivation.#
!
In# clinical# trials# of# computer# and# electronic# interventions# there# has# been# a#wide#
variation#in#the#strategies#utilised.#Differences#exist#in#the#type#of#intervention,#the#
technology#used,#the#number#of#contacts#made,#the#number#of#factors#attempted#to#






Health# behaviour# encompasses# a# broad# group.# This# can# be# to# do# with# lifestyle#
factors# that# are#promoted# such# as# healthy# eating# and#maintaining# good# levels# of#
physical#activity#but#also#involves#avoidance#of#other#harmful#behaviours#such#as#
smoking,# excess# alcohol# consumption.# The# prescription# of# medications# has#
increased# in# the# last# century#and# is# likely# to# increase# further#with# the#guidelines#
advocating#earlier#preventative#interventions#in#the#apparently#healthy#population#




For# those#who# are# likely# to# benefit# from#medications# careful# explanation# of# the#
benefits# and# harms# of# pharmacotherapy# in# addition# to# other# positive#
encouragements#is#likely#to#lead#to#better#understanding,#empowerment#and#likely#
improved#compliance#of#medications.#A#recent#randomised#controlled#study#using#
text# messages# showed# significant# improvement# in# medication# compliance# 72.#
However,# there# was# no# difference# noted# between# the# 2# groups# with# regards# to#
follow#up#BP#or#cholesterol#levels.#A#number#of#potential#reasons#may#account#for#
this# including# the# volunteering# effect# in# those#who# take#part# in# studies# and# thus#
potentially#being#healthier#than#the#general#population.#Lifestyle#modifications# in#






avenue# for#health#care# intervention#delivery# for#a#number#of# reasons:# (1)#People#
tend#to#carry#their#phone#with#them#everywhere,#(2)#they#are#now#widely#adopted#
and#in#the#USA#for#example#more#than#83%#of#the#adult#population#have#an#active#
mobile# phone.# The# availability# and# use# of# mobile# phones# has# increased# in#
developing# countries# and# rural# farmers# in# India# for# example# can# now# take#
advantage#of#them#in#trying#to#boost#their#productivity,#(3)#people’s#attachment#to#
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mobile# phones,# (4)# advanced# features# on# mobiles# that# allow# context# awareness#
and# sensing# which# tracks# phones# based# personal# information# such# as# activity#
levels#and#sleep#patterns73.#Mobile#phones#are#now#being#used#in#conjunction#with#
wearable# tracking# devices# that# allow# seamless# integration# and# instant# feedback#
that#allows#progress#recording#and#motivation.#
#
Research# on# the# clinical# effectiveness# of# these# recent# advances# are# still# limited,#
nevertheless,# the# market# has# now# become# a# multimillion# pound# industry# with#
intense# competition# and# a# race# to# bring# about# even# better# technology.# The#
disadvantage# of# desktop# computers# and# laptops# is# that# they# cannot# be# easily#
carried#around#as#compared#to#mobile#phones.#Whereas#a#computer#or#laptop#may#
be# shared#with# others,#mobile# phones# tend# to# have# sole# ownership# thus#making#
personalisation#easier.#People#customise#their#phones#to#their#settings#and#utilise#
them#on#a#daily#basis#to#call,#text,#schedule#and#carry#out#a#large#number#of#other#
activities.# With# easy# access# to# the# Internet# along# with# other# advanced# facilities,#
mobiles# are# ideally# placed# to# assist# in# health# interventions# both# in# the# primary#
prevention#and#secondary#prevention#settings.#
#









A# randomised#controlled#study#performed# in# the#Netherlands#used#ebcoaching# in#
familial#hypercholesterolaemia#but#found#no#significant#improvement#in#CVD#risk#
indicators# using# lifestyle# intervention# in# people# with# familial#
hypercholesterolaemia# as# compared# to# usual# care# 74.# 340# adults# with# familial#
hypercholesterolaemia# were# recruited# from# a# Dutch# Cascade# Screening#
programme# and# randomly# assigned# to# either# tailored#webbbased# lifestyle# advice#
and# personal# counselling# or# usual# care.# Intervention# was# personalised# health#
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counselling#intervention#using#a#combination#of#computer#generated#tailored#web#
advice# and# facebtobface# counselling# complemented# with# a# telephone# booster#
session.#The#goals#of# the# intervention#were#(1)#to# improve#awareness#of# the#CVD#
risk# though# increased# relevant# knowledge# cues# to# action# and# change# in# risk#
perception;# (2)# to# improve# motivation# for# healthy# behaviour# though# increased#
knowledge#and#change# in#attitude,#selfbefficacy#and#social# influence;# (3)#adopting#
and# maintain# a# healthy# lifestyle;# (4)# lower# objective# CVD# measures.# The# group#
developed#an# individually# tailored# lifestyle# intervention#or#CVD#risk# reduction# in#
familial# hypercholesterolaemia# patients.# They# used# the# integrated# model# for#
exploring# motivation# and# behavioural# change# (the# Ibchange# model# dividing# the#
process#into#awareness,#motivation#and#action).#
#
After# 12# months# they# noted# no# significant# difference# in# CVD# risk# indicators#
(namely# lipids,# systolic# BP,# glucose,# BMI# or# waist# circumference)# between# the#
groups.#The#cumulative#longbterm#impact#on#CVD#risk#of#small#improvements#in#all#
indicators#was#not#assessed.#The#authors#cited#the#need#for#future#studies#to#clarify#
this# further.# Some# of# the# limitations# of# this# study# included# that# in# this# familial#
hypercholesterolaemia#patients#only#less#than#half#the#intervention#arm#completed#
even# 1# out# the# 6# of# the# advice# modules.# Their# intervention# was# only# using# the#
computer# programme# and# did# not# have# addition# email# encouragements.# The#






















over# the# follow#up#periods# dynamic# tailoring#maintained# the# effect,#whereas# the#






Interestingly# there# does# not# appear# to# be# any# significant# difference# between# the#
types#of# communication# channels#used# (e.g.# print# vs.# computer# tailoring).#Only#3#
studies#were#identified#looking#at#automated#phone#delivery#thus#solid#conclusions#
could#not#be#drawn#about#this#communication#channel.#The#implication#of#this#may#
























A# systematic# review#carried#out#by#Chen#et#al.# studied# the#effectiveness#and#cost#
effectiveness# of# internet,# personal# computer# and# other# electronic# aids# to# help#
adults# to# stop# smoking# 77.# In# particular,# they# assessed# the# evidence# for#
effectiveness# of# Internet# sites,# computer# programmes,# mobile# telephone# text#
messaging#and#other#electronic#aids#for#smoking#cessation.#They#also#looked#at#the#
costbeffectiveness#of# implementation#of# these#tools# in# the#NHS#smoking#cessation#
programmes# and# identified# current# gaps# in# research# in# this# field.# Findings#
suggested#that#the# interventions#are# likely#to#be#helpful# in#smoking#cessation#but#
the# effect# is# small.# Some# forms# of# electronic# intervention# are# likely# to# be# costb
effective#when#delivered#alongside#brief#advice#or#intense#counselling.#
#
Sixty# relevant# RCTs# or# quasibRCTs#were# identified# from# a#wide# database# search.#
Pooled#estimates# for#both#prolonged#abstinence#and#point#prevalence#abstinence#
suggested# that# computer# and# other# electronic# aids# increased# the# likelihood# of#
smoking# cession# compared# to# selfbhelp#material# or#no# intervention# (relative# risk#
1.32# 95%# CI# 1.21# to# 1.45# and# relative# risk# 1.14# with# 95%# CI# 1.07# to# 1.22,#
respectively).#There#was#no#difference#seen#in#the#effect#when#comparing#smokers#
who# were# ready# to# quit# to# those# who# were# not# ready# to# quit# but# were# being#
actively#encouraged# to#stop.#Costbthreshold#analyses# indicated# that#some# form#of#






Txt2stop# was# a# single# blinded# RCT# by# Free# et# al# and# used# text# messaging# in#
smoking# cessation# using# an# automated# mobile# phone# textbmessaging#
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programme78.# They# enrolled# 5800# smokers# who# expressed# an# intention# to# quit#
smoking# and# allocated# them# randomly# to# either# receiving# motivational# text#
messages# in# addition# to# behavioural# change# support# or# a# control# group# who#
received# text# messages# that# were# unrelated# to# smoking# cessation.# At# 6# months,#
biochemically# verified# continuous# abstinence# was# significantly# higher# in# the#
intervention#group#compared#to#the#control#(10.7%#vs.#4.9%#respectively,#relative#
risk#of#2.2#with#95%#CI#1.8#–#2.68,#p<0.0001).#The#text#information#was#tailored#to#
information# that# was# provided# at# baseline# by# the# participant# and# both# groups#
could#avail#of#additional#smoking#cessation#support#from#other#services#that#they#
chose.# Despite# the# relatively# low# continuous# abstinence# rate# in# the# intervention#
group# it# still# represented# an# improvement.# Missing# data# on# participants# that#
withdrew#were#accounted# for#using#sensitivity#analysis#with#multiple# imputation#
techniques#based#on#predictors#of#missing#values.#They#subsequently#reported#on#




Electronic# tools# assisting# smoking# cessation# are# now# commonly# used# in# New#
Zealand#and#the#UK.#In#the#UK#the#NHS#Quit#Smoking#programme#allows#a#number#




are# also# available,# including# desktop# programmes# (widgets),# and# there# is# also# a#
smoking# cessation# application# programme# for# smart# phones# that# encourages#
setting#a#quit#date#and#updates#encouraging#advice.#A#number#of#other#initiatives#










management# on# top# of# usual# care.# They# found# that# the# nurse# led# Internet# based#
education#programme#in#this#group#led#to#a#greater#reduction#in#the#FRS#compared#
to#the#control#group#that#received#usual#care#alone,#although#the#effect#was#small#




The# concept# of# using# the# Internet# and# other# technologies# to# be# able# to# provide#
services# related# to# health# from# a# distance# hold# promise.# It# could# allow# frequent#
contact# between# health# professionals# and# the# patient.# This# could# also# be# cost#
effective# on# a# large# scale# and# could# potentially# function#without# over# burdening#
existing# health# care# facilities.# Patients# may# feel# empowered# and# motivated# by#
understanding#their#health#and#being#involved#in#the#management#process.#
Internet# programmes# that# target# multiple# lifestyle# interventions# have# shown#
variable# effectiveness# but# overall# in# the# systematic# review# by# Vegting# et# al# of# 9#





According# to# the# Office# of# National# Statistics# 2013# data,# London# has# the# highest#
rate#of#Internet#users#in#the#UK#at#90%.#Use#of#the#Internet#in#the#older#population#
still# remains#high,#with#80%#of# those#between#55b64#having#used# the# Internet#at#
least# once# in# the# previous# 3#months.# Libraries# provide# free# Internet# access# and#
there#are#many# Internet# cafes# that#allow#easy#access# to# those#who#may#not#have#
private#Internet#access.#Added#to#this,#acceptance#and#increased#use#in#the#general#
population#and#specifically# the#older#generation,#makes# this#an#exciting# tool#with#
great#potential.#Additionally,# in#the# last#5#years#the#use#of#smart#phones#has#now#
made#use#of# the# Internet,# even#easier#and# thus#not# restricting#access# to#home#or#




The# Heart# Attack# Prevention# Programme# for# You# (HAPPY)# programme# initially#
used#a#method#with#generic#lifestyle#ebcoaching#as#assessed#in#a#Dutch#population#
(n=1000)# over# 3# months.# 141# of# the# participants# with# an# intermediate# to# high#
cardiovascular#risk#were# followed#up#over#12#months.# #This#was#an#uncontrolled#
study# that# showed#a# relative# reduction# in# cardiovascular# risk#of#13.8%#based#on#






















In# this# chapter# I# discuss# the# use# of# nonbinvasive# cardiovascular# surrogate#
biomarkers# particularly# in# the# context# of# primary# prevention# of# CVD.# # I# discuss#
some#of#the#technical#aspects,#strengths#and#weaknesses#of#using#these#biomarkers#
in#order#to#justify#their#use#in#the#HAPPY#London#study.#The#primary#end#point#of#






a# discrepancy# between# the# predicted# and# the# actual# rates# of# events# that# occur.#
Biomarkers#are#tools#that#may#help#to#further#risk#stratify#patients.#
#
A# surrogate# end#point# is# a# biomarker# that#may#be# a# substitute# for# a# clinical# end#
point# 85.# NICE# states# that# a# biomarker# is# “a# characteristic# that# is# objectively#
measured#and#evaluated#as#an#indicator#of#normal#biological#processes,#pathogenic#
processes,# or# pharmacological# responses# to# a# therapeutic# intervention”86.# A#
surrogate# endpoint# in# the# form# of# a# biomarker# acts# as# a# substitute# for# clinical#
endpoints.#It#is#expected#to#predict#the#clinical#benefit#or#harm#based#on#scientific#
evidence.# Changes# in# surrogates# are# often# detected# earlier# than# actual# hard#
endpoints# and# thus# may# utilise# less# resources.# This# facilitates# clinical# trials#
allowing#less#time#and#lower#cost#and#making#trials#more#feasible#to#conduct.#For#a#
biomarker# to# be# considered# a# surrogate# for# cardiovascular# endpoints# it# must#
satisfy#certain#criteria.#The#AHA#have#outlined#6#required#criteria#for#evaluation#of#
a#novel#risk#marker#including#proof#of#concept,#prospective#validation,#incremental#
value,# clinical#utility,# clinical#outcomes#and#costbeffectiveness# 86.#Other# important#





aging# that# could# be# used# in# primary# and# secondary# CVD# prevention# were#
scrutinised#by#the#ESC#Working#Group#on#Peripheral#Circulation.#Biomarkers#that#
were# deemed# to# fulfil# most# of# the# criteria# required,# and# thus# close# to# being#
considered# clinical# surrogate# endpoints# included# carotid# ultrasound,# ankleb
brachial#index#and#carotidbfemoral#PWV#87.#Biomarkers#that#were#deemed#to#fulfil#
some,#but#not#all#the#criteria#required#included#brachialbankle#pulse#wave#velocity#
(PWV),# central# haemodynamic/# wave# reflections# (pulse# wave# analysis)# and# Cb
reactive# protein# (CRP).# Flow#mediated# dilatation,# endothelial# peripheral# arterial#
tonometry,#oxidised#LDL#and#dysfunctional#HDL#were#considered#not#to#currently#
fulfil# the# essential# criteria# for# surrogate# endpoints.# The# group# identified# that# a#
prospective# study# in#which# all# vascular# biomarkers# are# studied#was# lacking# and#
considered# that# in# selected# cases#more# than#one#biomarker#may#be# required# for#
assessing#an#individual.#
#












Does# provide# incremental# information# above#
established#standard#risk#markers?#



















a# tailored# plan# the# risks# and# the# benefits# of# the# strategy#must# be# considered# in#
conjunction#with#the#individual’s#baseline#characteristics.#A#number#of#risk#scores#




classified# into# low,# intermediate#and#high# risk#and# this# then#helps#determine# the#
level#of#intervention#that#one#could#receive.#Thresholds#for#determining#the#level#of#






Gaps# exist# between# the# calculated# and# the# actual# event# rates,#which# can# lead# to#
under#or#over#estimation.#Risk#scores#need# to#be#calibrated# to# the#contemporary#
CVD#event#rates#of#the#country#where#it#is#being#implemented#and#need#to#take#into#
account# the# changing# population# characteristics# and# the# impact# of# other# health#
interventions.#
#
Some# of# the# factors# identified# accounting# for# discrepancies# include,# but# are# not#
limited#to#extrapolation#of#the#risk#score#to#populations#that#are#different#from#the#
original#cohort#used.#The#Framingham#score,#for#example#was#originally#based#on#a#
white# AnglobSaxon,# predominantly# male# cohort# from# Framingham# USA.# This#
equation# was# previously# used# in# the# UK# on# people# of# South# Asian# origin.# It#
subsequently# became# apparent# that# in# this# group# the# risk# was# often#
underestimated#16.#Other#factors#include#the#time#delay#between#the#observational#









Although# a# large# number# of# biomarkers# fulfil# the# first# 2# criteria# outlined# above#
(proof#of#concept#and#prospective#validation),#they#do#not#always#add#incremental#
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of# death# are# both# consequences# of# atherosclerosis.# Arterial# stiffness# occurs# as# a#
consequence# of# aging# and# arteriosclerosis# rather# than# from# atherosclerosis.#
Arteriosclerosis#is#a#disease#of#the#media#and#related#to#the#normal#or#accelerated#
aging# process.# Atherosclerosis# on# the# other# had# is# principally# a# disease# of# the#
intima,# affecting# the# vessel# in# a# patchy#manner.# Loss# of# compliance# results# in# an#
increased# PWV# as#waves# travel# faster# in# rigid# tubes.# An# elevated# PWV# is# thus# a#
hallmark#of#arteriosclerosis#87.#
#
Arterial# stiffness# is# recognised# as# an# independent#marker# of# cardiovascular# risk#
beyond# the# established# traditional# risk# factors# 90b92.# It# has# predictive# value# for#
cardiovascular#and#allbcause#mortality#93.#The#aorta#is#the#largest#artery#in#humans#
and#is#one#of# the#most#commonly#used#vessel# for#assessment#of#arterial#stiffness.#
Aortic# stiffness# is# increased# in# a# variety# of# common# diseases,# such# as# CHD# and#
hypertension,# and# may# be# an# early# marker# of# atherosclerosis.# Increased# aortic#
stiffness# has# been# shown# to# predict# cardiovascular# risk# with# hazards# ratio# 2.45#




stiffness# and# the# conditions# that# are# associated# with# it.# The# dominant# effect#
appears# to# be# related# to# aging# and# BP.# Other# factors# include# CVD# risk# factors,#
genetics,# endbstage# renal# disease,# and# chronic# inflammatory# conditions.# Arterial#
stiffness#is#thus#considered#a#measure#of#the#end#organ#damage#on#the#arterial#wall#
from# these# conditions.# Numerous# studies# have# validated# the# predictive# value# of#
arterial#stiffness,#and#in#particular#for#carotidbfemoral#PWV,#including#in#essential#
hypertension#93,95,#type#2#diabetes#96,#endbstage#renal#disease#97,#the#elderly#98#and#
the# general# population# 99.# Arterial# stiffness# is# a# robust# predictor# of# allbcause#
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mortality# suggesting# that# the# role# of# arterial# stiffness# may# extend# beyond#
conditions# that# affect# the# cardiovascular# system.# It# is# also# a# robust# predictor# of#
cardiovascular#mortality,#nonbfatal#and#fatal#coronary#end#points#and#fatal#stroke#
92.#The#predictive#ability#is#higher#in#subjects#with#a#higher#baseline#cardiovascular#




the# afterload# pressure# encountered# by# the# heart.# This# can# have# further#
pathophysiological#consequences#on#the#cardiovascular#system#such#as#promoting#
left#ventricular#hypertrophy#(LVH)100.#As#arteries#stiffen#the#heart#is#forced#to#work#
harder# to# allow# the# same# stroke# volume# to# be# pumped# against# the# increased#
resistance.#This#may#lead#to#an#increased#time#for#the#systolic#phase#of#the#cardiac#
cycle,#which#may#have#a#consequent#negative#effect#on#coronary#perfusion#due#to#a#
reduction# in# the# time#available# for# the#diastolic#phase#of# the#cardiac#cycle.#Aortic#
stiffness#is#thought#to#result#in#increased#mortality#due#to#its#haemodynamic#effect.#
Elastin# fibres# in# the# wall# of# the# aorta# normally# bear# the# aortic# stresses# 101.#
Mechanical#fatigue#and#fragmentation#of#the#elastin#fibres#within#the#aortic#media#
is#believed#to#result#in#dilatation#of#the#proximal#aorta#and#thus#transfer#of#load#to#
stiffer# elements# of# the# aortic# wall# such# as# collagen.# Consequently,# aortic# wall#
stiffness#causes#a#corresponding# increase# in# the#PWV,#resulting# in# the#premature#
arrival#of# the# reflected#pressure#waves# in# late# systole# rather# than#diastole#which#
augment#the#pressure#102.#
#









thus# can# be# useful# in# this# older# age# group# to# assess# risk# but# also# to# look# for#
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potential# improvements# following# intervention.# Augmentation# index# (AI)# on# the#






considered# the# gold# standard# index#of# aortic# stiffness,# as# it# is# a# relatively# simple#
method#with# reported# accuracy,# good# reproducibility# and# is# an# independent# and#
strong# predictor# of# adverse# outcomes# (nonfatal# and# fatal# cardiovascular#
complications)# over# traditional# risk# factors# in# patients# with# disease# and# in# the#
general# population# 99,104,105.# The# most# validated# used# technique# and# one# that# is#
most#commonly#practiced# to#date# involves# the#assessment#of#pulse#waves#over#a#
significant#portion#of#the#arterial#tree#such#as#the#carotidbfemoral#PWV#(CFPWV).#
Brachial#ankle#PWV#is#an#alternative#to#CFPWV#and#involves#putting#inflation#cuff#
around#all#4#extremities.#This# technique# is#predominantly#used# in# Japan#with# the#
potential#advantage#that#measuring#over#a#longer#distance#may#provide#additional#
information.#However,#it#only#meets#some#of#the#9#essential#criteria#in#order#for#it#







factors# on# the# arteries.# It# is# a# validated# nonbinvasive# test,# relatively# easy# to#
perform,#relatively#cheap#and#has#been#extensively#validated.#However,#individual#
risk# factors# (such#as#BP)# can# fluctuate#over# a# short#period#of# time#and#may# thus#
make# it# a# less# reliable# measure# of# long–term# outcome.# The# working# group,#
























Figure! 1.! Measurement! of! carotid2femoral! PWV! with! foot2to2foot! method!
using!the!equation!distance!(ΔL)/!transit!time!(Δt).!Laurent#S,#Cockcroft#J,#Van#
Bortel# L# et# al,# Expert# consensus# document# on# arterial# stiffness:# methodological#




In#a#metabanalysis#of#16#studies# looking#at# the#predictive#ability#of#PWV# for#CVD#
events,#CVD#events# increased#by#30%# for# every#1# standard#deviation# increase# in#
CFPWV# with# a# 95%# CI# of# 1.18# –# 1.43# even# after# adjustment# for# traditional#
cardiovascular# risk# factors# 107.# The# authors# suggested# that# PWV#had#potential# to#
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enable#better#identification#of#highbrisk#populations#that#might#benefit#from#more#
aggressive# CVD# risk# factor# management.# CFPWV# has# also# demonstrated# added#
value# over# and# above# global# risk# scoring# systems# that# take# multiple# risk# factor#
interactions#into#account,#such#as#the#SCORE#from#the#ESC#108.#
#
Metabanalyses# have# demonstrated# a# good# net# reclassification# index# (NRI)# of#
CFPWV# in# patients# at# intermediate# risk.# In# an# individual# data# metabanalysis# of#
17,635#individuals,#the#5#year#overall#NRI#for#CHD#was#14.8%#and#19.2%#for#stroke#
107.# To# date# there# have# been# no# randomised# controlled# studies# assessing# the#
potential#of#CFPWV#as#a#target#for#therapy#and#if#such#a#strategy#is#likely#to#lead#to#
improved# outcomes# 87.# One# study# in# end–stage# renal# disease# patients# showed#
improved#outcomes#for#those#with#a#lowering#of#their#arterial#stiffness#109.#
#
Costbeffectiveness# studies# for# the# use# of# arterial# stiffness# in# clinical# practice# are#
lacking.# It# is# thought# that# the# there# is# a# potential# for# cost# saving# from# the# high#
reclassification# index# and# the# relatively# low# cost# for# an# individual# patient,#
particularly#if#performed#on#a#large#scale#87.#
#
Reference# values# for# healthy# subjects# have# been# published# based# on# 1455#
individuals# and# also# in# patients# with# cardiovascular# risk# factors110.# The# mean#
values# in# the# normal# group# showed# a# trend# to# wards# an# increase# in# PWV# by#





of# hypertension# advocates# the# use# of# CFPWV# in# clinical# practice.# Initially# a#
threshold# of# 12#m/s# was# suggested# to# determine# significant# pathology# of# aortic#
function# in# middlebaged# hypertensive# subjects# 111.# It# should# be# noted# that# the#










Central# haemodynamic# outputs# are# either# central# BP# parameters# and# its#
derivatives#(including#central#systolic#BP,#pulse#pressure#and#augmented#pressure)#
or#measures# that# quantify#wave# reflections# (such# as# AI,# wave# intensity# analysis,#
forward# and# backward# waves).# Although# invasive# measures# provide# accurate#








be# the#most# realistic# describes# the# pressure# and# flow#waves# as# being# generated#
with# every# heartbeat.# These# are# then# propagated# to# the# peripheral# system# and#
from# there# they# are# reflected# back# towards# the# heart.# The# reasons# for# the#
backward# reflection# include# stiffness# gradients,# the# presence# of# bifurcations# and#
the#abrupt#diameter#gradient#in#the#arteriole.#The#reflected#waves#then#merge#with#









reflected# pressure# waves# increases# further# with# vasoconstriction.# These# two#
processes# lead# to# increased# central# systolic# pressure,# lowering# of# diastolic#
pressure# and# the# degeneration# of# the# elastic# component# of# the# arterial# wall.#
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Increased# central# systolic# pressure# is# likely# to# lead# to# increased# oxygen#
consumption#with#increased#cardiac#afterload#and#lower#diastolic#pressure#leading#
to# decreased# myocardial# perfusion# pressure.# The# net# effect# leads# towards#
myocardial# ischaemia# and# an# impairment# of# LV# function,# mainly# affecting# the#
diastolic# function# 87.# Central# haemodynamic# measures# can# also# be# particularly#
useful# in# young# individuals# with# isolated# elevation# of# systolic# BP.# It# can# help# to#
identify# those#who# do# not# have# associated# increased# central# pressures# and# thus#
avoiding#the#need#for#further#investigations#or#pharmacotherapy#114.#
#
The# classical#pulse#wave#analysis# involves# assessment#of# the#pressure#waveform#
alone#from#the#radial,#brachial#or#carotid#artery#(Figure#2).#A#transfer#function#in#
the#form#of#a#mathematical#algorithm,#in#addition#to#calibration#to#a#non–invasively#
measured# pressure# provides# central# waveform# parameters# including# aortic#








augmentation! pressure,! and! the! ratio! of! augmentation! pressure! to! pulse!
pressure!defines! the!AI! (in!percent).!Laurent#S,!Cockcroft#J,#Van#Bortel#L#et#al,#
Expert# consensus# document# on# arterial# stiffness:# methodological# issues# and#
clinical# applications,# Eur# Heart# J.# 2006;# 27(21):# 2588b605,# by# permission# of# the#
European#Society#of#Cardiology90!
#
In# a#metabanalysis# of# 11# longitudinal# studies# including# 5648# individuals,# central#
systolic# BP,# central# pulse# pressure# and# AI# were# independent# predictors# of#
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cardiovascular#events.#Central#AI#was#also#noted#to#be#an#independent#predictor#of#
allbcause# mortality# 112.# AI# predicted# clinical# events# independently# of# peripheral#












A# consensus# statement# on# the# use# of# central# BP# measurements# and#
antihypertensive#medication#use#along#with#reference#values#for#these#parameters#




the# central# pressure.# Central# pressures# cannot# thus# be# derived# by# itself#without#
peripheral# pressure# measurement.# Also# central# BP,# central# PP,# and# AI# are#
dependent# on# the# speed# of# wave# travel,# the# amplitude# of# reflected# wave,# the#









It# is# related# to# the# vascular# wall# biology# and# a# large# number# of# studies# have#
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supported# its# use# for# risk# assessment.# High# sensitivity# (hsCRP)# levels# correlate#
with#traditional#risk#factors#including#BMI,#systolic#BP,#lipids#and#fibrinogen#levels.#
In#a#metabanalysis#of#160,309#subjects#the#risk#ratio#for#CHD#was#1.37#for#every#SD#
increase# in#the# log#(e)#CRP#concentration#(a#3–fold# increase)#even#after#adjusting#




statin# therapy,# despite# absence# of# dyslipidaemia,# resulting# in# beneficial#
cardiovascular# outcomes.# This# study# reinforced# the# relationship# between#




The#ESC# guidelines# advocate# its# use# in# those# at# intermediate# cardiovascular# risk#
only.# The# most# recent# 2013# ACC/AHA# advocate# its# use# in# only# a# limited# group#
where# treatment# decision# is# uncertain# and# is# likely# to# be#modified# following# the#
test# results# 19.# Currently# it# has# very# limited# use# in# clinical# practice# for# CVD# risk#
assessment#in#the#general#population.#
HsCRP# levels# can# transiently# increase# due# to# common# inflammatory# processes#
such# as# viral# upper# respiratory# infections.# It# should# thus# be#measured# in# a#well#





quality.# CMR# also# allows#modelling# of# the# LV#without# geometric# assumptions# or#
dependence# on# acoustic# windows# and# thereby# showing# better# accuracy# and#
reproducibility# compared# to# echocardiography123.# CMR# is# the# current# gold#




effective# compared# to# echocardiography.# Other# useful# markers# that# can# be#




The# general# disadvantages# of# CMR# include# the# longer# image# acquisition# time.#
Presence# of# cardiac# devices,# such# as# pacemakers# and# defibrillators,# are# current#
contraindications#to#CMR#scanning.#MRI#conditional#devices#are#now#coming#onto#
the#market#but#have#specific#conditions#that#need#to#be#fulfilled#before,#during#and#
after# scanning.# There# is# also# concern# about# the# rare# but# serious# complication# of#
nephrogenic# systemic# fibrosis# that# has# been# reported# due# to# use# of# gadolinium#
based#contrast#media#in#patients#with#end#stage#renal#disease#or#those#on#dialysis.#
Although,# contrast# is#not# actually# required# for#assessment#of# arterial# stiffness#by#
CMR,# it# may# limit# the# comprehensive# study# of# the# cardiovascular# system.# Up# to#
10%# of# the# general# population# may# be# unable# to# tolerate# a# scan# due# to# severe#
claustrophobia# 128# .# It# has# recently# been# demonstrated# that# gadolinium# can#
accumulate#in#the#brain#after#its#administration#even#in#patients#with#normal#renal#






cine# sequences# using# electrocardiogrphy# (ECG)# gating.# The# change# in# the# cross#
sectional# area# of# the# aorta# can# be# accurately# measured# using# manual# or# semib
automated#aortic# contouring#and#area#measurement.#Velocity#encoded#CMR#with#
phase# contrast# sequences# allows# assessment# of# the# blood# flow# velocity# and# the#








possible# using# direct# aortic# path# length,# that# is# required# to# measure# the# aortic#







using# central# pressures.# Distensibility# of# the# ascending# aorta# correlated# strongly#









of# the# local# distensibility# and# the# regional# PWV# can# be# measured# at# different#
locations#of# the#arterial# tree#without# the# limitation#of# incomplete#visualisation#of#
the# aorta,# particularly# involving# the# aortic# arch.# CMR# is# very# versatile# and# also#








with# essential# hypertension# and#ECG# criteria# for#LVH#a# reduction# in#LV#mass,# as#
measured# by# echocardiography,# during# antihypertensive# treatment# is# associated#




These# findings# suggest# that# LV# mass# reduction# during# treatment# may# provide#
additional#information#and#may#act#as#a#surrogate#marker#for#disease#control#and#
for#prognostication.#This#theory#has#been#seen#in#some#ECG#studies#but#data#from#
echo# or# CMR# are# limited# but# do# support# the# association# of# LVH# regression#with#
lower# cardiovascular# endpoints# 139,140.# LVH# on# echo# is# associated#with# increased#
incidence# of# heart# failure,# ventricular# arrhythmia,# death# following# acute#
myocardial# infarction,# reduced# LV# ejection# fraction,# sudden# cardiac# death# and#
stroke#141.#Previous#outcome#studies#have#shown#that#a#~5g/m2#higher#indexed#LV#
mass#can#be#predictive#of#a#7b20%#increase#in#CVD#morbidity#and#mortality#142,143.#
In# studies# conducted# in# morbidly# obese# patients# undergoing# bariatric# surgery#
significant#changes#in#LV#mass#have#been#shown#144.#
#






regression# based# on# class# of# antihypertensive# treatment.# Indexed# LV# mass#
decreased#by#13%#with#angiotensin#II#receptor#antagonists#(95%#CIb#8%#to#18%),#



















advantage# over# oscillometric# methods# is# that# there# is# no# assumption/# error# in#
measuring# the#aortic#distance#which#can#be#measured#directly#using#aortic# slices#







distensibility# may# be# used# as# objective# evidence# of# functional# improvement.#










An# early# part# of# the# atherosclerotic# process# involves# the# infiltration# of# the# sub#
intimal# layer#of# the#arterial#wall#by# lipids#and# inflammatory#cells.#A# thick# intimab
media# serves# as# a# proxy# for# atherosclerosis# elsewhere# in# the# body# 149.# The#
presence#of#plaque# is# seen#as#a#more# severe# form#of# the#atherosclerotic#process.#
They# can# both# be# assessed# at# the# same# ultrasound# examination# and# provide#
complementary# information.# Carotid# ultrasound# allows# the# assessment# of# both#











and# spatial# resolution# the# echo# tracking# technique# is# an# alternative#method.#The#
reproducibility#of#both#techniques#appears#to#be#similar#in#patients#with#increased#
risk#or#atherosclerotic#disease# 152.# Increased#CIMT# is#generally#agreed#as#being#a#
measure#above# the#75th#percentile#value# for#a# reference#population.#The#ESC#has#
set# a# value# of# above# 0.9mm# in# recent# guidelines# as# a# marker# of# high# risk# 153.#
However,# this# simple# cut# off# value# may# lead# to# misclassification# where# the#
reference#population#values#differ.#
#
Prospective# cohort# studies# have# documented# the# predictive# value# of# CIMT# for#
future# cardiovascular# events.# A# metabanalysis# of# 36,984# subjects# showed# an#
increased#risk#for#future#cardiovascular#events#of#16%#for#every#0.1#mm#difference#
in#the#baseline#CIMT#154.#However,#another#larger#metabanalysis#of#45,828#subjects#
from# 14# cohort# studies# showed# that# common# CIMT# did# not# add# significant#
information# to# the# FRS#with# regards# to# the# first#myocardial# infarction# or# stroke#
event#155.#Incremental#value#of#CIMT#over#the#10byear#FRS#was#assessed#in#a#metab
analysis# involving# the# general# population.# Fourteen# populationbbased# studies#
involving#45,828#subjects#over#a#median#followbup#of#11#years#were#included.#The#
NRI# to# the# FRS#with# addition# of# common# CIMT#was# small# (0.8%;# 95%# CI# 01%b




of# novel# drugs# it# has# been# shown# that# CIMT# changes# do# not# have# a# prognostic#









or#possibly#a#different#phenotype#compared# to#CIMT.#Total#plaque#volume# is# the#
most# commonly# measured# parameter# with# good# interb# and# intrabobserver#
agreement# of# >90%# 156.# 3D# techniques# may# offer# a# better# estimate# but# robust#
studies#to#assess#this#are#pending.#In#a#clinical#setting#measures#that#can#be#easily#
obtained# and# show# good# reproducibility# include# (1)# the# presence# of# absence# of#
carotid# plaque,# (2)# the# number# of# plaques,# (3)# and# descriptions# such# as# plaque#
maximum# thickness# 157.# Lipid# lowering# medication# have# shown# to# lead# to#
reduction#in#plaque#volume#to#a#small#extent#158.!
Ultrasound# assessment# of# carotid# plaque# appears# to# have# a# higher# diagnostic#
accuracy# for# the#prediction#of# future# coronary#artery#disease,# compared# to#CIMT#
measurement#159.#The#presence#of#carotid#plaque#predicts#cardiovascular#mortality#
independent# of# the# risk# prediction# using# the# SCORE# algorithm# advocated# by# the#
ESC.#Presence#of#plaque#increases#the#risk#of#cardiovascular#mortality#by#2#fold#in#
the# intermediate# risk# and# 4# fold# in# the# low# risk# groups# 108,160.# The#Multi# Ethnic#




Carotid# ultrasound# driven# therapy# leading# to# improved# outcomes# has# not# been#
established#yet#87.#Higher#values#of#CIMT#or#presence#of#plaque#are#considered#as#












review# 34.# The# ESC/ESH# guideline# for# the# management# of# arterial# hypertension#
have# recommended# ultrasound# scanning# for# CIMT# and# plaque# detection# in#
management# of# hypertensive# patient# 111.# The# ESC# guideline# on# CVD# prevention#
previously# gave# a# recommendation# that# it# should# be# considered# in# intermediate#
risk# individuals# 153.# However,# the# updated# version# of# this# guideline# published# in#
2016#now#also#recommended#against#its#use#19.#The#guideline#group#raised#concern#
about# CIMT# assessment# including# the# lack# of# standardisation# regarding# the#
definition# and#measurement# of# IMT,# high# variability# in#measures# and# low# intrab
observer# reproducibility.#This# change# in# the# recommendations#against# the#use#of#
CIMT#has#been#driven#by#the#most#recent#metabanalysis#that#failed#to#demonstrate#





Lifestyle# modification# can# have# a# beneficial# effect# on# vascular# biomarkers.# For#
example#weight#reduction#lowers#CRP,#CIMT,#wave#reflections#and#arterial#stiffness#
164b166.# This# effect# is#more# pronounced#when#weight# reduction# is# combined#with#
increased# physical# activity# 167.# Endurance# exercise# improves# central#
haemodynamics,#whereas# resistance# training# has# a# detrimental# effect# on# arterial#




central# systolic#BP#such#as#cocoa170.#Caffeine#on# the#other#hand# increases#central#
BP# as# well# as# arterial# stiffness# in# healthy# individual# and# those# with#












In# this# chapter# I# outline# the#methods# for# the#HAPPY#London# study# including# the#
















care# that#would#be# offered#by# the#NHS#Health#Check#programme#or# through# the#
primary# care# services.# I# used# a# range# of# established# and# novel# cardiovascular#
markers# to# determine# the# clinical# efficacy# and# aimed# to# conduct# a# cost#
effectiveness#analysis#of#ebcoaching#and#gain#pathophysiological# insight# into#how#
lifestyle#modifications#affect# the#cardiovascular#system.#These#measures# included#






















HAPPY# London# provided# personalised# feedback# to# the# ebcoaching# group#
participants# throughout# the#6bmonth#period#and# incorporated#serial# surveys#and#
questionnaires,# which# allowed# dynamic# feedback# during# the# study# period.# In#
addition# to# these# tailored# questionnaires,# participants# completed# other#










London# webbbased# platform.# I# also# monitored# recruitment# rates,# agreement# of#
webbbased# estimated# cardiovascular# risk# with# QRISK2# score,# acceptability# and#
compliance# of# ebcoaching,# electronic# transfer# of# blood# test# results# into# the#
database,# CMR# imaging# protocol,# duration# of# visits# at# baseline,# 3b# and# 6bmonth#
clinic# visits.# The# pilot# phase#was# planned# as# a# gradual# recruitment# process.# The#




to# university# staff.# The# pilot# phase# lasted# about# 2# months# and# only# minor#
modifications# were# required# such# as# website# typo’s# and# availability# of#
questionnaires# to# the# participants# (with# alerts)# at# the# appropriate# visits.# An#











I# recruited# participants# from# the# London# area# through# advertisement# and#
invitations# predominantly# through# primary# care# practices.# I# worked# with# the#
National#Institute#of#Health#and#Research#(NIHR)#Primary#Care#Research#Network#
to# contact# GP# surgeries# that# were# interested# in# helping# with# the# recruitment#















prebscreening# tool# “minibcheck”# (www.happylondon.info),# which# is# based# on# the#
nonblaboratory#FRS#(≥10%#10byear#CVD#risk)#










4. Current# life# threatening# conditions# other# than# vascular# disease# (e.g.# very#
severe#chronic#airways#disease,#human#immunodeficiency#virus#positive,# lifeb
threatening# arrhythmias)# that# may# prevent# a# subject# from# completing# the#
study#
5. Only#for#subgroup#undergoing#cardiac#contrastbenhanced#magnetic#resonance#
studies:# Any# contraindication# to# a# contrastbenhanced# magnetic# resonance#





I# estimated# that# I# would# have# to# invite# approximately# 1500# London# inhabitants#
(Figure# 3).# Our# aim# was# to# have# a# good# representation# of# our# South# Asian#
population,#ideally#about#25%#if#possible#due#to#the#large#representation#of#South#
Asians# living# close# to# our# research# centre.# I# utilised# various# resources# for#




















Potential# participants# expressing# an# interest# in# this# study# were# directed# to# the#
www.happylondon.info#website#for#further#information#and#registration.#The#CVD#
risk#profile#was#estimated#using#a#webbbased#tool#(“minibcheck”).#The#purpose#of#
this# step#was# to# reduce# screening# visits.# Thus# reducing# potential# cost# and# other#




The# minibcheck# consisted# of# questions# regarding# potential# exclusion# criteria#
(previous#diagnosis#of#myocardial# infarction,# stroke#or# angina).#They#also#had# to#
tick# “yes”# to# a# question# asking# if# they# had# easy# access# to# the# Internet.# The# nonb






the# opportunity# to# book# an# appointment# for# a# physical# examination# using# the#
online#booking#calendar.#If#the#participants#did#not#want#to#proceed#with#the#study,#






From# this# prebscreened# population# I# invited# participants# with# an# estimated#
intermediate#to#high#risk#(estimated#minibcheck#10byear#risk#score#of#10%#or#more#
for#CVD#events),#to#attend#the#research#centre#to#assess#the#actual#CVD#risk.#They#









The# screening# visit# took# place# at# the# Heart# Centre,# William# Harvey# Research#
Institute,#Queen#Mary#University#London#and#lasted#approximately#35#minutes.#As#
the#visit#required#the#participant#to#fast#for#the#blood#test,#visits#were#limited#to#the#
morning# time# usually# starting# at# 9am# and# the# last# slot# at# 12pm.# If# participants#
specifically# requested# an# earlier# or# later# time# this# was# accommodated# where#
possible.#Participants#who#were#on#treatment#were#advised#to#call#prior#to#the#visit#
to#get#advice#on#which#medications#to#avoid#on#the#morning#visit#to#avoid#potential#
hypoglycaemia.# # The# research# doctor# or# nurse# ensured# that# the# participant# was#
satisfied# with# the# information# provided# on# the# PIS# and# the# consent# form# was#
completed#by#the#participant#and#countersigned#by#a#member#of#the#research#team#
who#had#completed#appropriate#Good#Clinical#Practice#training.#Additional#clinical#
risk# profiling# was# performed# based# on# medical# history# questions# required# to#
calculate#the#QRISK2#score#(diagnosis#of#atrial#fibrillation#or#rheumatoid#arthritis,#
treatment# for# hypertension# and# post# code),# selfbreported# smoking# status,# age,#
gender#and# family#history#of#premature#coronary#artery#disease.#Anthropometric#
measurements# (height,# weight,# waist# circumference# and# hip# circumference)# and#
BP#were#taken#(See#Table#2#for#schedule#of#assessments#for#each#visit).#Participants#
were#advised#to#fast#for#8#hours#prior#to#the#visit#for#a#fasting#blood#test#checking#
total# cholesterol,# LDL# cholesterol,# HDL# cholesterol,# triglycerides,# glucose,# hsCRP#
and# renal# function# (creatinine# and# estimated# glomerular# filtration# rate# eGFR).#
Based#on#these#measures,#the#tenbyear#risk#of#developing#CVD#was#calculated#using#
the# QRISK2# algorithm# which# is# available# on# their# www.qrisk.org# website.#
















limited# funding.#We#would# ideally# have# liked# to# perform#more# CMR# scans# to# be#
sufficiently# powered# to# assess# change# in# LV#mass# over# the# study#period#but# this#





All# randomised# participants# received# email# confirmation# of# the# second# visit#
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b# X# b# X#
CMR!scan! b# X# b# X#
Spirometry! ! # X# #
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advised# to# avoid# caffeine,# alcohol# and# cigarette# smoking# prior# to# the# visit# for# a#
more#accurate#PWV#measurement.#This#visit#could#take#place#in#the#morning#or#the#






questionnaire# that# would# form# the# basis# for# lifestyle# advice# in# conjunction#with#
discussion#of# the# results# from# the# screening# visit# (e.g.# BP,# blood# tests,# BMI).# The#
questionnaire#assessed#recent#dietary#habits#during#a#typical#week,#including#fruit,#
vegetable,# dairy,# meat# products# including# processed# meats,# daily# alcohol# intake#
over# the# preceding# week,# questions# to# gauge# psychological,# stress# and# anxiety#
levels# and# physical# activity# questions# that# tried# to# elicit# duration# of# moderate,#
vigorous#activities#of#more#than#or#equal#to#10#minute#blocks.#
#
During#this#visit#participants#were# informed#of# the#results#of# the#risk#assessment#
(conforming# to# information# that# would# normally# be# available# in# a# primary# care#
setting)#and#received#personalised#advice#from#the#research#doctor#in#accordance#
with# guideline# recommendations# from# the#NICE# and# the# ESC# regarding# smoking#
cessation,# weight# loss,# BP# control# etc.# The# personalised# lifestyle# and# risk# factor#
advice# was# given# over# 10b15# minutes,# based# on# information# from# the# lifestyle#
questionnaire# and# the# information# available# from# the# first# visit# including# blood#
test.# Additionally# Vicorder# assessment# and# ultrasound# scan# (for# carotid# plaque,#
CIMT#and#femoral#artery#assessment#(30#minutes)#were#performed.#
#
Participants# randomised# to# the# ebcoaching# group# were# shown# how# to# use# the#
personalised#website#(10#minutes).#Participants#were#asked#to#complete#additional#















to# CMR# imaging# and# I# routinely# checked# for# these# (e.g.# pacemaker,# defibrillator,#
vascular# clips,# cochlear# implants,# significant# claustrophobia).# The#CMR# scan# took#
about#60#minutes.#
#
Participants#were# informed#that# there#was#very# little#risk#with# taking#part# in# the#
study.# Some# of# the# potential# risks# with# contrast# agent# injection# (rare)# were#
explained# in# the# patient# information# sheet.# They# were# also# told# prior# to# the#
investigations#that#they#would#only#receive#information#that#they#would#expect#to#




to#avoid# test# results#potentially# influencing#behaviour#change#and# thus#making# it#
difficult# to# answer# the# study# questions.# # The# PIS# also#mentioned# that#we#would#
inform# the# GP# about# important# findings# during# the# study#with# their# permission#
(this#was#obtained#on#the#consent#form).##At#the#end#of#the#study#they#were#shown#
the# images# of# their# carotid# ultrasound# and# if# there# was# atheroma# present.# For#






baseline# visit# 1# (35# minutes),# including# blood# test,# BP# measurements,#
anthropometric# measurements# (weight,# waist# and# hip# circumference),# lifestyle#








for# all# participants# (50# b# 60# minutes),# including# blood# test,# BP# measurements,#
anthropometric#measurements#(weight,#waist#and#hip#circumference),#SFb36,#EQb
5Db3L,#RPAQ#and#nonbinvasive#measures#of# vascular# function#using# the#Vicorder#
device.#The#CIMT#and# femoral# artery# assessment#were# repeated.# In# addition,# the#





Participants# were# asked# to# complete# the# consent# form# once# they# were# satisfied#
with# the# aims,#methods,# anticipated# benefits# and# potential# hazards# of# the# study.#
This#information#was#provided#prior#to#the#visit#in#the#form#of#the#PIS.#At#the#visit#
the# researcher# also# provided# a# brief# summary# and# clarified# any# queries# or#
concerns# from# the# participant.# The# Investigator,# or# appropriate# Good# Clinical#
Practice# trained# person# delegated# by# the# Chief# Investigator,# obtain# written#





I# based# our# sample# size# calculations# on# using# a# twobsample# tbtest# with# equal#
variances.# The# Type# I# error# was# set# at# 5%# (twobsided).# The# inputted# standard#






10b12#months.#Sample#sizes#required# for# type# II#errors#of#5,#10#and#20%#and# for#
four#different#effect#sizes#are#presented#in#Table!3.##
#
In# summary,# we# proposed# a# sample# size# of# 200# patients# in# each# treatment# arm#
assuming# a# dropout# rate# of# 15b20%# at# the# followbup# visit# and# having# enough#
power#(80%)#to#detect#a#small#but#clinically#relevant#change#in#PWV.#I#also#include#
a# sensitivity# table# for# sample# size# calculation# for# assessing# change# in# LV# mass#
change#using#CMR.#Although#I#was#not#sufficiently#powered#to#detect#change#in#LV#
mass#with#only#50#people#in#each#treatment#group#in#the#CMR#subbstudy,#I#wanted#
to# assess# for# effect# size# of# CMR# surrogate#markers#with# lifestyle# changes# over# a#
short#period#of# time#(6#months).#This#would#be#useful# for#design#of# future# larger#
phase#2#primary#prevention#trials#with#behavioural#interventions.#
#





Type!1!error!5%! 95%#power# 90%#power# 80%#power#
0.1!m/s! 220# 178# 133#
0.15!m/s! 99# 80# 60#
0.2!m/s! 56# 46# 34#





Type!1!error!5%! 95%#power# 90%#power# 80%#power#
2g/m2! 182# 147# 110#
3g/m2! 82# 66# 50#
4g/m2! 47# 38# 29#
5g/m2! 30# 25# 19#














group# was# performed# after# confirming# eligibility.# # The# randomisation# tool# was#
created# using# PC# software# and# the# sequence#was# incorporated# into# an# inbhouse#
computer# programme,# which# allocated# the# treatment# group# once# participant#
identifier,# and# their# QRISK2# score# was# entered,# to# enable# stratification.# Our#





The# website# was# hosted# in# the# Netherlands# through# the# HAPPY# Globally#
Foundation.#The#web#team#ensured#that#Dutch#and#UK#legal#standards#were#met#to#






no# medications.# However,# in# cases# where# medication# was# deemed# appropriate#



















visit.# Compliance# to# the# ebcoaching# tools# was# measured# as# frequency# of# HAPPY#
London#Web#site#log#ins.#
!






for#analysis,#unless#a#patient#withdrew#consent# to#use# the#data.# In#such#case# that#






BP# was# taken# at# screening,# 3# months# and# 6# months.# The# cuff# was# deemed# an#
appropriate#size#for#the#individual#if#it#covered#at#least#2/3#of#the#arm.#Systolic#and#
diastolic#BP# (BP,# in#mmHg)#were#measured#with#a# cuff# around# the# left# arm#after#
relaxing#in#a#seated#position#for#at#least#5#minutes#with#the#left#arm#rested#on#table#
at# about# the# level# of# the# nipple.# Legs# were# uncrossed# and# the# participant# was#
requested#not# to# talk,# in#accordance#with#NICE#guidelines# 28.#At# least#2#measures#
were#taken#using#a#fully#automated#BP#monitor#(Calibrated#Omron#705IT#BP).#This#
was#repeated#if#there#was#a#difference#of#10mmHg#in#the#systolic#or#5mmHg#in#the#








Height# (in# cm)# was# measures# on# bare# feet# with# a# portable# device# (Seca# 704s,#
Hamburg,#Germany),#which#also#had#a#calibrated#scale#for#the#body#weight#(in#kg)#
with#the#participant#in#light#clothing#and#without#shoes.#Height#was#only#measured#
at# the# first# visit# and# along#with# the# serial# weight#measures.# BMI#was# calculated#
using#the#formula#b#BMI=#weight#(in#kg)/#height2#(in#meters).#
#
Waist# circumference# (in# cm)#was# taken#with# a#measuring# tape# at# the#mid# point#









Blood# tubes# were# labelled# with# the# subjects’# number# and# date# of# collection.#
Samples# were# analysed# in# The# Doctors# Laboratory,# 60# Whitfield#
Street#London#W1T# 4EU.# I# asked# participants# to# allow# longbterm# storage# of#
samples#for#future#analysis#of#biomarkers#(see#consent#form#in#Appendix).#
#
The# parameters# measured# were# total# cholesterol# (mmol/l),# HDL# (mmol/l),# LDL#
(mmol/l),# triglycerides# (mmol/l),# hsCRP# (mg/l),# glucose# (mmol/l),# creatinine#
(umol/l)#and#eGFR#(mL/min/1.73sqm).#The#blood#tests#were#performed#3#times#in#






scoring# system,# namely,# gender,# ethnicity,# home# address# postal# code# for# the#
Townsend# deprivation# score,# first# degree# family# history# of# premature# coronary#
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The#10#year#QRISK2# score#was# computed#using# the#website#www.qrisk.org#once#
blood#tests#result#was#available#for#the#screening,#3bmonth#and#6bmonth#visits.#This#
usually# occurred# on# the# next# working# day# after# the# visit.# However,# during# the#
course#of#the#study#its#developers#updated#the#QRISK2#algorithm.#To#ensure#I#used#







of# life# (SFb36# and# EQb5Db3L# surveys)# and# physical# activity# (RPAQ).# These#
questionnaires# were# chosen# following# advice# from# Professor# Myriam# Hunink,# a#




Additional# questions,# designed# by# the#web# team,# to# assess# lifestyle# factors#were#
administered.# The# above# questionnaires# were# completed# at# baseline,# 3bmonths#
and# 6bmonth# visits.# A# Thomas#Dohmen# questionnaire# to# determine# the# ‘big# five’#

















The# research# nurse# or# I# performed# the# PWA# and# CFPWV# measurements.# The#
patient# was# allowed# to# lie# on# the# bed# for# about# 10b15# minutes# before# the#
measurements#were#taken.#The#room#was#temperature#controlled#and#the#patient#
was#in#a#supine#position.#Patients#were#specifically#advised#to#refrain#from#caffeine,#




A# brachial# BP# reading#was# taken# just# prior# to# Vicorder#measurements# using# the#
same#automated#OMRON#machine#used# for#other#BP#measurements# in# the#study.#
This# BP# was# used# to# calibrate# the# peripheral# waveforms# obtained# from# the#
Vicorder.#The#Vicorder#digitally#computed#a#brachial#pressure#wave#trace#with#the#
cuff# statically# inflated# to# 70# mmHg# using# a# highbfidelity# cuff# and# volume#
displacement# technique# on# the# left# arm# in# all# cases.# A# brachialbtobaortic# transfer#
function#was#then#applied#by#the#Vicorder#software#to#calculate#the#waveform#and#
values# for# central# BP# 102.# The# first# and# second# central# systolic# peaks# were#
automatically#identified#by#the#software#and#used#to#calculate#the#AI#(difference#in#
amplitude# between# first# and# second# systolic# peak/pulse# pressure# x# 100).# The#
measurement# was# repeated# 3# times# and# average# of# 3# good# quality# traces# was#









used# as# potential# surrogate#markers# for# CVD# # (Table# 4).# For# the# purpose# of# this#
thesis#only#the#results#of#the#oscillometric#PWV#(i.e.# the#CFPWV#derived#from#the#
Vicorder).# The# results# of# the# CMR# derived# PWV,# including# correlations# with# the#
Vicorder# derived# CFPWV,#will# be# presented# in# future# publications# as# it# does# not#
constitute#the#primary#end#point#and#need#further#analysis#before#being#published.##
#








Proof!of!concept# 4+! 4+! 4+! 3+!
Prospective!
validation#
3+! 4+! 3+! 3+!
Incremental!value# 3+! 4+! 3+! 2+!
Clinical!utility# 2+! 3+! 2+! 3+!
Clinical!outcomes# 1+/b! 1+! 1+! 2+!
Cost2effectiveness# 1+! 1b! 1b! 1+!
Ease!of!use# 2+! 3+! 3+! 4+!
Methodological!
consensus#
2+! 3+! 3+! 3+!
Reference!values# Yes! Yes! Yes! 2# mg/L#
cutboff!





For# the# assessment# of# CFPWV,# cuffs# were# inflated# gently# around# the# thigh# and#
neck,# to# detect# the# timing# of# the#waveform# between# these# sites,# from#which# the#







were# recorded# simultaneously# for# a# target# of# about# 10# consistent# beats# using# a#
volume# displacement# method.# The# footbtobfoot# transit# time# was# measured# and#








The# average# of# 2# PWV# measures# was# used.# PWV# measurements# that# were#
suboptimal# due# to# poor# quality#were# excluded# if# they#met# 2# criteria;# 1.# If# the# 2#
measures# were# ># 1m/s# different# from# each# other# at# the# same# visit# suggesting#
significant# variability# in# measure# and# thus# reduced# accuracy.# 2.# If# the# semib
automated# waveform# detection# by# the# computer# software# appeared# grossly#









Participants# were# advised# to# wear# thin# lower# trousers# or# shorts# to# facilitate#
putting#on# the# femoral# cuff.# If#participants#had# thick# trousers#or# jeans# they#were#
requested# to# remove# their# trousers#and#were# covered#with#a#bed# sheet#once# the#
cuff#was# attached.# I# had#a# female# researcher# (Armida#Balawon)#who# I# trained# to#
perform# both# the# femoral# cuff# attachment# (for# CFPWV)# and# femoral# artery#
ultrasound# (for# presence# of# femoral# artery# plaque).# Female# participants# were#
given# the# option# for# a# chaperone# or# a# female# to# perform# the# tests.#Only# about# 4#
females#specifically#requested#a# female# to#perform#it# for# them#and#the#remaining#







45◦# towards# the# contralateral# side# of# the# carotid# artery# being# measured.#
Automated#measure#of#the#CIMT#was#taken#from#the#posterior#artery#wall#of#both#
carotid#arteries#with#24#spatial#measurements#over#a#1cm#region#of#interest,#1cm#
caudal# from# the# flow#divider# located# at# the# carina# of# the# common# carotid# artery#
bifurcation.# A# vascular# probe# (Panasonic)#was# used,#with# the# frequency# set# at# 9#
MHz,# according# to# the# protocol# outlined# by# the# American# Society# of#
Echocardiography# consensus# statement# 150.# I# assessed# for# evidence# of# carotid#
plaque# and# measured# an# automated# CIMT.# Using# the# same# ultrasound# probe,# I#
assessed#the#femoral#arterial#bed#in#the#groin#to#look#for#evidence#of#atheroma.#The#








were# designed# to# identify# any# internal# or# external# ferromagnetic# material# or#
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implants,# particularly# pacemakers# or# implantable# defibrillators.# Questions# were#
also# specifically# asked# about# preceding# history# of# blackouts# or# seizures,# any#
problem#with#previous#medical#scanning#and#any#history#of#renal#impairment.#All#
participants#had#a#renal#function#test#2b4#weeks#prior#to#the#scan#and#if#eGFR#was#
noted# to# be# less# than# 30ml/min/1.73m2# then# the# scan# was# deemed# to# be#
contraindicated# due# to# the# risk# of# nephrogenic# systemic# fibrosis.# This# safety#
precaution#was#to#ensure#for#a#second#time#that#the#participants#did#not#have#any#
contraindications.# The# subsequent# visits# required# all# the# questions# to# be#
completed#again.##
I# performed# the# CMR# scans# under# the# supervision# of# an# experienced# CMR#
technician#or#CMR#physicist.#CMR#scanning#required#lying#still#in#a#supine#position#
attached#to#an#ECG#with#the#participant#wearing#ear#protection.#The#subjects#were#
asked# to# breath# hold# in# expiration# for# up# to# 15# seconds# during# each# image#




Analysis# of# CMR# data# was# performed# blinded# to# the# intervention.# The# analysis#
entailed#LV#volumes#and#mass#determination,#measures#of#global#and#regional#LV#
systolic# and# diastolic# function# using# steady# state# free# precession# imaging# and#
tagging.#Aortic#stiffness#was#assessed#using#global#PWV#(results#of#the#CMR#derived#
PWV#will#not#be#presented#in#this#thesis#and#will#form#part#of#further#work#that#our#
research# group# and# I# will# undertake# in# the# future# towards# publications# in# peer#
reviewed#journal)#and#regional#assessments#(aortic#distensibility#of#the#ascending#
thoracic,# descending# thoracic# and# abdominal# aorta).# I# acquired# phase# contrast#
imaging#for#PWV.#One#pre#and#3#post#contrast#‘Look#Locker’#type#sequences#were#
acquired# for# assessment# of# fibrosis.# Late# gadolinium# enhancement# images# were#










The# aorta# was# assessed# at# 3# different# levels.# Perpendicular# to# the# ascending#









the# distance# between# 2# segments# and# postbprocessing# analysis# would# help# to#












The# velocitybencoded# phasebcontrast# sequence# was# set# to# 200# cm/s# and# was#
adjusted# in# the# case# of# aliasing.# Spatial# resolution# was# 1.22mm# X# 1.22mm.#
Repetition# time# was# 3.9# ms,# flip# angle# 15# degrees,# slice# thickness#




Peripheral# BP# was# measured# using# a# CMR# compatible# oscillometric#
sphygmomanometer# (Vicorder,# Skidmore# medical,# UK)# and# the# central# BP# was#






inner# lumen# of# the# vessel175.# The# three# levels# of# the# aorta# (TAA,# TDA# and# ABA)#
were# analysed# separately.# The# programme# then# tracks# the# endoluminal# border#
through#all#phases#of# the#cardiac#cycle#and#measured#the#crossbsectional#area#for#
each#phase.#This#was#achieved#by#the#radial#detection#of#a#signal#change.#A#manual#










using#both# the#2#and#4#chamber#cine# images#were#used# to#acquire# the#short#axis#
SSFP#cine#slices#from#the#atriobventricular#groove#to#the#cardiac#apex.#Acquisitions#
were#performed#breath#held#at#endbexpiration,#using#retrospective#ECG#gating.#The#
standard# sequence# settings# for# our# research# scans# were:# echo# time# 1.44# ms,#
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repetition# time# 2.9# ms,# inbplane# field# of# view# 205x380#mm,# acquired# voxel# size#
1.9×2.04# mm# (reconstructed# to# 1.46×1.48# mm),# acquisition# matrix# 108×186#
(frequency# encoding# ×# phase# encoding),# slice# thickness# 8# mm# and# a# 2# mm# gap#
between# slices,# 30# reconstructed# frames# per# cardiac# cycle# (typical# temporal#
resolution#of#46#ms#for#a#heart#rate#of#60#beats#per#minute),#and#a#60°#flip#angle.#
Post# processing# of# biventricular# endocardial# contours# was# performed# manually#
using# the# short# axis# cine# stacks.# Endbdiastolic# and# endbsystolic# frames# were#







mass#was#derived# from# the#myocardial# volumes#multiplied#by# the#density#of# the#








was#added# following#a#protocol# amendment# in#March#2014.#The#addition#was# to#







findings# in#detail# at# the# final# visit.# This#was#decided#on# the#basis# that# they#were#
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tests# that#would#not# ordinarily# be#performed#by# their# primary# care# team#and# to#
avoid# causing# any# confounding# to# the# results# of# the# intervention# under# study.#




the# tests# and# the# findings#were# also# communicated# to# the#GP,#with# the# patients’#
permission.# Discussion# about# serious# findings# took# place# at# the# time# of# the#




be# referred# via# the# GP# for# a# vascular# surgical# opinion.# This# was# based# on# local#




Incidental# myocardial# infarction# detection# with# CMR# scanning# in# asymptomatic#
older#adults#is#recognised.#A#study#suggested#that#the#incidence#in#adults#(ages#67–
93# years)# may# be# as# high# as# 17%# 178.# I# thus# expected# to# find# such# incidental#
findings# especially# since# our# cohort# had# an# elevated# cardiovascular# risk.# If# an#
infarction#was#detected# this#was# confirmed#with# the# study#principal# investigator#
(Steffen# Petersen,# a# cardiology# consultant# specialising# in# CMR).# The# patient#was#
informed#and#the#result#communicated#to#the#GP.#If#the#participant#was#not#already#
on# medication# recommended# for# secondary# prevention,# then# this# was# also#
recommended#for#initiation.#
#
In# case#of# suspicion#of# other# significant# cardiac# or# extrabcardiac# finding# this#was#
communicated# to# the# participant# after# consultation# with# a# radiologist# and#










Computerbtailored# ebcoaching# was# provided# to# the# intervention# group# for# 6#
months# (“HAPPY# London”)# in# addition# to# the# SOC# that# would# be# expected# from#
NHS#primary#care#visit.#HAPPY#London#consisted#of#frequent#personalised#emails#
to# update# the# individual# profile#with# behaviour# questionnaires# on# the# identified#
subboptimal#behaviours.#The#tailoring#was#based#on#a#combination#of#feedback#to#
the# participant's# motivation# for# change,# feedback# comparing# participant's#
behaviour# to# current# recommendations,# feedback# comparing# participant's#
previously# set#goals# to# the#participant's#behaviour,# the#behaviour#of#peers# to# the#
participant's# previous# behaviour,# feedback# tailored# to# participants’# selfbefficacy,#
their# intentions#and#attitudes#and# the#potential#benefits#or#barriers# to#behaviour#
change.#The#website#contained#educational#tools,#information#on#support#websites#
such#as#NHS#Choices,# links# to# social#media# and#other#health#websites# and#health#
news# items.# See# chapter# 4# for# more# details# on# the# website# development# and#
functions.##
#
For#those# in#the#active# intervention#or#ebcoaching#arm,# in#addition#to#the#facebtob
face#advice,#they#also#received#personalised#webbbased#advice#according#to#results#
of# the# lifestyle# questionnaire#with# a# computed# lifestyle# score# out# of# 10,#with# 10#
being# excellent)# and# a# heart# risk# score.# Due# to# technical# and# potential# copyright#




The# ebcoaching# group# received# an# additional# 10#minutes# (on# top# of# the# 10# b# 15#
minutes#discussing#results#and#suggested# lifestyle# interventions# that#both#groups#
received).# This# was# to# show# them# how# to# navigate# through# the# website# and#
personalise# some# of# the# features# of# the#web# tool# and# emails.# Ideal# targets#were#
highlighted# as# goals# and# the# information# (lifestyle# factors,# lifestyle# score,# risk#
factors#and#risk#score)#was#updated#at#3#and#6#months#allowing#the#participant#to#
view# their# progress,# to# provide# dynamic# tailoring# which# has# been# shown# to#
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increase# efficacy# over# time# 6.# Participants# were# not# given# the# option# to# interact#
with# the#system.#They#could#not#ask#questions#or#make#comments#about#specific#





Ebcoaching# involved# computerbtailoring,# a# method# of# assessing# individuals’#






had#a#green#bar,#between#6b8#out#of#10#an#orange#bar#and# less# than#6#a# red#bar.#
Lifestyle# and# CVD# risk# factors# were# also# colour# coded# for# each# participant# with#
coloured#heart#shapes.#Green#smiley#hearts#represented#optimum#factors,#orange#
heart#shapes#represented#factors#that#were#mild#to#moderately#suboptimal#and#sad#
red# heart# shapes# represented# more# than# moderately# suboptimal# factors# that#
required# more# attention.# # Participants# were# advised# to# log# in# as# often# as# they#
wanted.# I# did# not# specify# a# minimum# or# maximum# number# of# times# they# were#













For# those# in# the# control# arm# or# SOC# group# they# did# not# have# access# to# their#







to# their# risk# factors# and# subboptimal# lifestyle# factors.# This#was# based#mainly# on#
2012# guideline# recommendation# from# the# ESC# and# subsequently# included# the#
updated# advice# guideline# recommendations# from# the# Joint# British# Society#
consortium#version#3#(JBS3),#which#was#published#during#the#study#period#(April#
2014)# 17,153.#All#participants#were# informed#about# their#BP#and#whether# this#was#
optimal# or# not.# A# BP# of# >140/90#mmHg#was# classified# as# high.# Below# is# a# brief#













for#men#was# to#consume#<21#units#of#alcohol# for#men#and#<14#units# for#women.#
However,# it#was# also#mentioned# that# studies# suggesting# the#potential# benefits# of#































Likewise,# for# a# family#history#of# premature#CVD#may# confer#higher# risk# and# this#












urgently# to# have# their# BP# rechecked# with# a# view# to# initiating# antihypertensive#
treatment#with#a#letter#for#the#participant#to#take#to#their#GP.#If#the#BP#was#lower#











of# processed# food# and# foods# containing# those# with# transbsaturated# fats.# It# was#
recommended#that#red#meat#consumption#be#moderated#to#about#1b2#times#a#week#
and# to# reduce# junk# food# intake# such# as# cakes,# pastries,# biscuits# and# crisps.# Fish#
consumption# was# encouraged# 2b3# times# a# week# with# 1# portion# of# oily# fish# per#
week.#
#
Physical# activity,# weight# reduction,# increased# fibre,# fruit,# vegetable,#
polyunsaturated# oils# such# as# olive# oil,# nut# consumption# (walnuts,# brazil# nuts,#






try# and# combine# dietary# changes# with# increased# physical# activity.# The#







the# cholesterol# level# was# significantly# elevated,# were# recommended# to# consider#
statin#therapy#as#primary#prevention#medication#as#per#NICE#guidelines#at#the#time#
of#the#study179.#Participants#with#a#lower#QRISK2#score#between#10#and#20%#were#








All# aspects#of# the# study#were#conducted# in#accordance#with# the#principles#of# the#
Declaration# of# Helsinki.# The# HAPPY# London# study# received# a# favourable# ethical#
opinion# from# the# National# Research# and# Ethics# Committee# London# –# Central# on#
February#21,#2013# (13LO/0094).#The#ethical# approval# letter# can#be# found# in# the#







1.# Add# Yes/No# boxes# to# consent# form# to# participants# to# say# they# do# not# give#
permission#for#longbterm#storage#use#of#blood#samples.##




















The# work# was# primarily# funded# as# part# of# a# Barts# Charity# large# project# grant#
(437/1412).#This#work#also# forms#part# of# the# research#areas# contributing# to# the#
translational#research#portfolio#of#the#Cardiovascular#Biomedical#Research#Unit#at#
Barts,# which# is# supported# and# funded# by# the# NIHR.# The# HAPPY# London# team#
acknowledges# the# support# of# the# NIHR,# through# the# Clinical# Research# Network.#
The# Barts# Charity# and# the# NIHR# had# no# role# in# the# design# of# the# study;# the#






treatment# effects# as# per# protocol# (as# treated).# Mean# ±# standard# deviation# was#




difference# in# the# change# of# PWV# between# the# two# treatment# groups.# Tbtest#was#
used# for# normally# distributed# continuous# measures# and# Chi2# for# categorical#
variables.# Where# variables# were# not# normally# distributed,# nonbparametric# tests#
were# utilised# (MannbWhitney# test).# Changes# in# PWV# and# other# parameters#
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between# the# treatment# and# control# arms# over# 6# months# were# compared# for#
statistical#difference.##
#
In# future# analysis# I# plan# to# use# linear# regression# models# to# determine# the#
treatment# effects# adjusted# for# the# preb# specified# covariates# (including# gender,#














The# request#was# approved# and#we# subsequently# consented# participants# for# this#
prospectively#(see#consent#form#in#Appendix).#Participants#were#asked#to#sign#the#











study,#with# a#particular# emphasis# on#how# this# related# to# their# use#of# the#HAPPY#
London#website#and#ebcoaching#tool.#The#HAPPY#London#website#was#produced#in#
collaboration# with# the# HAPPY# Globally# Foundation# and# their# web# team.# The#












In# order# to# take# part# in# the# study# all# participants# were# required# to# visit# the#
www.happylondon.com#website.#The#main#home#page#provided#brief#information#
about# the# aims# of# the# study# and# steps# required# for# those# wishing# to# take# part#
(Figure#6).#Additional#tabs#provided#further#information#about#the#study#and#what#
would#be#required#to#enrol.#Inclusion#and#exclusion#criteria,#how#to#register#details#
about# the# international# HAPPY# project# was# also# provided.# A# ‘Contact’# page# was#
available# for#any# specific#queries#with# the#option#of# emailing# the#query# from# the#
website#along#with#a#contact#number#for#the#research#team.#
#
Participants# had# to# register# in# order# to# complete# a# minibcheck# questionnaire# to#
confirm#if#they#met#eligibility#criteria.#Once#registered#participants#were#able#to#log#
into#a#personal#account.#For#those# in#the#ebcoaching#treatment#arm#this#provided#
personalised# information# based# on# results# of# selfbcompleted# questionnaires# and#
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results# from# the# screening# visit.# Access# to# the# lifestyle# and# other# questionnaires#
was# available# for# completion# by# all# participants# randomised# into# the# study.# For#







Registration# was# relatively# simple# and# required# a# valid# email# address# and# the#
name#of#the#participant#in#order#to#make#the#website#personalised#(Figure#7).#Once#
registration#details#were#submitted,#an#activation#email#would#be#sent#to#the#email#



















Potential# participants# were# informed# in# advance# of# the# inclusion# and# exclusion#
criteria#and#what#they#needed#to#do#to#enrol#for#the#study#(Figure#9).#Previous#CVD#
was#an#exclusion#criterion#in#view#of#the#primary#prevention#nature#of#the#study.#
The# steps# in# the# process# were# outlined# and# it# is# also# mentioned# that# eligible#
participants# would# have# access# to# their# information# onbline# information# in# the#
group# randomised# to# ebcoaching.# They# were# informed# that# a# ‘minibcheck’#










The# ‘contact’# page# allowed# potential# participants# to# contact# the# team# regarding#
technical# issues# about# the# website# or# queries# about# the# study# (Figure# 10).#








Once# the#minibcheck# questionnaire#was# completed,# they#were# given# information#
about# their# estimated#10byear#CVD# risk# group.# If# this#was#below#10%# they#were#
informed# that# they# did# not#meet# the# risk# threshold# requirement.# If# it#was# above#
10%#then# they#were# invited# to#attend# the#screening#visit# (Figure#11).#They#were#
also# informed# that# if# they#decided#not# to# take#part# in# the#study# then# they#should#































Once# the# appointment# slot#was# selected# they#were# given# a# summary# of#what# to#
expect#at# the# first#visit#and# the#address#of# the#research#unit#on# the#website#page#
(Figure#14).#They#also#received#an#email#confirming#these#details#with#attachments#
that#included#the#study#PIS,#a#copy#of#the#consent#form#that#they#would#be#asked#to#
complete# at# the# visit,# a#map# of# the# venue#with# directions# for# travel.# Participants#
that# were# potentially# eligible# for# CMR# scans# also# received# the# MRI# safety#















status.# Blood# test# results# such# as# cholesterol# and# glucose# were# automatically#
transferred# to# the#www.happylondon.info#website# from#the# laboratory#within#24#





asked# to# complete# a# lifestyle# questionnaire.# For# those# randomised# to# ebcoaching#
they#got#this#combined#information#to#view#from#their#home#page.#(The#home#page#
provided#a#summary#score#of#the#participants#lifestyle#and#heart#risk#score#(Figure#










This# provided# a# colourful# summary# of# the# lifestyle# factors# in# the# form# of# heart#
shapes.# Green# smiley# hearts# represented# factors# that# were# within# the#
recommended# range.# Orange# hearts# represented# borderline# factors# and# red# sad#
hearts# represented# suboptimal# factors# that# should# be# addressed.# It# was#
recommended# that#participants#aim# to#get#as#many#green#smiley#hearts#over# the#
study#period#as#possible,#as#their#personal#targets.#At#subsequent#visits#these#were#
updated#based#on#the#3bmonth#and#6bmonth#lifestyle#questionnaires#and#the#BMI#
as#measured# a# by# the# research# team.#A# summary# score# of# the# lifestyle# factors# is#
calculated# for# each# participant# based# on# the# combination# of# lifestyle# factors#
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highlighted# in# the# lifestyle# section# with# the# best# achievable# score# of# 10.# On# the#
website#a#score#of#above#8#was#deemed#to#be#very#good#gave#a#green#bar,#between#
6# and#8# an#orange#bar# and# less# than#6# a# red#bar,# suggesting#need# for# significant#
improvement.#The#aim#for#the#participant#was#to#get#as#close#to#the#highest#score#










































visits.# These#were# available# after# logging# onto# their# page# as# a# yellow#box#with# a#
message#asking# them# to# complete# the#appropriate#questionnaires#during#various#
prebspecified# periods# during# the# study.# Alternatively,# questionnaires# could# be#
found#by#going#to#the#‘settings’#tab.#The#section#labelled#‘Questionnaires’#provided#














News# items#based# on# recent# studies# or# topical# issues# in# the#media# pertaining# to#

















This# formed#one#of# the#main#components#of# the#web#page.# It#provided#a# tailored#
plan#for#each#individual#based#on#the#factors#that#were#deemed#to#be#suboptimal#
and# that# the# participants# were# encouraged# to# improve# on# (Figure# 21).# These#
factors#also#formed#the#main#points#that#would#be#discussed#on#a#facebtobface#basis#












would# be# and# further# information# about# that# particular# risk# factor# and# ways# of#
improving# over# the# study# period.# This# page# aimed# to# improve# participants#
understanding# of# the# importance# of# the# risk# factor# and# its# relationship# to# future#
CVD#complications.# It#also#provided#links#to#other#websites#that#provided#further#
information# or# support# links# such# as# the# NHS# choices# website##
















































colour# coding# a# green# happy# heart# represented# factors# that# were# within# the#
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recommended# ranges# from# the# guidelines.# Orange# heart# symbols# represented#
borderline# or# mildly# elevated# risk# factors# and# sad# red# hearts# represented#
suboptimal# factors# that# should# be# actively# addressed,# particularly# if# reversible#
such#as#BP.#Clicking#on#each#of#the#factors#on#the#heart#risk#page#opened#up#further#
information# links# on#BP,# cholesterol,# glucose# levels,# diabetes,# age# and#hereditary#






































This# page# provided# a# colourbcoded# summary# of# important# factors# related# to#









































Over# the# course# of# the# study# the# home# page# for# the# ebcoaching# participant# got#










This#section#of# the#website#allowed#participants# to#share#some#of# their#goals#and#
achievements#on#social#media#as#a#means#of#making#others#aware#and#helping#to#
motivate#them#further.#They#were#also#given#the#opportunity#to#nominate#a#‘buddy’#
(Figure# 40).# The# nominated# individual# received# emails# about# the# personalised#
goals# of# the#participant# during# the# course# of# the# study.#Buddies#were# advised# to#
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participant.# It# included#a#summary#of#all# the#visits# that#had#already#occurred#and#
ones#that#were#booked#for#future#visits.#It#provided#summary#details#on#the#front#
















confirmation# that# they# received# the#PIS# and# the# consent# form.#An# explanation#of#
the# study#was# given#with# any# queries# or# concerns# raised# after# information#was#





below# including# BP,# height# and# weight# (for# BMI),# waist# circumference,# hip#
circumference# and# CVD# risk# factors# that# form# part# of# the# QRISK2# algorithm#
including#history#of#smoking,#diabetes,#family#history#of#premature#coronary#artery#














Blood# test# results#were#automatically# transferred# to# the#participants’# result#page#
from# the# lab# information# technology# transfer# system.# This# was# available# to# the#





to# based# on# the# randomisation# software# tool# was# also# entered.# It# was# also#
confirmed#whether#they#were#going#to#have#the#CMR#scan#and#the#date#and#time#of#
the#next#visit.#The#information#was#entered#onto#the#lab#results/approval#page#and#
submitted# (Figure# 43).# The# provisional# 2nd# visit# date# and# time# was# usually#
discussed#at#the#first#visit#and#conformed#via#email.#This#process#then#generated#an#
automated# email# that# was# sent# to# the# participant.# The# email# informed# the#
participant# whether# they# had# been# enrolled# into# the# study# and# provided#
information# on# where# they# should# go# for# the# 2nd# visit,# with# a# different# venue#
depending# on# whether# a# CMR# was# to# be# performed# or# not.# CMR# patients# were#
given# the# address# for# the# Barts# Health# CMR# scanning# department# and# all# other#
participants# were# asked# to# attend# the# main# research# centre.# Participants# also#
received#a#summary#of#what#to#expect#at#the#2nd#visit#regards#tests#and#were#asked#










This# then# formed# the# main# focus# of# the# facebtobface# advice# that# the# participant#



















The# risk# factors# and#measurements# for# the#3bmonth#visit#were# taken#at# the# visit#









The# data# input# page# provided# the# opportunity# to# note# down# the#measurements#
from#the#6bmonth#final#visit#to#obtain#the#risk#factors#required#to#acquire#a#QRISK2#






and#any#hospital# admissions# that#may#have# taken#place#during# the# study#period,#
although#this# information#was#not#entered#onto#the#website# for#simplicity.# It#was#
however#documented#in#their#records#and#a#tally#was#kept#of#how#many#had#any#















their# ebcoaching#web# page.# They#were# advised# to# visit# the# page# as# often# as# they#
wished.#The#ebcoaching#group#also#received#tailored#emails#in#addition#to#access#to#
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their# lifestyle# and# risk# factor# results.# The# number# of# emails# were# personalised#
based#on#the#number#of#potentially#suboptimal#factors.#Participants#with#more#sub#
optimal# factors# would# receive# more# frequent# emails# covering# the# various# risk#
factors# that# needed# addressing.# General# health# emails# were# also# sent# based# on#















guidelines# on# cardiovascular# risk# assessment# to# try# and# identify# how# ebcoaching#
could#be#incorporated#into#the#system.#I#considered#factors#such#as#risk#assessment#
and# the# recommendations# that# the# guideline# author’s# make# regards# its# use# in#
identifying# target# populations# or# for# making# decisions# on# management# and#














International# Guideline# Library,# National# Guideline# Clearinghouse,# National#
Library# for# Health# Guidelines# Finder,# Canadian# Medical# Association# Clinical#
Practice# Guidelines# Infobase,# and# Web# sites# of# organisations# responsible# for#
guideline#development#were#searched.#
#
Study! selection:# 2# reviewers# screened# titles# and#abstracts# to# identify# guidelines#




Data! extraction:# 2# reviewers# independently# assessed# rigor# of# guideline#
development# using# the# Appraisal# of# Guidelines# for# Research# and# Evaluation# II#
instrument,#and#1#extracted#the#recommendations.#
#
Data! synthesis:# Of# the# 21# guidelines,# 17# showed# considerable# rigor# of#
development.#These#recommendations#address#assessment#of#total#cardiovascular#
risk#(5#guidelines),#dysglycaemia#(7#guidelines),#dyslipidaemia#(2#guidelines),#and#
hypertension# (3# guidelines).# All# but# 1# recommendation# advocated# for# screening,#
and# most# included# prediction# models# integrating# several# relatively# simple# risk#
factors# for# either# deciding# on# further# screening# or# to# guide# subsequent#
management.# No# consensus# on# the# strategy# for# screening,# recommended# target#
population,#screening#tests,#or#treatment#thresholds#exists.#
#
Limitation:# Only# guidelines# developed# by# Western# national# or# international#
medical#organizations#were#included.#
#
Conclusion:# Considerable# discrepancies# in# cardiovascular# screening# guidelines#







Many# national# and# international# bodies# highlight# primary# prevention# of# CVD#
through#risk#factor#reduction#as#a#potential#solution#to#reduce#future#burden#2.#The#
optimal# target# group# and# intervention# that#maximises# benefit,# however,# remains#
unclear.# Cardiovascular# screening# during# health# checks# is# now# widely#
implemented# in# many# Western# countries# to# systematically# detect# highbrisk#
persons#who#may#require#aggressive#risk#reduction#through#pharmacotherapy#or#
lifestyle# interventions89.# Guidelines# advocate# use# of# screening# with# the# aim# of#
improving#the#health#of#an#already#healthy#population#and#reducing#risk#factors#for#
future# CVD.# The# Institute# of# Medicine# defines# clinical# practice# guidelines# as#
“systematically#developed#statements#to#assist#practitioners#and#patient#decisions#
about#the#appropriate#health#care#for#specific#clinical#circumstances”#180.#However,#




find# implementation# of# prevention# strategies# challenging,# and# management# of#
persons#with#increased#CVD#risk#remains#suboptimal#181.#Time#constraints,#lack#of#
perceived# usefulness,# inadequate# knowledge,# and# inconsistency# in# published#
recommendations# have# been# cited# as# common# reasons# for# not# using# CVD#
prevention#guidelines#or#global#CVD#risk#assessment#tools#182.#Concerns#exist#about#
poor#uptake#of#the#NHS#Health#Check#program;#only#about#50%#of#those#invited—
much# lower# than# the# 75%# government# target—attended# 183.# In# addition,# a#
Cochrane# review# and# subsequent# Danish# randomised,# controlled# trial# raised#
doubts#about#the#morbidity#and#mortality#benefits#from#such#programs#184,185.#
#
Ferket# and# colleagues# performed# a# systematic# review# in# 2010,# which# identified#
differences# among# guidelines# that# would# lead# to# variations# in# allocation# of#
resources# for# prevention# among#Western# health# care# systems# 89.# Since# then,# the#
reviewed#guidelines#were#revised#and#replaced,#and#new#evidence#has#also#become#










recommendations# for# CVD# risk# assessment# in# the# apparently# healthy# adult#
population#not#already#receiving#treatment#for#highbrisk#cardiovascular#conditions,#
such#as#diabetes,#hypertension,#and#hypercholesterolemia.#I#searched#for#published#
guidelines# using#MEDLINE# and# CINAHL# between# 3#May# 2009# and# 30# June# 2016#
(See# Appendix).# The# 4# following# guidelinebspecific# databases# supplemented# our#
search:# National# Guideline# Clearinghouse# (USA),# National# Library# for# Health#
Guidelines#Finder#(UK),#Canadian#Medical#Association#Clinical#Practice#Guidelines#
InfoBase,#and#Guidelines# International#Network#International#Guideline#Library.# I#
also# searched#many#Web# sites#of# guideline#development#organisations,# including#



































































































References# that# met# the# Institute# of# Medicine's# definition# of# a# guideline# were#
included.# Guidelines# were# excluded# if# they# did# not# contain# recommendations#
involving#the#healthy#adult#population,#were#entirely#focused#on#early#detection#of#
CVD,# were# not# produced# on# behalf# of# a# professional# organisation,# or# were# not#
applicable#to#Western#countries.#In#addition,#only#guidelines#produced#or#updated#







Titles#and#abstracts#were#assessed#by#2# independent# reviewers# (Vinicius#Bicalho#
and# I).# Articles# were# excluded# only# if# both# reviewers# agreed# that# they# were#
ineligible.# Discrepancies# were# resolved# by# consensus# after# discussion.# Both#
reviewers#performed#the#final#selection#for#full#data#extraction.#
#
I# used# the# latest# 23bitem# Appraisal# of# Guidelines# for# Research# and# Evaluation#
(AGREE)# II# instrument# to#determine# the# rigor#of#development# for# each#guideline#
187.#This#domain#considers#reporting#of#methods#to#search#for#evidence;#criteria#for#
selection#of#evidence;#strengths#and#limitations#of#the#body#of#evidence;#methods#
for# formulating# the# recommendations;# health# benefits,# side# effects,# and# risks;#
explicit# link# between# recommendations# and# evidence;# procedures# for# external#
expert# peer# review;# and# the# updating# process.# Each# item# is# rated# on# a# 7bpoint#
Likert# scale.# Conforming# to# the# instructions# of# the# AGREE# II# tool,# 2# reviewers#
(Claudia# van#Waardhuizen# and# I)# independently# rated# the# items.#Both# reviewers#
assessed# background# information# on# the# guideline# development# process# from#
developers’#Web#sites.#Average#rigor#scores#were#obtained#by#expressing#the#sum#
of# the# individual# scores# as# a# percentage# of# the# maximum# possible# score.#
Reproducibility#of#the#2#reviewers’#scores#was#good,#with#an#interclass#correlation#
of#0.75#(comparing#the#agreement#of#the#total#rigor#of#development#score#obtained#
by# the# two# reviewers# (Claudia# van#Waardhuizen# and# I,# for# all# the# 21# guidelines#
assessed#with#the#AGREEII#tool;#where#a#score#of#1#would#mean#perfect#agreement#
between# the# scores).# I# ranked# the# guidelines# according# to# their# scores.# Editorial#






I# extracted# all# of# the# relevant# recommendations# from# the# guidelines# that# had# an#
AGREE# II# score# greater# than# 50%.# General# lifestyle# advice# was# not# included.# A#
recommendation# matrix# was# produced# and# grouped# by# the# conditions# being#
detected# by# screening.# Each#matrix#was# divided# into#methods,# target# group# and#
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delivery# of# screening,# recommended# screening# test,# and# followbup# thresholds.#
Consistent# with# our# previous# format,# the# strength# of# recommendation# was#
classified# as# “for”,# “consider,”# “not# for# not# against,”# “insufficient# evidence”,# and#
“against.”# If# feasible,# cardiovascular# risk# factors# were# classified# into# major,#









the# NIHR# had# no# role# in# the# design# of# the# study;# the# collection,# analysis,# and#





My# search# retrieved# 3553# titles,# of# which# 180# were# identified# as# potentially#
eligible.#On#the#basis#of#the#abstracts,#I#excluded#133#articles.#After#I#reviewed#the#
full# reports,# 26# more# were# excluded.# Such# guidelines# as# the# U.S.# Preventative#
Service# Task# Force# (USPSTF)# recommendations# on# aspirin# use# were# excluded#
because# they#did#not# include#recommendations#on#screening#healthy#adults# 189.# I#
included# 21# guidelines# on# cardiovascular# risk# assessment# # (Figure# 48).# Table# 6#
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# # # # #
Dysglycaemia# ! # # #
Diabetes#Australia,#
2010#196#




































# # # # #
Hypertension# # # # #
























Seventeen# of# the# 21# guidelines# had# a# rigor# score# of# 50%# or# greater.# Guidelines#
were#categorised#according#to#the#main#purpose#of#the#screening.#These#included#5#






















Country! Europe! United!Kingdom! Australia! United!States! United!States!
Year! 2016! 2014! 2012! 2013! 2011!
Appraisal!of!Guidelines!for!Research!
and!Evaluation!II!rigor!score,!%"
86! 86! 85! 83! 65!
Method!to!evaluate!evidence! Systematic!review! Systematic!review! Systematic!review! Systematic!review! Systematic!review!
Method!to!formulate!
recommendations!




















































Risk!factors& ! ! ! ! !
Age! *! *! *! *! *!
Sex! *! *! *! *! *!
BP! *! *! *! *! *!
Total!cholesterol!level! *! *! *! *! *!
LDL!cholesterol!level! †! †! †! –! –!
HDL!cholesterol!level! *! *! *! *! *!
Total!cholesterol–HDL!cholesterol!
ratio!
*! *! *! *! –!
Smoking! *! *! *! *! *!
Glucose!levels! –! †! †! –! –!
Underlying!risk!factors! ! ! ! ! !
Overweight/obesity! †! *! †! –! *!
Physical!inactivity! †! –! †! –! *!
Atherogenic!diet! –! –! –! –! –!
Socioeconomic!factors! †! *! †! –! –!
Family!history!of!premature!CVD! †! *! †! ‡! *!
Genetic/racial!factors! †! *! †! *! *!
Diabetes! †! *! *! *! *!
Antihypertensives! †! *! –! *! –!
Emerging!risk!factors! ! ! ! ! !
Triglyceride!levels! †! †! †! –! –!
Renal!function! †! *! †! –! *!
Heart!rate! †! –! –! –! –!
Apolipoprotein!lipoprotein!levels! §! –! –! –! –!
Glucose!therapy!for!insulin!
resistance!
–! –! –! –! –!
Prothrombotic!markers! §! –! –! –! –!












Thresholds! ! ! ! ! !

































































































































Variable& DAGDC& CDA& ADA& USPSTF& NICE&PH38& CTFPHC& ESC&
Country! Australia! Canada! United!States! United!States! United!Kingdom! Canada! Europe!
Year! 2009! 2013! 2016! 2015! 2012! 2012! 2013!


















Formal!consensus! Consensus! Consensus! Formal!consensus! Formal!consensus!

























































































Risk!factors! ! ! ! ! ! ! !
Age! *! *! *! *! *! *! *!
Sex! *! ! ! *! *! *! *!
Blood!pressure! ! ! *! ! ! ! *!
Total!cholesterol!
level!
! ! ! ! ! ! !
HDL!cholesterol!level! †! *! *! ! ! ! !
Total!cholesterol–
HDL!cholesterol!ratio!
! ! ! *! ! ! !









Underlying!risk!factors! ! ! ! ! ! ! !
Overweight/obesity! *! *! *! *! *! *! *!
Physical!inactivity! *! ! *! *! ! *! *!
Atherogenic!diet! ! ! ! ! ! *! !
Family!history!of!
premature!CVD!
! *! *! ! ! ! !
Genetic/racial!factors! *! *! *! *! *! *! !
Antihypertensive!
therapy!
*! *! *! *! ! *! *!
Emerging!risk!factors! ! ! ! ! ! ! !
TG!levels! †! *! *! ! ! ! !
Renal!function! ! ! ! ! ! ! !








































































































































































































































































Variable& CHEP& USPSTF& CTFPHC!
Country! Canada! United!States! Canada!

































Risk!factors!! ! ! !
Age! *! *! *!
Sex! *! ! !





























































































Recommendations! from!16!of! the!17! guidelines! supported!CVD! risk! assessment,!
either!as!the!primary!approach!(5!guidelines)!or!a!secondary!step!(11!guidelines).!
There! was! a! consensus! on! how! screening! tests! should! be! administered! in! the!
general! population.! A! selective! screening! system! based! on! knowledge! of! prior!
patient! characteristics! (record_based! screening)! or! used! during! non_preventive!
patient!visits!(case!finding!or!opportunistic!screening)!was!advocated!in!14!of!the!
17!guidelines.!Two!guidelines!did!not!explicitly!specify!a!screening!method!(1!from!




Authors! of!most! guidelines! recommended! integrating! age,! sex,! smoking,! BP,! and!
lipid! levels! into!CVD!risk!assessment!by!using!prediction!models.!However,! there!
was!no!consensus!on!which!prediction!model!to!use.!All!7!dysglycaemia!guidelines!
recommended! selecting! individuals! at! high! risk! for! type! 2! diabetes! mellitus!
through!formal!short_term!(10_year)!or!informal!diabetes!risk!algorithms!based!on!
antecedent!risk!factors,!along!with!the!often_used!threshold!of!40!years.!Diabetes!
risk! algorithms! were! also! used! to! decide! whether! further! formal! diabetes!
screening!with! blood! testing!was! required.! The!most! commonly!mentioned! risk!




and! cited! specific! high_risk! ethnic! groups.! The! UK! (NICE)! and! USA! (ACC/AHA)!
guidelines!use!ethnicity!in!algorithms!for!global!CVD!risk!score.!The!UK_based!CVD!
risk!score!calculator!(QRISK2)!advocated!by!NICE!includes!several!ethnic!groups.!
In! the! dysglycaemia! guidelines,! the! UK,! Australian,! and! Canadian! diabetes! risk!
assessment! questionnaires! all! incorporate! ethnicity! in! the! prediction! of! type! 2!
diabetes!onset.!
!
There!was! a! consensus! on! the! limited! role! of! novel! biomarkers! (for! example,! C_
reactive! protein,! Apo! lipoprotein,! and! prothrombin! markers)! and! markers! of!
subclinical! atherosclerosis! (for!example,! ankle–brachial!pressure! index,! coronary!
artery!calcium!score,!and!carotid!ultrasonography!result).!The!ESC!and!ACC/AHA!
are! the! 2! main! guidelines! that! consider! the! use! of! these! markers! in! limited!
situations.!The!ACC/AHA!suggests!that!in!selected!individuals!who!are!not!in!1!of!
the! 4! statin! benefit! groups! and! for!whom! a! decision! to! initiate! statin! therapy! is!
otherwise! unclear,! additional! factors! may! be! considered! to! inform! treatment!
decision_making.! These! factors! include! a! high_sensitivity! C_reactive! protein! level!
greater! than! 2! mg/L;! coronary! artery! calcium! score! of! 300! Agatston! units! or!
greater! or! categorisation! in! the! 75th! percentile! or! higher! for! age,! sex,! and!
ethnicity;! and! an! ankle–brachial! index! less! than! 0.9.! The! ESC! states! that! routine!
use! of! novel! biomarkers! is! not! recommended! for! refinement! of! CVD! risk!
stratification.! Carotid! ultrasonography! for! atheroma! detection,! measurement! of!
coronary!artery! calcification,! and! the!ankle–brachial! index!may!be! considered!as!
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risk! modifiers! in! CVD! risk! assessment! but! are! only! useful! in! persons! near!
thresholds!for!risk!categorisation.!
!
Thresholds! for! initiating! treatment! are! predominantly! based! on! 5_! or! 10_year!





Guidelines! authors! advocate! a! conservative! approach! to! aspirin! use! for! primary!
prevention.!Of! the!8!guidelines! that!make!recommendations!on!aspirin!use,!3!do!
not! recommend! routine! use! for! primary! prevention,! 3! of! the! dysglycaemia!
guidelines! recommend! considering! aspirin! therapy! but! only! in! the! presence! of!
additional! factors! putting! patients! in! a! high_risk! category,! and! only! 2! guidelines!
based! the! recommendation! on! age! alone.! The! CDC/AHA! guideline,! which! is! the!
only! guideline! in! this! review! that! is! sex_specific,! makes! recommendations! for!
women!only!and!suggests!aspirin!use! in! those!older! than!65!years;!however,! the!
Canadian!Hypertension! Education! Program! (Hypertension! Canada)! recommends!







There! was! a! consensus! on! the! importance! of! addressing! lifestyle! factors! in! all!
target!groups!independent!of!pharmacotherapy.!Recommendations!on!who!should!
receive! intensive! lifestyle! counselling! differed! among! the! guidelines,! with! no!
consensus! based! on! global! risk! scores.! However,! the! dysglycaemia! guidelines!
advocate! that! all! persons! at! high! risk! for! diabetes! (impaired! fasting! glucose! or!




There!were!no! firm!statements! regarding!screening! intervals.!However,! the! total!
CVD!risk!guidelines!advocated!rescreening!but!intervals!varied!from!2!to!6!years!in!
low_risk! persons.! Recommended! dysglycaemia! screening! intervals! in! persons!









for! total! cardiovascular! risk! (ACC/AHA!and!CDC/AHA),! dyslipidaemia! (American!
Association! of! Clinical! Endocrinologists),! and! dysglycaemia! (American! Diabetes!
Association)!along!with!the!Canadian!guidelines!for!dysglycaemia!(Canadian!Task!
Force! on! Preventive! Health! Care)! and! hypertension! (Canadian! Hypertension!
Education!Program!and!Canadian!Task!Force!on!Preventive!Health!Care)!advocate!




of! the! risk! assessment! process! or! in! guiding! therapy,! there! is! no! consensus! on!
which!model!to!use,!particularly!for!total!CVD!risk.!All!5!total!CVD!risk!guidelines!
use!different!calculators,! including! the!QRISK2!(NICE),!Systematic!COronary!Risk!
Estimation! (ESC),! 5_year! FRS! (National! Vascular! Disease! Prevention! Alliance),!
Pooled! Cohort! Equation! (ACC/AHA),! and! 10_year! FRS! ! or! Reynolds! Risk! Score!
(CDC/AHA).! These! risk! models! differ! in! the! end! points! and! risk! factors! they!
consider!in!their!development.!
!
Guidelines! on! total! cardiovascular! risk! differ! about! when! to! initiate! statin!
treatment.! There! was! no! consensus! about! CVD! risk! threshold,! although! direct!
comparison! is! challenging!because! all! 5! guidelines!used!different! risk!prediction!
models.! The! more! recent! ACC/AHA! and! NICE! recommendations! on! total!
cardiovascular!risk!have!lowered!their!threshold!for!initiation!of!statins.!However,!
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these! 2! updated! guidelines! have! also! changed! the! CVD! risk! equations! that! they!
now!use,!which!makes!direct! comparison! to!older! thresholds!difficult!because!of!
different!data! sets!or!end!points! that!are!used! in!developing! the!algorithms.!The!
NICE! guideline!now!advocates! for! the!QRISK2! algorithm,! and! the!ACC/AHA!now!
advocates! for!the!Pooled!Cohort!Equation!for!predicting!general!CVD.!Previously,!
they!both!used! the!FRS.!The!2016!ESC!guideline!has!maintained! the! same! statin!
thresholds! as! recommended! in! the! 2012! version.! Statin! recommendations! were!








There!was!no!consensus!on!the!use!of! lifetime!or!relative!risk! in!young!adults! to!
overcome! the! problem! of! 5_! to! 10_year! time! horizons! for! predictions.! The!
ACC/AHA!advocates!the!use!of!lifetime!risk!to!guide!intensive!lifestyle!intervention!
in!young!adults.!The!ESC!recommends!the!use!of!relative!risk!charts!for!informing!
young!adults!of! risk,!whereas! the!NICE!guideline! generally! advises! against!using!
lifetime!risk!tools.!
!
There! was! no! agreement! among! the! guidelines! on! which! subclinical!
atherosclerosis! screening! test! to! use.! Only! 2! guidelines! on! total! CVD! risk!
(ACC/AHA! and! ESC)! suggested! using! imaging! tests! (coronary! artery! calcium!
scoring!and!carotid!ultrasonography!for!atheroma!detection),!but!only!in!selected!
individuals! to! guide! management! decisions.! The! Australian! guideline! (National!





I! identified! 21! guidelines,! of! which! 17! were! rigorously! developed,! on!
cardiovascular!screening!interventions!that!could!be!done!within!a!cardiovascular!
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health! check! program.! The! aim! of! this! systematic! review! was! not! to! provide! a!







in! a! very! select! subgroup! of! individuals.! The! guidelines! advocate! a! conservative!







manual! search).! In! contrast! to!our!previous!article,! this! review!only! summarises!
recommendations! from! guidelines.! Other! reports,! such! as! position! and! scientific!
statements,!are!not!in!the!remit!of!the!AGREE!II!instrument!and!were!excluded.!All!
of! the! guidelines! included! in! this! review!were!published! in! the!past!7! years! and!
represent! the!most! recent! recommendations.! None! of! the! current! 21! guidelines!
were!included!in!the!previous!review!from!our!group89.!
!
Guidelines! generally! recommend! basing! management! decisions! on! global!
cardiovascular!risk!that!considers!multiple!risk!factors.!However,!they!differ!with!
regard!to!risk!thresholds.!This!is!partly!because!the!risk!models!advocated!in!the!
guidelines! vary!over!data! set!use,! the!predictors!used,! and! their! end!points.!The!
Systematic! COronary! Risk! Estimation!model! (ESC)! uses! only! hard! end! points! of!
CVD! mortality,! whereas! the! FRS! (CDC/AHA! and! the! National! Vascular! Disease!
Prevention!Alliance)! uses! the! broadest! end! points,! consisting! of! coronary! death,!
myocardial! infarction,! coronary! insufficiency,! angina,! ischaemic! stroke,!
haemorrhagic! stroke,! transient! ischaemic! attack,! peripheral! artery! disease,! and!
heart! failure.!Furthermore,! the!7.5%!risk! threshold! for! initiating!a!statin!used!by!
the!ACC/AHA!is!based!on!the!newer!Pooled!Cohort!Equation,!which!uses! the!10_
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year! nonfatal! myocardial! infarction,! CHD! death,! or! stroke! end! points34.! This!
variability! can! lead! to! the! same! groups! receiving! different! treatment,! makes!
comparison!among!several!health!care!systems!challenging,!and!could!also!lead!to!
health! care! inequality.!The!AHA/ACC!guidelines,! for! example,!would! recommend!
statins! for! nearly! all! men! and! two! thirds! of! women! older! than! 55! years.! This!
exceeds! the!proportion! that!would!be!eligible!based!on!other!guidelines,! such!as!
the! ESC,! when! tested! in! a! European! cohort207.! Standardisation! of! various! risk!





Programs! attempting! to! provide! population_based! interventions! that! determine!
the!overall!effect!achieved! face!many!challenges.!The!diversity! in!CVD!guidelines!
may!partly!reflect!the!uncertainty!of!the!benefits!of!screening.!Although!evidence!
supports! the! effectiveness! of! particular! interventions! to! appropriate! persons,!
screening! programs! face! such! difficulties! as! achievement! of! sufficiently! high!
uptake! rates! to! invitations,! ability! to! deliver! effective! interventions,! and! patient!
adherence!to!recommendations.!
!
Most! guidelines! recommended! a! selective! screening! strategy,! with! some! newer!
guidelines! advocating! a! lower! threshold! for! initiating! treatment,! such! as! statin!
therapy,! and! citing! recent!meta_analysis! and! the! reduced! costs! of! statins! due! to!
patent!expiry!as!the!main!reasons!for!this!shift!29.!Thresholds!used!for!determining!
high! risk! are! often! arbitrary! and! at! best! decided! on! by!mathematical!modelling.!








older! adults! (searches! up! to! December! 2013)! or! the! diagnosis,! assessment,! and!
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management!of!hypertension!(searches!up!to!September!2011)211.!This!systematic!
review! represents! contemporary! guidelines!with! a! broad! inclusion! of! conditions!




risk! prediction! models,! and! their! consequences! are! still! areas! of! disagreement!
across! guidelines! 89.! Over! the! past! 6! years,! there! has! been! a! trend! toward!
advocating! a! lower! threshold! for! initiating! intensive! lifestyle! modification! and!
statin!therapy.!Risk!prediction!models!have!been!updated!with!a!move!away!from!
the! FRS,! which! previously! predominated.! Guidelines! have! a! more! conservative!






screening!with! the!aim!of! trying! to!mould! it! into!a!system!that!eventually!shows!
benefit,!whereas!others!are!asking!for!the!programs!to!be!halted!until!such!a!time!





developed! by! Western! national! or! international! medical! organisations! were!
reviewed.! I! controlled! for! selection! bias! by! having! a! comprehensive! search!
strategy,! as!previously! generated!with! a! librarian,! and! the!articles!were! selected!
and! appraised! by! 2! independent! researchers.! However,! researchers! were! not!
blinded!to!the!organisation!names!or!countries!of!origin.!Of!note,!I!considered!the!








consensus! on! optimum! screening! strategies! or! treatment! threshold.! Physicians!
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In! this! chapter! I! present! the! findings! from! a! systematic! review! of! the! current!
lifestyle!recommendations!for!primary!prevention!of!CVD!advocated!by!authors!of!






Background:& CVD! remains! one! of! the! main! causes! of! morbidity! and! mortality!
globally.! This! review! identifies! lifestyle! advice! and! interventions! from! recent!
guidelines! on! primary! prevention! of! CVD! and! highlights! the! similarities! and!
differences.!
&





and! November! 20,! 2015!were! identified! using!MEDLINE,! CINAHL! and! guideline!
repositories! including! G_I_N! International! Guideline! Library,! National! Guidelines!
Clearing_house,! National! Library! for! Health,! Canadian! Medical! Association!
InfoBase.!
!
Study& selection:& Guidelines! on! primary! prevention! of! CVD! that! contained!








were! generally! developed! with! considerable! rigor! as! assessed! by! the! AGREE! II!
















CVD! is! a!major! cause! of! death!worldwide.! In! England! and!Wales! for! example,! it!
accounts!for!about!one_third!of!all!deaths!217.!Despite!reductions!in!death!from!CVD!
over! the! past! 3_4! decades,! it! still! remains! a! leading! cause! of! death! and! a!major!




those! over! 50! years! of! age.! Environmental! factors! identified! as! driving! the!
epidemic!of!CVD! include!smoking,!high!calorie!diets,! saturated! fats,!and!high!salt!
intake,! in! conjunction! with! low! intake! of! fruit! and! vegetables! and! sedentary!
lifestyles!4.!It!is!estimated!that!about!60%!of!the!CVD!mortality!decline!over!the!2!
decades!since!the!1980’s!was!attributable!to!a!reduction!in!major!CVD!risk!factors,!
primarily! smoking.! The! remaining! reduction! was! attributed! to!
pharmacotherapy219.! A! more! recent! analysis! confirms! that! improvements! in! a!
number! of! modifiable! risk! factors! including! smoking,! cholesterol! and! BP! can!
explain!much!of!the!reduction!in!CHD!mortality!220.!
!
Lifestyle! intervention!plays! an! important! role! in!prevention!of! a!number!of! CVD!
end! points! and! its! promotion! has! been! emphasised! in! many! CVD! prevention!
guidelines! 17,20,31,153,221.! Despite! this,!most! people! in!many!Western! countries! do!
not!meet!the!recommendations!for!diet!and!physical!activity!despite!known!health!
benefits! including! future! CVD! risk! reduction! 222.! Prevention! of! CVD! is! a! rapidly!
evolving! field! and! the! potential! for! long! term! health! care! benefits! from! timely,!
personalised!risk!factor!assessment!and!intervention!has!been!recognised!17.!The!
human!and!economic!arguments! in! favour!of!CVD!prevention!were!estimated!by!
NICE! as! overwhelmingly! positive,! and! other! committees! hold! very! similar! views!
58,223.! Prevention! strategies! are! now! predominantly! recommending! risk!
stratification!based!on!absolute!10_year!CVD!risk!prediction!to!guide!management.!
!
A! systematic! review! from! the! USPSTF! concluded! that! diet! and! physical! activity!
behavioural!counselling!in!persons!with!risk!factors!for!CVD!resulted!in!consistent!
improvements!across!various! intermediate!health!outcomes!up! to!2!years! follow!
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up! 222.! The! recent! ACC/AHA! guideline! on! the! treatment! of! blood! cholesterol! to!
reduce!atherosclerotic! cardiovascular! risk!disease! (ASCVD)! in!adults!emphasised!
that! lifestyle!modification! remains! a! critical! component!of!health!promotion!and!
ASCVD! risk! reduction,! both! prior! to! and! in! concert! with! the! use! of! cholesterol!
lowering! drug! therapies! 30.! Healthy! diet! or! lifestyle! modifications! were!
recommended! as! background! therapy! in! published!RCTs! of! cholesterol! lowering!
drug!therapy.!
!
The!aim!of! this!systematic!review!was!to! identify! the!similarities!and!differences!









for! guidelines! containing! recommendations! for! lifestyle! interventions! for! a!




I!performed!a! systematic! literature! search! to! identify!appropriate!guidelines! 89.! I!
searched! for! published! guidelines! using! MEDLINE! and! CINAHL! between!May! 3,!
2009! and! November! 20,! 2015.! I! supplemented! this! by! using! the! following!
guidelines! specific! databases;! 1)! The! National! Guideline! Clearinghouse! (US),! 2)!
National! Library! for! Health! on! Guidelines! Finder! (UK),! 3)! Canadian! Medical!
Association! InfoBase! (Canada),! and! 4)! G_I_N! International! Guideline! Library!
(http;/www.g_i_n.net).! I! also! carried! out! a! search! of! a! number! of! websites! of!
guidelines! development! organisations.! I! restricted! our! search! to! national!




Titles!and!abstracts!were!assessed!by!2! independent! reviewers! (Vinicius!Bicalho!
and! I).! Articles! were! excluded! if! both! reviewers! agreed! they! were! not! eligible.!
Discrepancies! between! reviewers! were! resolved! by! consensus.! Both! reviewers!
performed!the!final!selection!for!full!data!extraction.!
!
I! utilised! the! 23_item! Appraisal! of! Guidelines! for! Research! and! Evaluation! II!
(AGREE! II)! instrument! to! determine! the! rigor! of! development! for! each! of! the!
guidelines!224.!This!domain!of!the!AGREE!II! instrument!considers!the!reporting!of!
1)!method!to!search!for!evidence,!2)!criteria!for!selection!of!evidence,!3)!strengths!
and! limitations! of! the! body! of! evidence,! 4)! methods! for! formulating! the!
recommendations,! 5)! health! benefits,! side! effects,! and! risks,! 6)! explicit! link!
between! recommendations! and! the! evidence,! 7)! procedures! for! external! expert!
peer! review,! and! the! 8)! updating! process.! Two! reviewers! (Claudia! van!




as! a! percentage! of! the! maximum! possible! score! and! reproducibility! of! the! 2!
reviewers!scores!was!very!good,!with!an!interclass!correlation!of!0.80!(comparing!
the! agreement! of! the! total! rigor! of! development! score! obtained! by! the! two!
reviewers! (Claudia! van! Waardhuizen! and! I,! for! the! guidelines! included! in! this!
chapter).!Guidelines!were!ranked!according!to!their!scores.!Editorial!independence!















following! title! or! abstract! review! (Figure! 49).! Of! the! remaining! 35,! full! article!
review!retained!6!guidelines!that!met!our!inclusion!criteria!(Summary!of!selected!
guideline! characteristics! in! Table! 11).! The! guidelines! originated! from! the!USA! (2!
guidelines),! UK! (2),! Australia! (1)! and! Europe! (1).! Table! 12! Contains! the!
recommendation!matrix.!!
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!! !! Diabetes,! age! >40!
years,! CKD! stages! 3–
5,! Familial!
HypercholesterolQ



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































intensive! lifestyle! counselling.! This! commonly! included! presence! of! diabetes,!
although! no! consensus! exists! as! to! which! group! of! diabetics! (examples! include!










There! was! a! consensus! regarding! the! importance! of! smoking! cessation! advice.!
Only!the!ACC/AHA!did!not!have!recommendations!on!smoking,!as!it!was!not!in!the!
remit! of! the! guidelines! specific! clinical! questions.! Offering! additional! assistance,!
including! referral! to! counselling! services! and! pharmacotherapy,! was! also!












and! trans2saturated! fats.! Three! out! of! the! six! guidelines! specify! a! recommended!
percentage! for! intake!with! recommended! levels! below! 7%! (NICE)! or! 10%! (ESC,!
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All! recommendations!state! that!diets!should!be!rich! in! fruit!and!vegetables.!Only!
the!ESC!makes!a!distinction!in!the!proportion!of!intake!of!fruit!vs.!vegetables.!The!
UK! guidelines! recommend! five! portions! of! fruits! or! vegetables! (JBS3)! or! more!
(NICE)!per!day.!The!ESC!recommendations!refer!to!‘servings’!rather!than!portions,!














the! diet! and! other! sources! of! fibre.! There! are! general! recommendations! made!
encouraging! regular! intake! of!wholegrain,! beans,! seeds! and! nuts.! Only! the! NICE!
guideline! recommends! a! specific! quantity! and! suggests! at! least! 425! portions! of!





There! is!a! consensus!regarding! the! importance!of! limiting!salt! intake! in! the!diet.!
The! most! commonly! recommended! intake! of! salt! was! <6g/day! (approximately!
2,300mg! of! sodium).! The! lowest! recommendation! being! from! the! CDC/AHA!
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guideline!for!women!of!less!than!1,500mg!of!sodium.!This!cut2off!is!also!mentioned!












There! is! a! general! consensus! in! the! recommendations! to! reduce! the! amount! of!
sugar!in!the!diet.!Particular!mention!is!made!on!the!avoidance,!or!at!least!limiting,!





There! is! a! general! consensus! that! people! who! are! overweight! (most! commonly!
defined!as!BMI!>!25!kg/m2)!or!obese!(most!commonly!defined!as!BMI!>!30!kg/m2)!
should!be!offered!advice!and!support!to!work!towards!achieving!and!maintaining!a!









All!guidelines!agree!on! the! importance!of!physical!activity! in!CVD!risk!reduction.!
All! agree! on! a!minimum! of! 150!minutes! per!week! of! at! least!moderate! activity.!
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There! is! also! general! consensus! that! if! vigorous! activity! is! undertaken! then! the!
amount!required!is! less!(NVDP!only!mentions!suggestions!for!moderate!activity).!
They! recommend!75!minutes! of! vigorous! physical! activity! (half! of! the!moderate!
requirement).!Many! of! the! guidelines! also! recommend! that! the! physical! activity!
take!place! in!bouts!of!10!minutes!or!more.! (ESC,!ACC/AHA,!CDC/AHA!and! JBS3).!
The!general!recommendation!is!to!spread!the!activity!over!the!course!of!the!week.!
The!2!UK!based!guidelines! (NICE!and! JBS3)!and! the!CDC/AHA!also!mention! that!
twice! per! week! the! activity! should! be! of! the! form! that! also! provides! muscle!
strengthening.!The!2!UK!based!guidelines!also!recommend!referral!to!programmes!
where! support! or! supervision! is! provided! for! those! that! may! need! support! to!
change!their! lifestyle;!this! is!particularly!stated!for!people!who!are!considered!to!





Lifestyle! factors! mentioned! in! guidelines! specifically! for! lowering! of! BP! include!
weight! control,! increased! physical! activity,! moderation! of! alcohol,! sodium!
restriction,! increased! consumption! of! fruit! and! vegetables! and! low! fat! dairy!












sterols! can! lower! LDL! cholesterol.! The! NICE! guideline! on! the! other! hand! very!







There! is! a! general! recommendation! for! predominantly! consuming! white! meat,!
such!as!poultry.!Two!of!the!guidelines!specifically!emphasise!poultry!consumption!







guideline! does! not! mention! any! recommendation! on! alcohol! intake! as! they!
stipulate! it! is!outside! the!remit!of! the!specific!clinical!questions!addressed! in! the!











The! 2! dietary! patterns! that! have! most! often! been! mentioned! in! the! guidelines!
include! the! Mediterranean! (ESC,! NVDP,! JBS3)! and! the! DASH! (ESC,! ACC/AHA,!
CDC/AHA! and! JBS3)! diets.! The! NICE! guidance! opted! to! avoid! using! the! term!
Mediterranean!diet! in! its! recommendations!as! they! felt! the!description!was!non2






I! identified!6!guidelines! that!make!recommendations!on! lifestyle! factors! for! total!







The! recommendation! on! the! need! for! adequate! physical! activity! levels,! smoking!
cessation,! limiting! intake! of! saturated! fat! and! particularly! avoiding! trans! fats,!
having!a!diet!that!is!rich!in!fruit!and!vegetables,!that!includes!fish!and!wholegrain!
and! limiting! salt! intake! are! very! similar! between! the! guidelines.! There! is! also! a!
consensus! on! the! recommendations! to! reduce! intake! of! sugars! with! specific!
mention! of! sugar2sweetened! beverages.! This! is! particularly! topical! with! the! UK!
government’s! introduction! of! the! ‘sugar! tax’! and! this! being! preceded! in! other!
countries!such!as!Brazil!with!the!goal!of!tackling!obesity!and!diabetes.!
!
There! are! differences! noted! in! the! recommendations! for! what! is! considered!
acceptable!alcohol!intake,!regarding!intake!of!meat!products!in!general!rather!than!
specifically! those! that! constitute! saturated! fats! and! trans2fats.!There! is! a! general!
trend! to! recommending!poultry!over! red!meat!although! this! is!not!present! in!all!





advocate! specific! macronutrients! or! whole! foods! rather! than! concentrating! on!
micronutrients.! It! is! interesting! that! the! NICE! guideline! avoids! using! the! term!
Mediterranean!diet!in!their!recommendations!based!on!quality!of!the!evidence!and!
potential! ambiguity! with! the! term.! The! Mediterranean! diet! is! comprised! of!




diet! to! reduce! CVD! events! in! patients! at! elevated! CVD! risk.! The! multivariable!
adjusted!HRs!were!0.70!(95%!CI!0.54!to!0.92)!and!0.72!(95%!CI!0.54!to!0.96)!for!
groups! assigned! to! a!Mediterranean!diet!with! extra2! virgin!olive!oil! and! a! group!
assigned! to! a!Mediterranean!diet!with! nuts,! respectively,! versus! a! control! group!




It! should! be! borne! in!mind! that! individuals!may! have! difficulties! changing! their!
lifestyle! and! behaviour,! which! is! often! based! on! long2standing! behavioural!
patterns.!These!are!usually! framed!during!early!years!of! life!by!an! interaction!of!
genetic!and!environmental!factors.!These!factors!may!impede!the!ability!to!adopt!a!










who!may!be!at!high!risk! in! the! longer2term!to!encourage!earlier! recognition!and!






























prevention& in& highErisk& individuals:& A& randomised&





This! chapter! includes! the!outcomes!of! the!main! research!question!of! the!HAPPY!
London! study.! I! compare! the! change! in! primary! and! secondary! outcomes! to!
determine! if! e2coaching! is! more! effective! than! SOC! alone.! ! The! results! of! this!





Background:& CVD! remains! one! of! the! leading! causes! of! mortality! globally.!








a! personalised! website! and! email! prompts)! on! top! of! SOC! is! more! clinically!
effective! than! SOC! alone! in! reducing! cardiovascular! risk! in! asymptomatic!
individuals!with!high!102year!cardiovascular!risk.!
!
Methods:&A!22arm!RCT! (HAPPY!London)!was! conducted! from! July! 2013! to!May!
2015.!Participants!were! adults!with! a!high!102year! cardiovascular! risk!based!on!
the! UK! validated! QRISK2! score! (QRISK2! ≥10%)! and! free! of! manifest! CVD.!





included! change! in! cardiovascular! risk! scores,! quality! of! life,! physical! activity!
levels,!BP!and!CIMT.!
!
Results:& A! total! of! 402! participants! with! mean! age! 65.5! (SD! 5.6)! years! (62%!
males)!were!randomised;!205!(78,!38%!women)!were!allocated!to!the!intervention!
group! and! 197! (71,! 36%! women)! were! included! in! the! control! group.! Primary!




significant! improvements! were! seen! in! other! CVD! risk! factors! in! both! groups!
including! BP,! weight,! total! cholesterol,! physical! activity! levels,! Framingham! and!
QRISK2!scores.!!
!






CVD! remains! one! of! the! leading! causes! of! mortality! worldwide! accounting! for!
about!one2third!of!deaths!1.!Although!CVD!mortality!rates!have!decreased,!the!rise!
in! obesity,! diabetes! and! an! aging! population! in! both! Western! countries! and!
globally! raises! concern.! National! and! international! bodies! have! highlighted!
primary!prevention!of!CVD,!through!risk!factor!reduction,!as!a!potential!solution!to!
reduce! the! burden! of! CVD! 2.! The! magnitude! of! this! health! care! crisis! calls! for!
innovative! measures! to! improve! cardiovascular! health.! There! is! some! evidence!
that! behaviour! change! using! computer! tailoring! can! be! effective! in! changing!
lifestyle! and! risk! factors! 6,7.! Internet! and! email! use! has! seen! increased! global!
uptake! and! these! platforms! hold! potential! in! aiding! preventative! strategies,!
allowing! efficient,! easy! to!use! and! cost! effective!ways! to! improve! the!health! and!
wellbeing! of! many.! It! may! allow! a! way! to! maintain! frequent! contact! between!
healthcare! workers! and! patients,! without! overburdening! existing! healthcare!
facilities! and! facilitate! patient! involvement! with! increase! motivation! to! manage!
personal!health.!The!aim!of!e2coaching!is!to!help!encourage!individuals!to!improve!
suboptimal! factors! lead! a! healthier! lifestyle! by! identifying! needs,! setting! goals,!
using! strategies! to! support! change! and! reinforcement! through! encouragement!
during!the!process!6.!The!use!of!e2coaching!has!been!applied!to!single!risk! factor!









numbers! to! powerfully! detect! hard! cardiac! end! points.! This! creates! obvious!
resource!and!administrative!challenges.!Use!of!robust!surrogate!markers!can!help!
identify! potentially! useful! interventions! that! can! then! be! further! studied.! I!
therefore! used! PWV! which! is! the! most! validated! method! to! non2invasively!
measure! arterial! stiffness! and! is! recognised! as! a! surrogate! marker! for! future!
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HAPPY! initially! used! a!method!with! generic! lifestyle! e2coaching! as! assessed! in! a!
study!using!a!Dutch!population!(n=1000)!over!3!months!83.!141!of!the!participants!




The! primary! objective! of! this! study! was! to! assess! the! clinical! effectiveness! of!













See!methods!section!for!detailed! information.! In!brief! this!was!a!single2centre,!22
arm!RCT!(ClinicalTrials.gov:!NCT01911910).!From!June!2013!to!November!2014,!
402! adults! with! a! high! 102year! CVD! risk! score! (QRISK2! score! ≥! 10%)! were!








staff! and!word! of!mouth.! All! interested! individuals! had! to! register! on! the! study!













and! 6! months! from! baseline.! Email! appointment! reminders! were! sent! to!
participants! 2! weeks! and! also! 2! days! prior! to! their! visit.! Assessment! was!
performed! using! a! variety! of! measures! through! lifestyle! and! quality! of! life!
questionnaires! (EQ25D23L,! SF236,! RPAQ! and! the! ‘big2five’! personality! traits!
questionnaire!(from!Professor!Thomas!Dohmen),!BP!checks!(Omron!705IT,!Omron!
Corporation,!Kyoto,! Japan),!blood!tests!(following!an!82hour!fast,! for! lipid!profile,!
glucose,! hsCRP! and! eGFR),! ultrasound! scans! (Panasonic! CardioHealth! System,!
Panasonic! Healthcare! Co.! Ltd,! Yokohama,! Japan)! oscillometric! method! to! assess!
PWV!and!pulse!wave!analysis!(Vicorder!device,!Skidmore!Medical,!UK).!A!subgroup!
of! the! study! population! (50! from! each! randomised! group,! totalling! 100!
participants;!with!96!actually!having!a!scan)!also!underwent!baseline!and! follow!
up! CMR! multi2parametric! scanning.! All! non2CMR! visits! were! performed! at! the!

















In& brief,& the! HAPPY! London! web2based! tool! provided! each! e2coaching! group!
participant!with!a!personalised!score!for!their!lifestyle!and!102year!CVD!risk!score!




50).! Participants!with!more! suboptimal! factors! received!more! personalised! tips.!
Bi2weekly!health!and! lifestyle!motivational!news! items!with!general!advice!were!
posted! on! the! website! for! all! participants! to! view! to! encourage! healthier!
behaviour.! Links! to! social! networks,! such! as! Facebook!posting! and! the! ability! to!




















E2coaching! and! SOC! group! participant! received! personalised! face2to2face!
counselling! on! suboptimal! lifestyle! and! cardiovascular! risk! factors! based! on!
guideline! recommendations! during! the! second! visit,! lasting! about! 10215!
minutes225.! All! participants! initially! completed! a! lifestyle! questionnaire,! adapted!
from!the!original!HAPPY!study,!to! identify!suboptimal! factors.!Tailored!advice!on!







treatment! groups.! Secondary! outcomes! included! change! in! CIMT,! quality! of! life!
(EQ25D23L!and!SF236),!LV!mass!by!CMR,!Framingham!risk! score,!QRISK2!scores,!
self2reported! RPAQ! questionnaire,! BP,! alcohol! intake,! weight,! BMI,! cholesterol,!
glucose!and!high!sensitivity!c2reactive!protein!from!baseline!to!6!months.!At!the!62















of! global! arterial! stiffness.! Primary! outcome!was! the! change! in! PWV! between! 6!
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Analysis! was! performed! on! an! intention! to! treat! basis.! Mean±SD! was! used! for!
normally!distributed!variables.!Median!and!interquartile!ranges!were!used!for!data!
that! are! not! normally! distributed.! T2test! was! used! for! normally! distributed!
continuous!measures!and!Chi2!for!categorical!variables.!!Where!variables!were!not!
normally! distributed! non2parametric! tests! were! used! (Mann2Whitney! for!
continuous! and!Wilcox! rank! sum! test! for! categorical! variables).! Changes! in!PWV!
and! other! parameters! between! the! treatment! and! control! arms! over! 6! months!













up! completed! by!May! 2015.! Of! the! 900! people!who! completed! the! online! ‘mini2
check’! for!eligibility,!a! total!of!491! fulfilled! the!preliminary! inclusion!criteria!and!





of!participants!with!a!high!QRISK2! score!was! similar! in!both! the!e2coaching!and!
SOC!groups! (36%!vs.!31%,!p=!0.33!as!was! the!proportions!of! those!at!moderate!
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risk! (64%! vs.! 69%,! p=! 0.33).! Baseline! measures! were! generally! similar! in! both!
groups!with!no!statistical!difference!except! in!the!case!of!CFPWV!(e2coaching!8.5!
±1.6,! SOC!8.8!±1.5,! p=!0.027)! and!mean!of! the! combined!CIMT! from! the! left! and!
right!carotids!(e2coaching!0.705!±0.13,!SOC!0.736!±0.13,!p=0.02).!!
!
























































































Age&(years)&mean(SD)& 65.1!(6.3)! ! 65.9!(4.8)! 0.15!
Demographics! n&(%)! ! n&(%)! !
Male&sex&(%)& 127!(62.0)! ! 126!(64.0)! 0.75!
Smoking&history& ! ! ! !
&&&NonEsmoker& 104!(50.7)! ! 80!(40.6)! 0.053!!
&&&ExEsmoker& 86!(42.0)! ! 101!(51.3)! 0.076!!
&&&Light&(<10)& 9!(4.4)! ! 9!(4.6)! 1!
&&&Moderate&(11E19)& 6!(2.9)! ! 3!(1.5)! 0.53!
&&&Heavy&(>20)& 0!! ! 4!(2.0)! 0.12!
Ethnicity& ! ! ! !
&&&White& 182!(88.8)! ! 172!(87.3)! 0.76!!
&&&Indian& 9!(4.4)! ! 8!(4.1)! White!
&&&Pakistani& 6!(2.9)! ! 3!(1.5)! vs.!
&&&Bangladeshi& 0!! ! 2!(1.0)! Non2white!
&&&Other&Asian& 3!(1.5)! ! 0!! 2!
&&&Black&Caribbean& 1!(0.5)! ! 3!(1.5)! 2!
&&&Black&African& 0!(0)! ! 2!(1.0)! 2!
&&&Chinese& 2!(1.0)! ! 1!(0.5)! 2!
&&&Other& 2!(1.0)! ! 6!(3.0)! 2!
Medical&History! ! ! ! !
Rheumatoid&Arthritis& 8!(3.9)! ! 3!(1.5)! 0.25!
BP&medication& 105(51.2)! ! 83!(42.1)! 0.08!
Cholesterol&medication& 98(47.8)! ! 84(42.6)! 0.40!
Diabetes& 35!(17.1)! ! 22!(11.2)! 0.12!
Atrial&fibrillation& 9!(4.4)! ! 11!(5.6)! 0.75!
Family&History&CAD& 75(36.6)! ! 60!(31)! 0.25!














16!(9)! ! 17.8!(10)! 0.54!
Risk&Stratification! ! ! ! !
























Baseline&Measures! Mean&(SD)& & Mean&(SD)& &
Systolic&BP&&(mmHg)& 132.5!(13.3)! ! 132.3!(14.8)! 0.88!
Diastolic&BP&(mmHg)& 79.2!(9.2)! ! 80!(8.6)! 0.34!
Weight&(Kg)& 80.7!(18.4)! ! 79.7!(16)! 0.56!
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BMI&(Kg/m2)& 28.1!(5.6)! ! 27.4!(4.4)! 0.16!
Hip&circumference&(cm)& 104.7!(10.3)! ! 103.6!(8.2)! 0.25!
Waist&circumference&(cm)& 95.8!(15.2)! ! 95.4!(12)! 0.81!
Total&Cholesterol&(mmol/L)& 4.9!(1.1)! ! 5.1!(1.1)! 0.09!
HDL&(mmol/L)& 1.6!(0.5)! ! 1.6!(0.4)! 0.95!
LDL&(mmol/L)& 2.8!(1)! ! 2.9!(1)! 0.10!
Triglyceride&(mmol/L)&&
median&(IQR)&
1.1!(0.8!–!1.5)! ! 1.3!(0.8!–!1.5)! 0.31!
Glucose&(mmol/L)&&
median&(IQR)&
5.5!(5.1!–!6.0! ! 5.5!(5.1!–!5.9)! 0.71!!
hsCRP&(mg/L)&
median&(IQR)&
1.2(0.7!–!2.5)! ! 1.3!(0.7!–!2.4)! 0.76!
eGFR&(mL/min/1.73sqm)& 82.9!(20.1)! ! 81.9!(17.9)! 0.58!
Physical&activity&(min&pd)& 70.8!(75.6)! ! 64.9!(91.9)! 0.48!
Lifestyle&score&(out&of&10,&10&
being&optimum&score)&
6.9!(1.3)! ! 6.8!(1.3)! 0.22!
Surrogate&Markers! ! ! ! !
CFPWV&corrected&(m/s)! 8.5!(1.6)! ! 8.8!(1.5)! 0.027*!
CIMT&(mean&of&right&and&left&
CIMT,&mm)&
0.705!(0.13)! ! 0.736!(0.13)! 0.02*!











Carotid&plaque&present& 185!(90%)! ! 178!(90%)! 0.73!












































































4.8!(1)! 20.158! 4.9!(1)! 20.197! 0.04!(20.1!to!0.2)! 0.60!
HDL&(mmol/L)& 1.6!(0.5)! 20.027! 1.6!
(0.4)!
20.017! 20.01!(20.1!to!0)! 0.64!

























































































































12! ! 2! ! 8! 2!
BP&medication&
initiated&(n)&












different! cardiovascular! risk! factors! although,! again! there! was! no! difference!
between! the! e2coaching! and! SOC! groups,! respectively.! These! included! improved!
systolic! BP,! diastolic! BP,! weight,! hip! circumference,! waist! circumference,! fasting!
total!cholesterol,!fasting!LDL!cholesterol,!fasting!triglyceride,!fasting!glucose,!and!a!
reduction!in!the!102year!Framingham!Risk!score!(21.232!%!vs.!21.374!%,!p=0.79).!!
Lifestyle! factor! improvements!were! also! seen! to! a! similar! extent! in! both! groups!
including! a! reduction! in! alcohol! units! per! week! (20.778! vs.! 21.081,! p=0.54),!
increased! moderate! physical! activity,! measured! as! minutes! per! week! averaged!
over! a! 52day!week! (25.102! vs.! 8.448,! p=0.54),! and! an! improved! overall! lifestyle!







5.58,! 95%! CI! 20.65! to! 4.9,! p=0.79).! The! sum! of! the! visual! analogue! scale! value!
(which!gives!an!indexed!value!based!on!the!combination!of!the!5!dimensions!of!the!




the! two! groups.! There!was! no! difference! between! the! two! groups! in! the! change!
over! this! period! (0.014! vs.! 0.015! mm,! 95! CI! of! mean! change! 20.017! to! 0.015,!
p=0.91).!
!
































Baseline! Follow2up! Baseline! Follow2up!














172!(87)! 164!(89)! 0.67! 0.39!
BMI&&(<25&
kg/m2)&






















































To!my! knowledge! this! is! the! first! study! to! assess! the! impact! of,! personalised,! e2
coaching! in! a! high! risk! primary! prevention! cohort! using! robust! cardiovascular!
surrogate!markers.! This! study! showed! that! e2coaching,! using! Internet! and! email!
based!heart!attack!prevention!programme!on!top!of! the!SOC!compared!with!SOC!
alone! did! not! reduce! cardiovascular! risk! based! on! interval! change! of! the! PWV!
surrogate!marker!and!other!CVD!risk!markers.!E2coaching!and!SOC!both!modestly!













convenient! for! the! end! user! and! being! directly! relevant! to! that! individual!when!
personalised.!It!can!be!time!saving!for!the!individual!and!for!the!healthcare!system!





Challenges! surround! the! use! of! e2coaching! include! the! information! governance!




possibility! of! information! overload! especially! if! individuals! have! numerous!
suboptimal!factors!that!they!need!to!address!and!this!may!even!become!counter2
productive.! Long2term! adherence! to! the! behavioural! programme! may! diminish!
and! limit! its! effectiveness.! Finally,! without! proven! effectiveness! it! would! be!
difficult!to!implement!its!widespread!use!due!to!the!resources!and!cost!associated!
with! maintaining! such! a! program.! I! did! not! formally! undertake! a! cost! –
effectiveness!analysis!as!planned!as! there!was!an!absence!of!added!effectiveness!
from!with!e2coaching!over!SOC.!There!is!a!financial!cost!from!the!implementation!









In!general,! the!evidence!was!deemed!to!be!of! low!quality!due!to! lack!of!blinding,!
loss! to! follow2up! and! uncertainty! around! the! effect! size.! Few! studies! measured!
clinical!events!or!assessed!health!related!quality!of!life.!
!
Very! few! studies! exist! in! the! area! of! primary! prevention! and! a! meta2analysis!
assessing! the! effectiveness! of! internet2based! interventions! targeting! participants!
with!increased!CVD!risk!identified!5!RCTs!in!diabetic!patients!and!4!in!those!with!
increased!CVD!risk!predominantly!due!to!high!BP.!The!authors!noted!a!shortage!of!
studies! investigating! the! effectiveness! of! internet2based! interventions! in!
improving!direct!CVD!outcomes!such!as!cardiac!mortality!or!adverse!events,!which!
is! an! inherent! challenge! with! primary! prevention! studies! in! relatively! well!
individuals.! They! noted! some! evidence! to! suggest! that! interactive! self2
management! programmes! that! include! lifestyle! education! and! self2monitoring! of!





A! meta2analysis! on! computer! tailoring! found! that! it! is! unclear! how! elaborate! a!
computer2tailored! intervention! should! be! to! have! an! effect.! It! is! not! possible! to!
relate!the!effects!of!the! intervention!to! information!given!(the!dose),!because!the!
interventions! are! usually! not! described! in! enough! detail! to! make! meaningful!
comparison!possible!7.!
!
The! study! included! individuals! who! were! deemed! to! have! a! high! total!
cardiovascular! risk.! CVD! risk! assessment,! using! risk! calculators! to! guide!
management! is! a! concept! that! is! now! advocated! in! many! primary! prevention!
guidelines! 17,30,31,153.! The! study! also! utilised! a! number! of! robust! and! sensitive!
surrogate! markers,! which! confirmed! that! risk! reduction! programmes! have! a!





Internet! to! search! for! advice! and! information! on! their! condition! or! risk! factors.!
Although,!having!a!personalised!webpage!with!all!of!this!information!in!one!place!
with! blood! test! results! and! reminders!may! be! expected! to! positively! impact! on!
ease! of! access! to! information! and! patient! satisfaction,! it! does! not,! however,!
currently! translate! into! a!meaningful! clinical! benefit.! It!may! still! be! argued! that!
more!information!is!better!than!less!and!may!provide!motivation!for!future!change!
or! at! least! better! awareness! of! risk! factors! and! health! information.! However,! in!
most!resource!limited!health!care!systems!where!there!is!an!opportunity!cost!and!
other! services!with! strong!evidence!base!may!potentially!be!denied! funding!as!a!
consequence.! This! poses! an! ethical! and! resource! allocation! dilemma! leading! to!
rationalisation! of! intervention! that! does! not! show! objective! evidence! of! benefit.!






common! contemporary! cardiovascular! risk! markers! including! biomarkers,!
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physiological! surrogate! markers,! imaging! markers! and! questionnaires! to! assess!
lifestyle!and!quality!of!life.!I!included!a!large!number!of!participants!and!this!study!
forms!one!of! the! largest!of! its!kind.!Although!not!a!blinded!study!I! tried!to!avoid!




There! were! some! limitations! to! the! study.! Participants! and! the! researchers!
conducting!the!visits!were!not!blinded.!Although!we!were!very!strict!in!following!
the!pre2specified!protocol!this!may!have!led!to!possible!bias.!This!does!not!appear!
to! have! had! an! impact! on! the! final! results.! If!we! had!more! resources!we!would!
ideally!have!liked!to!include!more!blinding.!Another!limitation!was!that!we!did!not!
include!a!third!group!of!participants!who!could!have!just!had!baseline!and!follow2
up! assessment! without! any! type! of! intervention! (e2coaching! or! SOC)! to! better!
understand! the! natural! variation! in! the! population.! However! this! may! be! an!
unrealistic!strategy!as!those!identified!as!being!at!high!risk!would!normally!receive!
some! form! of! intervention! either! in! the! form! of! lifestyle! advice! or!
pharmacotherapy!following!assessment.!
!
Anecdotally,! the! participants! included! in! the! study! appears! to! included! a! large!
group!of!professionals!and!baseline!characteristics!such!as!physical!activity!appear!
to! be! better! than! population! average! and! thus!may! represent! a! healthier! group.!
This!may! reduce! the! impact! seen! from! the! programme.! Volunteering! effect!may!
have! been! present! and! the! cohort! may! have! been! healthier,! of! higher!
socioeconomic! and! educational! level! than! the! general! population! thus! making!
generalisability! challenging.! Follow! up! was! only! for! 6! months,! if! resources! had!
allowed! I! would! have! extended! the! study! period! to! a! minimum! of! 1! year.! The!
website!was!initially!a!Dutch!initiative!and!some!modifications!were!made!to!make!
it!more!relevant!for!the!British!population.!However,!certain!aspects!of!the!lifestyle!
questionnaires! and! website! content! may! not! have! been! culturally! suited! to! the!
population.! Ideally,! I! would! have! liked! the! full! content! of! the! programme! to! be!
tailored!to!the! local!cultural!and!language!preferences.!Only!people!with!Internet!
access! were! eligible! and! may! have! created! a! selection! bias.! Guideline! based!
intervention!is!not!necessarily!the!SOC!during!most!visits!due!to!time!constraints!
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and! experience! of! some! primary! care! staff! (e.g.! health! care! assistants! and! non2
specialist! nurses).! An! experienced! cardiology! research! doctor! performed!
interventions,!whereas! health! check! type! programmes! are! commonly! conducted!
by!health!care!assistants!or!nurses!and!less!frequently!by!a!doctor.!The!majority!of!
the! subjects!were!Caucasians! and! thus! it! is! difficult! to! generalise! the! findings! to!
other!ethnic!groups!due!to!differences!in!pathophysiology!and!cultural!differences.!
Although! we! did! try! and! target! ethnic! minorities! the! uptake! was! lower! than!








the! improvements! in! the! individual! factors! are!modest! the! combined! effect! of! a!








when! combined! with! current! SOC! in! a! high2risk! primary! prevention! cohort.!
Implementing! guideline! recommendation! that! promote! risk! factor! reduction! for!





Chapter& 8& –& Impact& of& electronic& coaching& on&
cardiovascular& risk& reduction& in& a& highErisk& primary&






CMR! sub2study! was! to! assess! the! changes! that! may! be! seen! following!
predominantly! lifestyle! intervention! over! a! 62month! follow2up! period.! This!
information!can!then!be!used!to!guide!whether!the!use!of!CMR!would!be!feasible!
and! useful! for! future! similar! studies.! The! results! could! also! be! used! to! calculate!





Background:& Powering! primary! prevention! clinical! trials! for! hard! clinical! end!
points! poses! logistic! and! resource! challenges.! CMR! imaging! offers! a! range! of!
powerful! imaging! parameters! that! can! be! used! as! outcome!measures! in! clinical!
trials!at!reduced!cost!and!follow2up!duration!and!can!inform!performance!of!larger!
scale! RCTs.! Use! of! these! surrogate! markers! in! primary! prevention! with!
predominantly!lifestyle!interventions!has!been!limited.!Robust!surrogate!markers!
can! help! assess! its! clinical! effectiveness! and! guide! future! widespread!
implementation.!
&
Purpose:&The!primary!aims!of! this! sub2study!were! to!1.!Assess! for!effect! size!of!
change! in! CMR! surrogate!markers! with! lifestyle! changes! over! a! short! period! of!
time!(6!months).!This!would!be!useful!for!design!of!future!larger!phase!2!primary!
prevention!trials!with!behavioural!interventions,!2.!To!assess!for!determinants!of!









addition! to! SOC! vs.! SOC! alone.! Estimated! 102year! cardiovascular! risk! of! 10%! or!
more!was!required!with!no!prior!history!of!CVD.!In!this!sub2study!CMR!scanning!
(Philips!1.5T),!Vicorder!device!based!CFPWV!and!cardiovascular!risk!assessment!
were!performed!at! baseline! and!62month! follow2up! in! the! first! 100!participants,!
with!1:1!allocation!based!on!treatment!arm.!Surrogate!markers!of!LV!mass,!aortic!
distensibility! by! CMR!were! assessed.! I! also! performed! oscillometric! CFPWV! and!




both! baseline! and! follow2up! CMR.! Compared! to! baseline! there! was! a! non2
significant! reduction! in! LV! mass! in! the! whole! group! following! predominantly!
lifestyle!intervention!(21.68g,!p=0.155).!I!did!however!see!significant!reduction!in!
the! distensibility! of! TAA! (mean! change! 20.20! x! 1023!mmHg21,! p=0.043),! and!TDA!
(mean! change! 21.61,! p<! 0.001).! This! appeared! to! be! due! to! a! combination! of!
increase! in! the! central! pulse! pressure! and! a! reduction! in! the! aortic! strain.! Both!
treatment!groups!showed!reduction!in!LV!mass!(e2coach!22.01g!vs.!21.27g,!p=!0.74)!
and! PWV! (e2coach! 20.30! m/s! vs.! 20.77! m/s,! p=! 0.08).! Findings! were! consistent!






Conclusions:&Multi2parametric! CMR! is! feasible! in! primary! prevention! studies! of!
lifestyle!interventions.!Further!studies!are!needed!before!CMR!and!other!surrogate!









Innovative! techniques! are! required! to! tackle! the! anticipated! rise! in! CVD! due! to!




as! myocardial! infarction! and! death,! poses! logistic! and! resource! challenges.!
Surrogate!markers!may!play!an!important!role!assessing!outcomes!particularly!in!
this!group!of!patients.!CMR!imaging!offers!a!range!of!powerful!imaging!parameters!
to! assess! changes! in! cardiovascular! structure! and! function,! particularly! in!
myocardial!infarction!studies!2312233.!These!can!be!used!as!surrogate!end!points!in!








HAPPY! London! Study! along! with! other! established! non2invasive! surrogate!
markers.!
!
LV!hypertrophy! and! aortic! stiffness!were! the!main!CMR! surrogate!markers:! The!
development! of! LV! hypertrophy! is! a! relatively! early! response! to! hypertension,!
demonstrable!in!children!and!adolescents!with!borderline!elevations!in!BP!234.!!LV!















design! of! future! larger! phase! 2! primary! prevention! trials! with! behavioural!






In! a! pre2defined! secondary! analysis,! I! wanted! to! see! whether! the! type! of!





Between! July! 2013! and! November! 2015,! 402! participants!were! recruited! into! a!
single!centre!RCT!comparing!e2coaching!in!addition!to!SOC!vs.!SOC!alone!with!a!6!
month! follow2up.! ! Estimated! 102year! cardiovascular! risk! of! 10%! or! more! was!
required!with!no!prior!history!of!CVD.!!
!
In!the!sub2study!of! the!HAPPY!London!clinical! trial! the! first!100!participants!(50!
from!each! treatment! arm!with!1:1! allocation)! from! the! total! cohort! of! 402!were!
allocated!a!baseline!and!6!month!CMR!scan!(Philips!1.5T)!along!with!the!standard!



































Circle! Cardiovascular! Imaging! Inc.,! Canada),! to! quantify! LV! end! diastolic,! end!
systolic,! stroke! volumes! and! ejection! fraction.! LV! epicardial! contours! were!
manually! segmented! at! end! diastole! for! calculating! LV! mass,! based! on! the!
summation2of2discs!method.! Values!were! indexed! to! BSA.! The! papillary!muscles!
were!excluded! from! the!LV!mass!measurement.!LV!mass!was!determined!by! the!














were! expressed! as! mean! ±! SD! for! parametric! variables! and! median! with!
interquartile!range!for!non2parametric!variables.!Differences!in!the!total!sub2study!
cohort,! over! the!62month! study!period,!were! assessed!using!paired! t2test.! I! used!
linear!regression!models!to!determine!the!treatment!effects!adjusted!for!the!pre2
specified! covariates! to! assess! relationship! between! change! in! risk! factors! and!
surrogate! markers.! Statistical! significance! was! defined! as! a! two2sided! p<0.05.!
Patients!were!compared!based!on!treatment!arm!of!e2coaching!vs.!SOC.!Differences!







































































































































































Of! those! who! did! not! have! a! baseline! scan! this! was! because! the! participants!
declined! a! scan!despite! no! contraindication! (n=!9),! contraindications! to! contrast!
due! to! renal! impairment! (n=1)! and! contraindication! due! to! metallic! implants!
(n=3).!Of!those!who!attended,!two!of!the!participants!from!the!SOC!group!did!not!










scans! that! were! performed! but! unable! to! retrieve! from! central! server! due! to!
technical!issues!at!time!of!analysis!(n=3).!
!








































































































In! the! whole! cohort! (e2coaching! and! SOC! combined)! there! were! modest! but!
statistically!significant! improvements!in!systolic!BP!(22.2%),!diastolic!BP!(24.7%),!
weight!(21.85%),!hip!circumference!(24.2%),!waist!circumference!(23.4%),! fasting!
glucose! (211.7%)! and! physical! activity! levels! (61.8%,! Table! 18).! Lifestyle!
questionnaire! scores! (10!being! the!best! score)!were!better!at! follow!up! (14.7%)!
and!there!was!a!reduction!in!the!stress!levels!based!on!the!reduced!stress!scores!(2
17.5%).!This!translated!in!an!overall!significant!reduction!in!the!Framingham!risk!




above! and! corresponding! reduction! in! the! risk! estimation! score! there! was! no!
significant!difference!noted!in!the!LV!mass!(baseline!96.0!g!vs.!94.7!g!at!follow!up,!
p=0.155).! I! did! however! see! significant! reduction! in! the! distensibility! at! TAA!
(mean!change!20.20!x!1023!mmHg21,!p=0.043)!but!not!at!TDA!or!ABA.!However,!this!































134.5! 131.5! 0.024*! 22.99! 25.58! 20.40!
Diastolic&BP,&
mmHg&
79.5! 75.8! <0.001*! 23.70! 25.05! 22.34!
Weight,&kg& 79.7! 78.3! <0.001*! 21.37! 21.86! 20.87!












4.7! 4.7! 0.53! 20.05! 20.20! 0.10!
HDL,&mmol/L& 1.5! 1.5! 0.199! 0.02! 20.01! 0.05!
LDL,&mmol/L& 2.6! 2.6! 0.511! 20.04! 20.18! 0.09!
Triglyceride,&
mmol/L&
1.3! 1.2! 0.346! 20.05! 20.14! 0.05!
Glucose,&
mmol/L&
6.0! 5.3! <0.001*! 20.66! 20.88! 20.45!
Creatinine& 79.9! 80.6! 0.447! 0.66! 21.06! 22.39!




85.0! 83.9! 0.217! 21.29! 23.36! 0.77!
Fruit&per&day,&
potions&
2.8! 3.0! 0.045*! 0.29! 0.01! 0.58!
Veg&per&day,&g& 208.1! 231.4! 0.041*! 21.73! 0.95! 42.52!
Alcohol&per&
week,&units&&

















6.8! 7.8! <0.001*! 0.94! 0.70! 1.18!
QRISK2,&10E
year&risk,&%&




18.8! 17.6! 0.022*! 21.29! 22.39! 20.19!
AI,&%& 22.3! 23.9! 0.023*! 1.70! 0.24! 3.15!
CFPWV,&m/s& 8.1! 7.5! <0.001*! 20.65! 20.91! 20.39!
CIMT&left,&mm& 0.71! 0.73! 0.038*! 0.03! 0.00! 0.05!






0.70! 0.72! 0.007*! 0.02! 0.01! 0.04!
& ! ! ! ! ! !
Heart&rate,&bpm& 62.9! 60.7! 0.031*! 22.15! 24.41! 20.20!
BSA& 1.90! 1.85! 0.095! 20.09! 20.19! 0.02!
LVEDV,&ml& 150.4! 152.2! 0.233! 21.80! 21.18! 4.78!
LVESV,&ml& 53.1! 54.8! 0.141! 1.66! 20.56! 3.88!
LVSV,&ml& 97.3! 97.4! 0.917! 0.14! 22.53! 2.81!
LVEF,&%& 65.2! 64.5! 0.292! 20.67! 21.92! 0.59!
LV&myocardial&
mass,&g&




961.2! 953.3! 0.010*! 216.24! 228.54! 23.94!
TDA&area&max,&
mm2&
532.1! 532.8! 0.118! 25.36! 212.11! 1.39!
ABA&area&max,&
mm2&
483.1! 485.2! 0.175! 28.55! 220.98! 3.88!
TAA&strain,&%& 0.11! 0.10! 0.013*! 20.01! 20.02! 20.00!
TDA&strain,&%& 0.11! 0.12! 0.521! 0.00! 20.01! 0.01!





























Univariate! regression! analysis! showed! some! significant! relationship! in! changes!
seen!in!LV!mass,!PWV,!combined!CIMT!(average!of!left!and!right!CIMT)!or!thoracic!
aortic! distensibility!with! changes! in! participant! risk!markers! such! as!BP,!weight!
and! lipid!profile!and!glucose!(see!Table!19!for! full! list).!A!significant!relationship!
was! noted! between! TAA! distensibility! with! systolic! BP! change! (β! =! 20.017,!





(derived! from! systolic! and! diastolic! BP)! is! used! to! calculate! distensibility.! There!
was! also! a! positive! relationship! of! total! cholesterol! and! the! average! of! the!





Changes! in! TAA! strain! and! distensibility! were! the! only! factors! predictive! of! a!
change! in! LV!mass! over! the! 62month! period! (β=284.939,! p=0.002! and! β=24.622,!
p=0.001,! respectively).! Suggesting! that! a! rise! in! LV! mass! is! associated! with! a!
reduction! in! TAA! strain! and!distensibility.! A! reduction! in! TDA!distensibility!was!
predictive! of! a! rise! in! CFPWV! (β! =! 20.156,! p=0.009).! CIMT! changes! were! not!
associated!with! changes! in! other! surrogate!markers! using! univariate! regression.!
Changes! in!TAA!distensibility!were!associated!with!change!in!QRISK2!score!(β=!2






























& Univariate! Univariate! Univariate! Univariate!
& β! P!value! β! P!value! β! P!value! β! P!value!
& ! ! ! ! ! ! ! !
Δ&Systolic&BP,&mmHg& 0.046! 0.642! 0.001! 0.904! 50.001! 0.321! 50.017! 0.036*!
Δ&Diastolic&BP,&mmHg& 0.279! 0.134! 0.008! 0.643! 50.002! 0.127! 50.024! 0.123!
Δ&Weight,&kg& 50.022! 0.965! 0.041! 0.362! 50.002! 0.526! 50.124! 0.003*!
Δ&Hip&circumference,&
cm&
50.142! 0.630! 50.005! 0.864! 50.002! 0.370! 50.005! 0.075!
Δ&Waist&circumference,&
Δ&cm&
50.288! 0.133! 50.019! 0.364! 50.000! 0.837! 50.020! 0.6224!
Δ&Total&cholesterol,&
mmol/L&
0.775! 0.648! 50.114! 0.443! 0.022! 0.046*! 0.122! 0.454!
Δ&Glucose,&mmol/L& 51.442! 0.222! 50.077! 0.451! 50.004! 0.677! 0.202! 0.040*!
Δ&HsCRP&mg/L& 50.167! 0.379! 0.001! 0.963! 50.000! 0.921! 50.012! 0.422!
Δ&Physical&activity,&mins&
over&5&days&
0.012! 0.243! 0.001! 0.517! 50.000! 0.914! 50.001! 0.280!
Δ&Lifestyle&score&(out&of&
10)&
52.014! 0.127! 50.190! 0.086! 50.000! 0.992! 0.220! 0.054!
Δ&QRISK2&score,&10&year&
risk&%&
0.080! 0.874! 50.044! 0.334! 0.003! 0.448! 50.048! 0.025*!
Δ&Framingham&risk&
score,&10&year&risk&%&
0.229! 0.320! 50.027! 0.181! 0.003! 0.087! 50.034! 0.075!
Δ&Augmentation&index& 0.268! 0.129! 0.006! 0.681! 50.000! 0.847! 0.016! 0.301!
Δ&CFPWV,&m/s& 0.175! 0.893! 5! 5! 50.001! 0.952! 0.169! 0.133!
Δ&CIMT&left,&mm& 55.214! 0.634! 0.187! 0.846! 5! 5! 50.007! 0.994!
Δ&CIMT&right,&mm& 2.627! 0.808! 50.335! 0.728! 5! 5! 50.193! 0.834!









Δ&TDA&strain,&%& 50.808! 0.134! 52.610! 0.405! 50.143! 0.529! 1.907! 0.502!
Δ&ABA&strain,&%& 513.407! 0.661! 50.022! 0.994! 50.203! 0.317! 52.704! 0.275!
Δ&TAA&distensibility,&10M
3&mmHgM1&
54.622! 0.001*! 50.181! 0.133! 50.002! 0.853! 5! 5!
Δ&TDA&distensibility,&10M
3&mmHgM1&
50.215! 0.761! 50.156! 0.009*! 50.007! 0.151! 0.275! <0.001*!
Δ&ABA&distensibility,&10M
3&mmHgM1&




In# this# sub,study# cohort# weight# and# BMI# reduced# significantly# more# in# the# e,
coaching#group#(e,coach#,2.02#kg#vs.#,0.68#kg#in#SOC,#p=0.006#and#,0.70#kg/m2#vs.#,
0.27#kg/m2)#but#without#a#significant#difference#seen#in#the#LV#mass#(Figure#55).#
There# were# similar# modest# changes# in# the# systolic# BP,# diastolic# BP,# hip#


























( (n=#44)# (n=#42)# # #
Systolic(BP,(mmHg( ,0.50# ,5.60# ,10.21#–#0.03# 0.051#
Diastolic(BP,(mmHg( ,2.50# ,4.96# ,5.15#–#0.22# 0.071#
Weight,(kg( 92.02( 90.68( 0.39(–(2.29( 0.006*(
BMI,(kg/m2( 90.70( 90.27( 0.08(–(0.78( 0.016*(
Hip(circumference,(
cm(
,4.68# ,4.11# ,1.17#–#2.30# 0.519#
Waist(
circumference,(cm(
,3.99# ,2.52# ,1.18#–#4.13# 0.273#
Total(Cholesterol,(
mmol/L((
0.02# ,0.12# ,0.44#–#0.17# 0.365#
HDL,(mmol/L( 0.01# 0.03# ,0.03#–#0.08# 0.404#
LDL,(mmol/L( 0.03# ,0.13# ,0.44#–#0.11# 0.242#
Triglyceride,(
mmol/L(
,0.04# ,0.05# ,0.21#–#0.17# 0.850#
Glucose,(mmol/L( ,0.68# ,0.64# ,0.38#–#0.47# 0.831#
Creatinine( 0.07# 1.43# ,1.94#–#4.93# 0.389#
HsCRP,(mg/L( ,2.17# 0.06# ,0.57#–#5.01# 0.116#
eGFR,(
mL/min/1.73sqm(
,0.26# ,2.88# ,7.23#–#0.96# 0.132#
Fruit(per(day,(
potions(
0.34# 0.24# ,0.67#–#0.47# 0.732#
















0.83# 1.05# ,0.26#–#0.71# 0.361#
QRISK2,(109year(
risk,(%(




,0.39# ,2.24# ,4.06#–#0.35# 0.098#
AI,(%( 1.60# 1.79# ,2.73#–#3.11# 0.897#
CFPWV,(m/s( ,0.47# ,0.84# ,0.90#–#0.16# 0.171#
CIMT(left,(mm( 0.04# 0.01# ,0.08#–#0.01# 0.139#
CIMT(right,(mm( 0.01# 0.02# ,0.04#–#0.05# 0.786#
( # # # #
Heart(rate,(bpm( ,1.70# ,2.62# ,4.81#–#2.98# 0.642#
Body(surface(area,(
m2(
,0.10# ,0.07# ,0.18#–#0.24# 0.760#
LVEDV,(ml( 2.11# 1.48# ,6.65#–#5.40# 0.837#
LVESV,(ml( 2.10# 1.20# ,5.35#–#3.55# 0.688#




LVEF,(%( ,0.88# ,0.45# ,2.08#–#2.95# 0.731#
LV(myocardial(
mass,(g(
,2.01# ,1.27# ,3.89#–#5.47# 0.738#
LVEDV(i,(ml/m2( 0.21# ,0.53# ,5.99#–#4.50# 0.779#
LVESV(i,(ml/m2( 0.42# 0.23# ,2.86,#2.47# 0.887#
LVSV(i,(ml/m2(( ,0.23# ,0.79# ,4.54#–#3.42# 0.782#
LV(myocardial(
mass(i,(g/m2(
,1.73# ,1.42# ,3.50#–#4.12# 0.871#
( # # # #
RVEDV,(ml( 1.50# 8.09# ,1.34#–#14.52# 0.102#
RVESV,(ml( 5.76# 6.67# ,5.72#–#7.55# 0.785#
RVSV,(ml( ,4.26# 1.41# ,0.01#–#11.36# 0.050#
RVEF,(%( ,3.03# ,1.65# ,1.24#–#4.00# 0.298#
RVEDV(I,(ml/m2( 0.30# 2.87# ,3.89#–#9.03# 0.431#
RVESV(I,(ml/m2( 2.55# 2.88# ,3.89#–#4.56# 0.875#













with# CMR# evidence# of# previous# myocardial# infarctions# that# was# not# previously#
known.# This# is# a# lower# percentage# than# previously# published# population#
observational# studied#178.#One#of# the#participants#was#diagnosed#as#being#human#
immunodeficiency#virus#positive#(but#was#stable#on#antiretroviral#medications#for#















Regards# side# effects#1# subject#who#was# anxious# at# the# time#of# the# scan# reported#
headache# that# settled# after# 1,2# days# but# he# declined# the# follow# up# scan.# 1#
participant# that# had# a# BMI# in# the# obese# range# and# a# large# waist# circumference#







of# this#was#not#seen# in# the#LV#mass.# #Peripheral#measurements#of#BP#showed#an#
average# reduction# in# the# group,# however# there#was# a# reduction# in# distensibility,#
which#was#unexpected#suggesting#that#the#arteries#became#stiffer.#This#was#driven#
partly#by#an#increase#in#central#aortic#pulse#pressure#and#a#small#reduction#in#the#
aortic# area# and# strain.# # The# clinical# implication# of# this# is# not# clear# and# needs#
clarification.#Participants#were#advised# to#avoid#alcohol,# caffeine#and#smoking#on#





impact# on# the# aortic# distensibility.# The# acute# impact# of# fluid# volume# and# blood#
pressure#reduction#has#been#documented#in#patients#with#end#stage#renal#disease#
before# and# immediately# after# haemodialysis235.# # The# improvement# in# aortic#
distensibility#following#dialysis#(from#1.9#cm2.dyn,1.10,6#to#2.6#cm2.dyn,1.10,6)#was#
driven# by# a# large# reduction# in# pulse# pressure# from#53#mmHg# to# 39#mmHg#with#
similar#diameters#for#the#aorta#as#measured#by#echocardiography#of#the#ascending#
aorta# using# the# parasternal# long# axis# view.# In# another# study# comparing# elite#
rowers#to#sedentary#controls#it#was#noted#that#there#was#no#significant#difference#
in# the# aortic# distensibility# between# the# groups#with# the#physically# active# rowers#









may# include# the#modest# reductions# that#may# limit# the#power# to# show#difference#
combined#with# a# relatively# short# interval# of# 6#months.#The# subjects# in# the# study#
were# possibly# too# healthy.# Volunteers# taking# part# in# such# studies# are# generally#
motivated# before# taking# part# in# the# trial# and# the# vast# majority# did# not# have#
evidence#of#ventricular#hypertrophy#at#baseline,#suggesting#that#control#of#factors#
such#as#BP,#were#good#to#start#with#or#that#the#cohort#did#not#contain#patients#with#




weight# were# substantially# greater# then# seen# in#my# study.# It# should# be# borne# in#





CMR#and#other# surrogate#markers#are# technically# feasible# in#primary#prevention#
studies#of#predominantly# lifestyle# factors# in#asymptomatic#participants.# I#noted#a##
relationship# between# measured# risk# factor# changes# and# changes# in# surrogate#
markers# including# FRS,# left# and# combined# CIMT.# However# TAA# and# TDA#
distensibility#also#changed#significantly#but#surprisingly# in# the#opposite#direction#
to#what#we#predicted.# #This#may#partly#be#due# to# the#modest#changes# that#occur#
with# lifestyle# interventions# and# the# relatively# short# duration# of# follow# up# of# six#
months# along#with# the# points# discussed# above.# To# accurately# identify# long# term#
beneficial# effects# of# small# changes# in# variables# such# as# BP# and# weight# a# larger#
number# of# scans# would# be# required# to# sufficiently# power# the# study,# but# then#
challenges#of#sustainability#of#lifestyle#behavioural#changes#will#come#into#play.#
#
In# summary,# CMR# use# is# feasible# in# a# primary# prevention# setting# looking# for#










Although# improvements#were# seen# in# CVD# risk# factors,# these#were#modest.# The#
follow,up# scan# was# performed# at# 6# months# and# included# with# participants# in# a#
fasted# state,# which# was# not# necessarily# the# case# at# the# baseline# scan.# A# longer#
duration# follow,up#scan#at#one,year#or# longer#may#be# required# to#allow# time# for#
structural# and# functional#differences# in# this# group.# Inter,scan#variability#was#not#
assessed#and#ideally#this#should#have#been#done#to#provide#a#better#understanding#
of# the# variability# of# measurements# in# order# to# more# accurately# power# future#
studies.# Although# analysis#was# performed# blinded# to# the# intervention# there#was#








changes# to#be# seen.# Further# studies# are#needed#before#CMR#and#other# surrogate#












e,coaching# in# reducing# cardiovascular# risk# in# a# primary# prevention# cohort# with#
moderate# and# high# cardiovascular# risk# using# robust# cardiovascular# imaging# and#
functional#surrogate#markers#to#assess#change#over#6#months.##
#
Through# the# HAPPY# London# study,# I# have# demonstrated# that# personalised# e,
coaching,#using#a#web,based#information#portal#and#motivational#emails,#does#not#
show#clinical# effectiveness# in# cardiovascular# risk# reduction#when#combined#with#
the#current#SOC#in#a#high,risk#primary#prevention#cohort.#I#showed#that#promoting#
primary# prevention# guideline# recommendation# through# face,to,face# counselling#
can# produce# modest# but# significant# improvements# in# a# number# of# different#
cardiovascular# risk# factors# in# the# medium# term.# This# can# be# achieved# through#









the# assessment# of# behavioural# change.# I# was# also# able# to# demonstrate# that# it# is#
feasible#to#use#other#imaging#markers#including#CMR#(namely#LV#mass#and#aortic#
distensibility)# and# carotid# ultrasound# although# evidence# for# change# in# these#
correlating#with#long,term#prognosis#needs#to#be#demonstrated.#
#
In# the# systematic# review# of# the# guidelines# on# cardiovascular# risk# assessment# I#
found# a# number# of# guidelines# that#make# recommendation# on# the# assessment# of#
risk# and# screening# for# cardiovascular# risk# factors.# There# were,# however,#
considerable# discrepancies# in# the# guidelines# with# no# consensus# on# optimum#
screening# strategies# or# treatment# threshold.# I# found#no# consistent# agreement# on#








I# did,# however,# find# that#most# of# the# current# guidelines# from#Western# countries#
agree#on#many#of#the# lifestyle#advice#and#interventions#that#should#be#promoted,#
particularly# for# individuals#deemed#to#be#at#high#risk# for#developing#CVD.#This# is#
useful#to#allow#incorporation#into#an#e,coaching#tool.#
#
I# found# that# using# CMR# in# a# primary# prevention# clinical# trail# is# feasible# and#
generally#well#tolerated.#The#ideal#surrogate#marker#to#use#in#a#short,term#trial#is#
not#yet#clear.##There#is#limited#data#on#the#long,term#prognostic#effect#of#changes#in#





individual# with# additional# monitoring# and# feedback# through# the# use# of# inbuilt#
activity# monitors# and# dynamic# feedback.# It# would# be# useful# to# assess# the#
effectiveness# of# these# advanced# tools# to# determine# if# they# could# be# useful# in#
shaping# behavioural# change.# Alternative# strategies# could# include# simple# text#





prioritise# change.# # The# number# of# questionnaires# in# the# trial#may# have# deterred#
people# in# the# e,coaching# group# from#actually#using# the#web# site.# # Future# studies#
should# limit# the#questionnaires# and#use#activity#monitors,# for# example,# to# assess#
physical#activity#change#objectively.###
#
For# future#work# I# plan# to# analyse# the#potential# impact# on#behaviour# change# and#
CVD#risk#reduction# from#personality# trait#data# (from#the# ‘big# five’#questionnaire)#





life.# # I# also#plan# to# compare# the# correlation#between# the#oscillometric#PWV# from#
the#Vicorder#against#the#CMR#derived#PWV.#
#
In# summary,# to# my# knowledge# my# study# is# the# first# RCT# of# a# novel# computer,
tailored#e,coaching#approach# to#modify# lifestyle#and#multiple# cardiovascular# risk#
factors#in#a#high,risk#primary#prevention#population#to#reduce#cardiovascular#risk#
measured# using# reproducible# and# accurate# cardiovascular# surrogate# endpoints#
known# to# be# associated#with# important# cardiovascular# outcomes.# Addition# of# e,
coaching#to#guideline#based#SOC#does#not#have#additional#effectiveness.#Currently,#
there#is#limited#evidence#to#recommend#widespread#use#of#e,coaching#in#high#risk#





















I#was# involved# in# the#design#of# the#study.# I#gained#ethical#and#NHS#Research#and#
Development#approval#for#the#HAPPY#London#study.#I#applied#and#was#successful#
in# getting# the# study# added#onto# the#NIHR#portfolio,#which# resulted# in# significant#
improvement#in#the#recruitment#of#participants#through#funding#from#the#NIHR#to#
enable# recruitment# through# primary# care# practices# and# for# additional# research#




I# saw# all# the# participants# during# the# baseline# and#6#month# follow#up# visit# and# a#
large# proportion# of# those# attending# the# screening# and# 3,month# visit.# As#
participants#attended#3#of#the#visits#fasting,#I#offered#and#on#many#occasions#made#
the# tea# and# toast# for# them.# I#was# responsible# for# giving# the# tailored# face,to,face#
advice# to# all# participants# at# the# baseline# visit# and# showing#participants# in# the# e,





responsible# for# the# data# analysis,# writing# the# manuscripts# and# thesis# chapter#
writing# with# the# supervision# of# Professor# Steffen# Petersen.# I# also# lead# the# 2#
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Cost,effectiveness# of# periodic# risk# assessment# vs.# the# Polypill# approach# for#









Impact# of# electronic# coaching# on# cardiovascular# risk# reduction# in# a# high,risk#
primary#prevention#population:#The#Heart#Attack#Prevention#Programme#for#You#
(HAPPY)# London# Randomised# Controlled# Study.# M( Khanji,# A# Balawon,# R#
Boubertakh#et#al.##
#







The# Applicability# Of# Current# Cardiovascular# Risk# Scores# And# Cardiovascular#





Cost,effectiveness# of# periodic# risk# assessment# vs.# the# Polypill# approach# for#
prevention# of# cardiovascular# disease:# A#modelling# study.# B# Ferket,#M#Hunink,#M(
Khanji( et# al# –# Accepted# for# poster# presentation# at# American# Heart# Association#
Scientific#Sessions#for#November#2016,#New#Orleans,#USA.##
#
Cardiovascular# risk# reduction# using# contemporary# guideline# recommendations:#
Outcomes# of# the# Heart# Attack# Prevention# Programme# for# You# (HAPPY)# London#
Study.# M( Khanji,# A# Balawon,# R# Boubertakh# et# al.# BCS# conference.# June# 2016,#
Manchester,#UK.#
#
The# applicability# of# current# global# cardiovascular# risk# scores# and# cardiovascular#
surrogates# in# chronic# obstructive# pulmonary# disease:# A# case,control# study.# M(
Khanji,# I# Stone,# WY# James# et# al.# Journal# of# Cardiovascular# Magnetic# Resonance#
2016,#18(S1):P134#SCMR#conference#January#2016.#Los#Angeles,#USA.#
#
A# comparison# of# cardiac# motion# analysis# software# packages:# application# to# left#








Cardiovascular# magnetic# resonance# feature# tracking# in# patients# with# acute#
myocarditis# and# normal# ejection# fraction:# potential# for# improved# diagnosis# and#
prognosis#–#Top#6#Moderated#best#oral#poster#session##







increased# cardiovascular# risk:# role# of# traditional# risk# factors# and# lung#
hyperinflation.#M( Khanji,# I# Stone,# A# Balawon,# et# al.# # Journal# of# Cardiovascular#
Magnetic#Resonance#2015,#17(S1):P398##
#
Splenic# switch,off,# a# potential# novel# marker# of# lack# of# adenosine# response:#




Splenic# switch,off,# a# potential# novel# marker# of# lack# of# adenosine# response:#
prevalence# and# measurement# reproducibility.# M# Koulouroudias,# A# Lighton,# F#




to# Improving# Cardiovascular# Magnetic# Resonance# Tolerability.,# T# Castiello,# M.#
Westwood,# et# al.# Eur# Heart# J# Cardiovasc# Imaging# May# 2014#
doi:10.1093/ehjci/jeu085##
#
Age# and# Gender# Patterns# of# Referral# for# Stress# Perfusion# MRI.# A# 5,Year#





Cardiovascular# magnetic# resonance# feature# tracking# in# patients# with# acute#
myocarditis# and# normal# ejection# fraction:# potential# for# improved# diagnosis# and#













Interpreting# and# Using# Cost# Effectiveness# Analysis.# Invited# talk# as# conference#
faculty.# M( Khanji.# Clinical# Trials# Workshop.# SCMR/EuroCMR# Joint# Scientific#
Sessions#2015.#Nice,#France#
#
Why# is# this# Nurse# Still# Breathless# after# His# Primary# PCI?# Should#We# Open# it# or#
Close# It?#M( Khanji.# Society# of# Cardiovascular# Magnetic# Resonance# 16th# Annual#
Scientific#Session.#San#Francisco,#USA#2013#
#







Faculty#member# SCMR# Scientific# international# conference.# Los# Angeles,# USA,# Jan#
2016#
#
Faculty# member# Clinical# Workshop# on# CMR# Stress# Imaging.# Barts# Health# NHS#
Trust,#London,#UK,#Oct#2015#
#
Faculty#member# Joint# SCMR/# EuroCMR# Scientific# international# conference.# Nice,#
France,#Feb#2015#
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The# MEDLINE# search# syntax,# as# previously# described,# served# as# a# basis# for# all#
search#strategies.#In#brief,#the#syntax#had#the#3#following#elements#intersected#by#
the#Boolean#term#“AND”:#subject#headings#and#free,text#terms#for#the#interventions#
about# the# health# check# contents# (that# is,# risk# assessment,# screening,# early#
detection,# early# diagnosis,# early# intervention,# periodic# evaluation,# periodic#
examination,# periodic# check,up,# prevention,# and# risk# management),# subject#
heading#and#free,text#terms#for#the#conditions#that#could#define#high#risk#for#CVD#
and# CVD# outcomes# that# should# be# prevented# (that# is,# arteriosclerosis,#
atherosclerosis,#hypertension,#hyperlipidaemia,#diabetes,#CVD,#CHD,#heart# failure,#
and#aortic#aneurysm),#and#publication#types#and#title#words#that#cover#the#clinical#
practice# guidelines# (that# is,# practice# guidelines,# guideline,# guidance,# standards,#
statement,#position#paper,#position#stand,#recommendation,#and#consensus).#
The#references#retrieved# from#the#search#were#considered#guidelines# if# they#met#
the# definition# of# the# Institute# of# Medicine.# Only# guidelines# recommending#
cardiovascular# risk# assessment# specifically# aimed# to# prevent# the# first# CVD# event#










((MH# “Cardiovascular# Diseases”)# OR# (MH# “Aortic# Aneurysm+”)# OR# (MH#
“Myocardial# Ischemia+”)# OR# (MH# “Arteriosclerosis+”)# OR# (MH# “Cerebrovascular#
Disorders+”)# OR# (MH# “Peripheral# Vascular# Diseases”)# OR# (MH# “Heart# Failure,#
Congestive+”)# OR# (TX# (cardiovascular# N3# disease*))# OR# (TX# (coronary# N3#




(TX# (aort*# N5# aneurysm))# OR# (TX# (abdominal# N5# aneurysm))# OR# (TX#








((MH# “Cardiovascular# Diseases/PC”)# OR# (MH# “Preventive# Health# Care”)# OR# (MH#
“Health# Screening”)# OR# (MH# “Risk# Assessment”)# OR# (MH# “Cardiovascular# Risk#
Factors”)#OR#(MH#“Early#Intervention”)#OR#(TX#prevent*)#OR#(TX#(risk#N3#reduc*))#





((PT# Practice# Guidelines)# OR# (TI# guideline*)# OR# (TI# guidance*)# OR# (TI# (position#






















































































You# are# being# invited# to# take# part# in# a# clinical# trial.# Before# you# decide,# it# is#
important#for#you#to#understand#why#the#research#is#being#done#and#what# it#will#
involve.##Please#take#time#to#read#the#following#information#carefully#and#discuss#it#











and# lack# of# exercise,# obesity,# diabetes# and# high# blood# pressure.# Changes# in# life,
style# and# diet# can# significantly# reduce# the# risk# of# heart# diseases.# Your# General#
Practitioner#will#invite#40#to#74#year#olds#who#have#no#known#heart#disease#to#take#
part# in# the# NHS# Health# Check,# which# measures# each# person’s# individual# risk# of#
developing#a#heart#attack#or#stroke#and#encourages#them#in#a#face,to,face#meeting#










attack#or# stroke#over# the#next#10#years.#This# is# an#estimated# risk,# not# your# actual#








you#will# be# given# this# information# sheet# to#keep#and#you#will# be# asked# to# sign#a#
consent#form#at#your#first#visit#to#one#of#our#centres.#Even#after#consenting#you#are#
still#free#to#withdraw#at#any#time#and#without#giving#a#reason#(If#you#would#give#us#












You# have# already# completed# the# internet# based# form# (www.happylondon.info),#





• Attend#our#Centres#4# times#over# the#6#months.#At# the# first#visit#you#will#be#
given# an# explanation#of# the# study# and#you#will# have# the# chance# to# ask# any#
questions#about#it,#before#signing#a#consent#form.##







• Complete# questionnaires# about# your# personality,# including# your# attitudes#
towards#risk#(economic#preferences)#at#the#beginning#of#the#study.#
• Only# some# participants# undergo# a#magnetic# resonance# (MRI)# scan# of# your#
heart# and# blood# vessels# at# the# London# Chest# Hospital# or# Barts# Hospital#
(depending# on# availability)# twice:# at# the# beginning# and# at# the# end# of# the#
study.##
• If( you( are( a( smoker(or( ex9smoker( you(may(be( asked( to(perform( lung(
function(tests(which(will(measure(how(well(your(lungs(are(working.((
• Use#your#HAPPY#London#website#as#often#as#you#like,#if#you#are#allocated#to#
that# group,# for# latest# health# news# and# for# checking# on# your# progress# on#
changing#your#life#style#etc.#
#









and# the# second# will# receive# standard( care( and( get( access( to( Happy( London#
tailored#e,coaching.##










you#would#get# from# the#NHS#Health#Check:# total# cholesterol,# good# (HDL)# and#bad#
(LDL)# cholesterol,# triglycerides# (these# are# all# related# to# fat# circulating# in# your#





the# same# amount# of# blood# on# the# last# visit.# Hence# 40#ml# of# blood#will# be# taken#

















not#undergo#magnetic# resonance# imaging#and#we# routinely# check# for# these# (e.g.# if#
you#have#a#pacemaker,#defibrillator,#vascular#clips,#cochlear#implants,#kidney#failure#
or#significant#claustrophobia).#You#do#not#in#any#case#have#to#agree#to#have#the#MRI#






The#consent# form#will#ask#you# if#you#are#willing# for#us# to#store#a#sample#of#your#
blood# for# future# research#by#our# institute# and#our# research#partners.#This# is# not#
compulsory.# Samples#will# not# be# sold#or# given# to# commercial# bodies.# #Any#other#
use#that#we#may#want#to#make#of#your#sample#will#require#approval#by#a#Research#
Ethics# Committee,# which# is# an# independent# panel# of# experts# who# assess# all#
research# projects# for# safety,# ethical# acceptability# and# who# protect# volunteers’#
interests.# None# of# the# work# that# we# envisage# doing# will# have# any# direct#
implications#for#your#personal#health.##
#
We#will# use# information#held#by# the#NHS,# your#General#Practitioner# and# records#
maintained# by# the# Office# for# National# Statistics# (ONS)# to# follow# up# your# health#
status#during#the#study.##
#








You# will# need# to# have# “good”# access# to# Internet# every# day# so# that# you# can# take#




We# are# testing# a# new#method# of# helping# people# to# reduce# their# risk# of# developing#








The# techniques# used# in# this# study# are# inherently# safe# and#widely# practised.# You#may#
however#have#minor#pain#and/or#bruising#after#blood,taking.##
#
Extremely# rarely,# people#may# experience# nerve# and#muscle# twitching# during# an#MRI#
scan.#If#you#are#participating#in#the#MRI##sub,study,#then#the#MRI#scan#is#a#very#precise#





of# causing# harmful# effects.# There# are# very# small# risks# of# side# effects# from# the# MRI#
contrast#agent# if#your#kidney# function# is#normal#or#almost#normal#(and#we#will#check#




































kept# strictly# confidential# and# will# be# kept# in# a# locked# room# and# stored# on# a#
password,protected# computer.#Only# the# investigators# and# the#website# admin# staff#
who#will#deal#with#the#technical# issues#of# the#website#will#have#access#to#the#data.#
The#website#is#designed#with#strict#security#measures#to#protect#your#personal#data.!















individual# or# their# results# will# be# identifiable# in# any# form# of# publication.# The#
results# from# the# research# will# be# presented# locally# and# internationally# to# other#
medical# colleagues.# The# results# will# also# be# written# up# as# a# full# paper# and# be#
submitted# for# publication# in# an# international# journal.# Some( of( the( baseline(
results( from( this( study( may( be( pooled( and( compared( with( results( from( a(








































( Patient( Advice( and( Liaison( team( (PALS)( provides( free# and# confidential#
information# to# patients/# families/# carers.# They# provide# information# and# advice#
regarding# any# issues# or# concerns# that# you# may# have.( Telephone# number–# 020#
3594#2040#(based#at#The#Royal#London#Hospital)#
#
Thank#you#for#considering#participating#in#this#study!#
#
You$will$be$given$a$copy$of$the$information$sheet$and$a$signed$consent$form$to$
keep.#
#
#
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Study(Consent(Form
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